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Summary
Variability in raw materials presents a challenge for pharmaceutical companies. The vary-
ing physicochemical properties can critically influence drug release and bioavailability of
the final dosage form. Therefore, a strategy to control this variability is required. In this
study the well-established antiepileptic drug carbamazepine (CBZ) was selected as the
model drug as it presents one example where variability in raw materials has been linked
to bioinequivalence and clinical failures. CBZ shows poor solubility, low potency, and
a narrow therapeutic index. Furthermore, CBZ exhibits at least four polymorphic forms
and it transforms into the less soluble CBZ dihydrate in water.
The purpose of this work was to study the impact of variability in CBZ samples of four
different suppliers on the drug release and to suggest a strategy to deal with the sample
variability. Thus, the CBZ samples were characterized at preformulation as well as at a
formulation level.
Polymorphism and morphology of CBZ samples were analyzed by differential scan-
ning calorimetry, X-ray powder diffraction, sieve analysis, and scanning electron mi-
croscopy. CBZ samples were characterized by a unidirectional dissolution method mea-
suring disc intrinsic dissolution rate (DIDR) of CBZ raw material and initial drug release
in presence of the tablet fillers microcrystalline cellulose (MCC) and mannitol (30–90%
drug load). Furthermore, CBZ samples were recrystallized in 1% polyvinylpyrrolidone
ethanol solutions as an approach to reduce the sample variability. At the formulation level,
a high-dose CBZ tablet was developed with the aim of a tablet formulation that is robust
towards the variability in CBZ samples and that conforms to the USP requirements of CBZ
tablets for immediate release. Therefore, the superdisintegrant crospovidone (CrosPVP)
and the dry binder hydroxypropyl cellulose (HPC) were used, as both are reported to
inhibit transformation to CBZ dihydrate. The tablet filler was MCC.
All CBZ samples were of p-monoclinic form but differed in their polymorphic pu-
v
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rity, particle size, morphology, and intrinsic dissolution rate. The DIDR profiles showed
high variability among the CBZ samples. Two inflection points could characterize indi-
vidual transformation behavior of anhydrous CBZ to CBZ dihydrate. Presence of MCC
reduced drug release variability. Recrystallizing CBZ resulted in strongly reduced vari-
ability in dissolution and tablet strength and the transformation to CBZ dihydrate was
inhibited. However, particle size and morphology could not be controlled and drug re-
lease from binary mixtures with MCC presented deviation for one of the recrystallized
CBZ samples. For the tablet formulation the optimal condition was with 6% HPC and 5%
CrosPVP, where tablet properties of all CBZ samples were at least 70 N tablet hardness,
less than 1 min disintegration, and within the USP requirements for drug release. None-
theless, dissolution curves of the various CBZ samples differed. Excluding the additive
sodium laurylsulfate required by the USP monograph and analyzing the optimized tablet
formulation in water only, the dissolution curves of the various CBZ samples could not be
distinguished anymore (ANOVA, p > 0.05).
The impact of variability in CBZ raw materials on the drug release could be char-
acterized by an individual transformation behavior to the CBZ dihydrate. The applied
unidirectional dissolution method can be suggested as a straightforward monitoring tool
in preformulation studies conforming to the basic tenet of quality by design of FDA’s PAT
initiative. To allow a certain variability in CBZ raw materials, it is suggested to incorpo-
rate the excipients CrosPVP, HPC, and MCC into the design of a CBZ tablet formulation.
The strategy proposed of how to control the variability in CBZ samples includes the mon-
itoring at preformulation level combined with the design of a robust tablet formulation.
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Chapter 1
Theoretical Introduction
1.1 Preformulation Studies
Preformulation studies assess the physicochemical and biopharmaceutical properties of a
drug candidate. These properties show whether the drug candidate can be formulated and
they hint at potential problems in the drug performance and stability (Wells and Aulton,
2007). A thorough understanding of the drug properties is not only effective to reduce
drug development time and cost but is also crucial to the quality and safety of the drug
formulation. Therefore, preformulation is part of the official requirements for investiga-
tional new drugs and new drug applications by the Food and Drug Administration (FDA).
Also commercial requirements on drug delivery and dosage form can be a driving factor
for preformulation studies (Carstensen, 2002).
An overview on the studies performed in preformulation is shown in Table 1.1. For the
very first physicochemical studies the synthesis of a drug is not at its final scheme. After
scale-up less impurities and more relevant data can be obtained, only then preformula-
tion studies with higher precision make sense. Also studies on powder flow, compaction
properties, and excipient compatibility are important characteristics of a drug, however,
they are often analyzed at a later stage as only small amounts (mg) of the new drug are
available at earlier stages (Carstensen, 2002).
In case of abbreviated new drug applications (ANDAs), also called generics, the pre-
formulation studies are less intensive (FDA, 2007). Nonetheless, physicochemical proper-
ties of a drug can vary with the source and this variation may lead to irregular dissolution
behavior and clinical failures of the drug formulation (Wang et al., 1993; Meyer et al.,
1
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Table 1.1: Preformulation studies on a new chemical entity (NCE) according to Wells and
Aulton (2007).
Method Characterization
Spectroscopy Simple UV assay
Solubility Phase solubility, purity
— aqueous Intrinsic solubility,
pH effects
— pKa Solubility control, salt formation
— salts Solubility, hygroscopicity, stability
— solvents Vehicles, extraction
— partition coefficient Lipophilicity, structure activity
— dissolution Biopharmaceutics
Melting point DSC-polymorphism, hydrates,
solvates
Assay development UV, HPLC
Stability
— in solution and solid state Thermal, hydrolysis, oxidation,
photolysis, metal iones, pH
Microscopy Morphology
particle size
Powder flow Tablet and capsule formulation
— bulk density
— angle of repose
Compaction properties Excipient choice
Excipient compatibility
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1992, 1998; Davidson, 1995; Jung et al., 1997; Lake et al., 1999; Mittapalli et al., 2008).
1.1.1 Biopharmaceutics Classification System (BCS)
Important guidance for the formulation scientist is the Biopharmaceutics Classification
System (BCS) proposed by Amidon et al. (1995). It allows classifying drugs accord-
ing to their solubility and permeability (Figure 1.1). Furthermore, also the dose has to
be considered and therefore the FDA’s Center of Drug Evaluation and Research (FDA
CDER, 2009) defined the limits of the cut-off values for the BCS classes including the
drug dose. High solubility is defined as highest dose strength soluble in < 250 ml water
over a pH range of 1.0–7.5 and high permeability is defined as the absorption of > 90%
of an administered dose. The permeability is determined by a transport model and human
permeability results. The four BCS classes and their implications on the drug formulation
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Figure 1.1: Biopharmaceutics Classification System (BCS).
are discussed below (He, 2008):
• Class I: High solubility and high permeability of the drug, formulation for immedi-
ate drug release can be achieved without major challenge.
• Class II: An increasing number of the new chemical entities (NCEs) belong to this
class of low solubility and high permeability, where the bioavailability is dissolution
rate controlled. The challenge here is to overcome the low solubility.
The following options are available to improve solubility and thereby shift the drug
from class II to I: (1) salt formation, (2) particle size reduction, e.g., nano particles,
(3) metastable forms or amorphous state, (4) solid dispersion, (5) complexation,
e.g., with cyclodextrins, (6) lipid based formulations, e.g., self-emulsifying drug
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delivery systems, and (7) inhibition of precipitation / crystallization in the gastroin-
testinal tract (He, 2008).
• Class III: High solubility but low permeability of the drug, the oral route of admin-
istration can only be an option if prodrugs or permeability enhancers are available.
• Class IV: Solubility as well as permeability problems have to be addressed, it is most
difficult to achieve formulation from class IV drugs. Alternative delivery routes,
such as intravenous administration are often the only solution. In general, poor
permeability is rarely overcome by formulation approach.
The BCS has been refined to classify drugs according to their stage of development
(Papadopoulou et al., 2008). Whereas new chemical entities can be classified based on
the solubility-dose ratio and permeability estimates, marketed drugs can be classified by
mean dissolution time (MDT) and mean permeation time (MPT) of the gastrointestinal
wall. Zakeri-Milani et al. (2009) were able to classify drugs according to the BCS by
intrinsic dissolution rate, which is much faster obtained compared to the drug solubility.
Besides the BCS, also the metabolic or chemical instability of a drug may ask for
special formulation measures (He, 2008). Acid sensitive drugs could be protected by an
enteric coating, whereas gastrointestinal metabolism can be minimized by coadministra-
tion with enzyme inhibitor. Also the effect of the P-gp efflux pump can be minimized by
coadministration of an inhibitor. A further approach is to use carrier-mediated transport
by designing a prodrug that is a substrate for the transporter.
1.1.2 Preformulation Studies in the Context of the PAT-Initiative.
Preformulation studies have to be placed in the context of FDA’s initiative on Process An-
alytical Technology (PAT). It presents ”A Framework for Innovative Pharmaceutical De-
velopment, Manufacturing, and Quality Assurance” (FDA, 2004). The PAT initiative aims
for scientific understanding of the pharmaceutics of a drug candidate. Beginning with the
therapeutic objective, the patients, the route of administration, the pharmacokinetics and
pharmacodynamics, followed by the physicochemical and biopharmaceutical properties,
the drug formulation, and finally by the manufacturing processes. A drug formulation
and process should be achieved by design and its critical parameters should be known in
order to obtain a robust formulation with risk-based processing and built-in quality. The
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PAT initiative has the final aim of real time release of a product with predefined quality.
Therefore, a wide range of tools are necessary, tools for multivariate designs, to analyze
and control the processes, and tools for the data and knowledge management to ensure
continuos improvement.
In the following sections the preformulation topics polymorphism, morphology, sol-
ubility and dissolution rate are discussed in detail. In Section 1.5, the model drug carba-
mazepine (CBZ) is presented from several preformulation and formulation aspects. The
choice of excipients is addressed in the Section 1.8 on formulation studies.
1.2 Polymorphism
The term polymorphism has its origin in the greek words poly (πoλυ´) for ”many/ much”
and morphe¯ (µoρϕη´) for ”form” (Hilfiker, 2006). In chemistry, polymorphism is the
ability of a single molecule to crystallize in more than one distinct crystal architecture
(Rustichelli et al., 2000). This is analog to allotropy, the chemical term for elements that
crystallize in more than one crystal form. Among polymorphic forms there is always
one crystal form that is the thermodynamically most stable form. The comparatively less
stable form is called metastable and the absence of a crystal structure, meaning no long-
range order, is the amorphous state (Yu, 2001). An estimate of 90% organic compounds
can exhibit multiple solid states including crystalline polymorphs (about 50%), solvates
and noncrystalline forms (Stahly, 2007).
1.2.1 Crystal Lattice
The crystal lattice is the geometric arrangement of molecules in a crystal architecture. The
lattice parameters are described by the axes a, b, and c and the angles α, β, and γ of a unit
cell, the smallest unit of a crystal. There are seven different crystal systems, where the
cubic form presents the simplest cell with all axes of same length and all angles at 90°.
Some unit cells allow a further molecule to be positioned at the center, the base or at the
face of the unit cell and a total of 14 different lattices can be formed (Rodrı`guez-Hornedo
et al., 2007). Table 1.2 presents an overview on the possible crystal lattices and Figure 1.2
shows the p-monoclinic cell (monoclinic, simple) of carbamazepine as an example.
Crystal lattices can be further distinguished by the way they are formed. Packing
polymorphism refers to rigid molecules of fixed conformation that are packed in different
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Table 1.2: The seven crystal systems and their lattice parameters (Patterson and Bailey,
2007; Cullity and Stock, 2001).
System lattice parameters Bravais lattices
Triclinic α ￿= β, β ￿= γ, α ￿= γ simple (p)
a ￿= b, b ￿= c, a ￿= c
Monoclinic α = γ = 90°, β ￿= α simple (p)
a ￿= b, b ￿= c, a ￿= c base-centered (c)
Orthorhombic α = β = γ = 90° simple (p)
a ￿= b, b ￿= c, a ￿= c base-centered (c)
body-centered (i)
face-centered (f)
Tetragonal α = β = γ = 90° simple (p)
a = b ￿= c body-centered (i)
Trigonal α = β = γ ￿= 90°, ≤ 120° simple (p)
a = b = c
Hexagonal α = β = 90°, γ = 120° simple (p)
a = b ≤ c
Cubic α = β = γ = 90° simple (p)
a = b = c body-centered (i)
face-centered (f)
and additives with different crystal planes exposed on a
surface may be deduced from the shape of 2-D nuclei and
the kinetic anisotropy of the growth steps along crystal-
lographic directions. These techniques have been success-
fully applied for identifying the cryst l growth
mechanisms and kinetics of small molecules (71, 72, 89)
and proteins (91–94, 103).
CRYSTAL MORPHOLOGY
Crystal growth is governed by both internal and external
factors. Internal factors, such as the 3-D crystal structure
and crystal defects, will determine the nature and strength
of the intermolecular interactions between the crystal
surface and the solution; whereas external factors, such as
temperature, supersaturation, solvent, and the presence of
impurities, will affect the type of interactions at the solid–
liquid interface. The external shape or morphology of a
crystal is a consequence of the relative growth rates of the
faces, with the slowest growing faces impacting the crystal
morphology to the largest extent. Examination of crystal
morphology can reveal the molecular events occurring at
the crystal face–liquid interfaces during growth. Conse-
quently, even when morphology does not play a significant
role in quality control, studying it is essential to understand
the kinetics of crystallization (104).
Crystal Structure and Nomenclature
Crystals are comprised of the long-range, 3-D periodic
order of atoms held together through intramolecular
covalent and ionic bonds and intermolecular noncovalent
bonds. It is this long-range order that differentiates a
crystalline solid from a glassy or amorphous solid which
only demonstrates periodic order over a short range of
atoms. When a chemical entity exists in more than one
crystalline state—polymorph or solvate—each of these
forms will have a different arrangement of atoms in the
3-D structure. Consequently, in addition to different
physical and chemical properties, each of these forms has a
unique crystal structure.
Considering the crystal from a purely geometric view
(i.e., ignoring the exact arrangement of atoms), each
crystal can be described by the smallest repeating
translational unit in three dimensions, known as the unit
cell. A unit cell is a parallelepiped, which can itself be
described by six geometric measurements, three axes
(designated “a,” “b,” and “c”) and the angles between
these axes (designated “a,” “b,” and “g”), known as the
lattice parameters. The relationship between the six lattice
parameters defines to which of the seven unique crystal
systems a particular crystal belongs (Table 3). Whereas the
crystal system describes the geometric arrangement of the
unit cell, the space group describes the individual
translational and symmetrical relationships of the actual
atoms within the unit cell. The combination of the lattice
parameters, crystal system, space group and, ultimately,
the individual atomic coordinates defines each unique
crystal structure that exists for a crystalline solid. An
example of the unit cell (with lattice parameters) and
atomic coordinates for an anhydrous polymorph of the
drug carbamazepine is shown in Fig. 10. This polymorph
belongs to the monoclinic crystal system and the P21/n
space group (105).
Table 3 Crystal systems and lattice parameters
System Relationship between lattice parameters
Cubic a ¼ b ¼ c
a ¼b ¼g ¼ 908
Tetragonal a ¼ b – c
a ¼ b ¼ g ¼ 908
Orthorhombic a – b – c
a ¼ b ¼ g ¼ 908
Rhombohedral
(or Trigonal)
a – b – c
a ¼ b ¼ g – 908
Hexagonal a ¼ b – c
a ¼ b ¼ 908, g ¼ 1208
Monoclinic a – b – c
a ¼g ¼ 908 , b – 908
Triclinic a – b – c
a – b – g – 908
Fig. 10 Unit cell of anhydrous monoclinic carbamazepine.
Lattice parameters are marked with “a,” “b,” “c,” “a,” “b,” and
“g.” (From Ref. 105.)
a
b
c!
"
#
Crystallization: Significance in Product Development, Processing, and Performance 681
Figure 1.2: Unit cell of p- onoclinic carbamazepine (Rodrı`guez-Hornedo et al., 2007).
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arrangements, while conformational polymorphism refers to flexible molecules packed
with different conformations (Aaltonen et al., 2009).
1.2.2 Cocrystals and Solvates
Cocrystals or solvates are formed if a drug crystallizes together with guest molecules in
the unit cell. In cocrystals the different molecules are in solid state, whereas in solvates
they are in liquid state at ambient conditions. Also cocrystals and solvates can crystallize
into different polymorphic forms (Aaltonen et al., 2009).
Pharmaceutical Hydrates
Solvates with water are called hydrates. Crystallization of a drug molecule including
molecules of water leads to a higher stability in aqueous conditions. However, some hy-
drates are also kinetically stable at ambient conditions, which makes it possible to choose
the hydrate form for the drug development (Aaltonen et al., 2009). The water molecule
is of small size and it is capable of multidirectional hydrogen bonds. Hydrates can be
classified according to the arrangement of the water molecules (Vippagunta et al., 2001).
Class I hydrates show isolated water molecules. Class II hydrates are channel hydrates,
with either a clear two-dimensional arrangement of water molecules (class IIa) or with
nonstociometric amount of water, where the lattice expands at higher relative humid-
ity to include more water molecules. The class III hydrates show ion-associated water
molecules, this class of hydrates can only form drug molecules with metal-ions.
1.2.3 Transformation
As soon as a drug exhibits multiple solid-states the question of transformation arises.
Thermodynamics determine the relative stability of a solid-state and show which trans-
formation can take place at what conditions. The duration of a transformation, however,
is determined by the kinetics. Furthermore, a solid-phase does not transform without
molecular recognition. Therefore, transformation is governed by the three principles of
thermodynamics, kinetics, and molecular recognition as shown in Figure 1.3 (Rodrı`guez-
Sponga et al., 2004).
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!
Molecular Recognition 
Thermodynamics Kinetics 
Figure 1.3: Schematic diagram of the influences governing the solid-phase transforma-
tions (Rodrı`guez-Sponga et al., 2004).
Thermodynamics
The Gibbs’s phase rule (Equation 1.1) describes the relationship between the different
solid phases:
P + F = C + 2 (1.1)
where C is the degree of freedom and C and P are the number of components and phases
that exist in equilibrium, respectively. In a system of one single substance (C = 1) and
one polymorphic form (P = 1) the degree of freedom is F = 2. Therefore temperature and
pressure can both vary without changing the number of polymorphic forms. However,
two polymorphic forms of the same substance (P = 2, C = 1) can only coexist in equilib-
rium if either temperature or pressure is constant (F = 1). In this case a fixed transition
temperature (Tt) exists at atmospheric pressure (Giron, 1995; Grant, 1999).
Polymorphic transformation is the transition of one polymorphic form (I) to another
(II) at Tt. Depending on the melting point (Tm) of the forms two transition cases ex-
ist (Figure 1.4). If Tt < Tm, the transition is reversible and the polymorphic forms are
enantiotropic. In this case form I is thermodynamically more stable below Tt, whereas
above Tt form II is more stable. On heating, the transition is endothermic. In the other
case, if Tt > Tm, form I melts before the transition to form II, the transformation of form
II to I is exothermic and irreversible. The polymorphic forms are monotropic (Giron,
1995; Brittain, 1999). Enantiotropic and monotropic phase transition is not limited to
the solid-solid phase transition but include also the solid-liquid and solid-gas transition.
Phase diagrams of pressure versus temperature show the different transitions by equilib-
rium curves. Components with enantiotropic behavior (Figure 1.5a) present a liquid-vapor
equilibrium curve (CD) that meets the two solid-vapor curves after the point of intersec-
tion with the solid-solid equilibrium curve. There is a solid I – solid II equilibrium curve
(BF) and a reversible transition point I to II at a specific pressure. At the transition point,
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Figure 1.4: Free energy phase diagrams of polymorphic forms (I, II) in an enantiotropic
(a) and monotropic (b) system. Tt and Tm are the temperature of transition and melting,
and L is the melted phase (Zhang et al., 2004).
Figure 1.5: Temperature (T) – pressure (P) diagrams of a single substance with enan-
tiotropic (a) and monotropic (b) transition behavior (Giron, 1995).
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the free energy of the two forms is the same. AB shows the equilibrium of solid I – vapor,
BC the equilibrium solid II –vapor, and FC the equilibrium of solid II – liquid phase. In
case of components with monotropic behavior (Figure 1.5b) the liquid-vapor equilibrium
curve (ED) crosses the solid I – vapor curve (AE) before the points B and C. AB shows
the solid I – liquid equilibrium curve. The dashed curves represent equilibrium curves of
the metastable polymorphic form (Giron, 1995).
Kinetics
The kinetics influencing transformation depend on the energy barriers in the system. The
ability to undergo transformation and the relative thermodynamic stability of two poly-
morphic forms at constant pressure are given by the Gibbs free energy G [J] (Equation
1.2),
∆G = ∆H − T∆S (1.2)
whereH is the enthalpy [J], T the temperature [K], and S the entropy of system [JK−1]. A
difference in entropy ∆S reflects disorder and lattice vibration between two polymorphic
forms and difference in enthalpy ∆H is related to structural or lattice energy. The differ-
ence in Gibbs free energy ∆G shows the relative stability of the system by three distinct
situations: (1)∆G is negative and transformation can take place spontaneously and trans-
formation can continue as long as the free energy of the system is negative; (2) ∆G = 0,
the system is at equilibrium, both phases have the same free energy and no transformation
occurs; (3) ∆G is positive and transformation is not possible under the fixed conditions
(Rodrı`guez-Sponga et al., 2004).
The schematic diagram in Figure 1.6 shows the balance between kinetic and thermo-
dynamic factors by the hypothetical transition of two different solid phases I and II, where
phase I is the the more stable and less soluble form (GI < GII). The initial state (GX)
presents a negative ∆G for both forms, giving the thermodynamic driving force of the
transition. Although the absolute ∆G value is higher for solid phase I, the kinetic barrier
is smaller for form II (G∗I > G∗II) and transition my be in favor of form II (Rodrı`guez-
Sponga et al., 2004).
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bonds. A major conclusion of this work was to
establish a connection between the molecular assem-
bly processes that precede nucleation and the molec-
ular arrays in the crystal state:
Molecule X Molecular assembly X
Molecular network X Crystal
These findings motivated investigations on the supra-
molecular aspects of crystallization processes and
have found great utility in explaining the appearance
or disappearance of polymorphs [14], the role that
solvents and additives have on the directed nucleation
of polymorphs [17,27,54], and the kinetic stability of
metastable forms including amorphous solids [37].
The balance between the kinetic and thermody-
namic factors is illustrated by the free energy-reaction
progress diagram (Fig. 5) for a transition from the
initial state Gi, to two different solid forms A or B.
Form A is more stable and less soluble than B
(GA <GB). Gi may represent a supersaturated solution
in a multiple-component system, liquid or solid (mo-
lecular dispersion in amorphous system), or in the
case of a single component system an undercooled
liquid (melt) or an amorphous solid. The reaction
follows a path through an energy maximum between
the initial and final states. This resistance to the
transition from Gi to GA or GB arises because there
is an energy barrier for molecular diffusion, molecular
assemblies, and for the creation of an interface. For a
chemical reaction in a homogeneous system, this
energy maximum is the transition state and reflects
elementary reactions, bimolecular or trimolecular, that
yield products with new covalent bonds. In compar-
ison, a crystallization event or phase transformation
leads to heterogeneous systems in which a separate
new phase is created from a supramolecular assembly
by formation of non-covalent bonds.
A transition from the initial state Gi to state A or B
will depend on the energy barrier and according to the
reaction pathway in Fig. 5, the height of the energy
barrier for structure A (G*A!Gi) is greater than that
for B (G*B!Gi). Because the rate of nucleation is
related to the height of the energy barrier on the
reaction path, B will nucleate at a faster rate than A
even though the change in free energy is greater for A
(GA!Gi) than for B (GB!Gi). This is one of the
possible behaviors that could be observed in the order
of appearance of polymorphs and is referred to as
Ostwald’s law of stages. It states that ‘‘when leaving
an unstable state, a system does not seek out the most
stable state, rather the nearest metastable state which
can be reached with loss of free energy’’ [55].
However, Ostwald’s law of stages is not universally
valid because the appearance and evolution of solid
phases are determined by the kinetics of nucleation
and growth under the specific experimental conditions
[27,56,57] and by the link between molecular assem-
blies and crystal structure [16,58,59].
Crystallization involves both the nucleation and
growth of a phase. Because of the key role of
nucleation in the selective crystallization of poly-
morphs and the stabilization of metastable states, it
will be discussed in this review. Studies of growth
kinetics and crystal morphologies are useful in char-
acterizing intermolecular interactions on specific crys-
tal planes and as a consequence in identifying
additives or solvents that may preclude or promote
the crystallization of a particular polymorph. The
reader is referred to references that address these
concepts and strategies [15,17,18,27,54,60].
Fig. 5. Schematic diagram for a hypothetical transition from the
initial state, Gi, to two different solid forms A or B, with free
energies GA and GB. Form A is more stable and less soluble than B.
A transition from the initial state Gi to state A or B will depend on
the energy barrier and according to this reaction pathway the height
of the energy barrier for structure A, (G*A!Gi) is greater than that
for B, (G*B!Gi). Because the rate of nucleation is related to the
height of the energy barrier on the reaction path, B will nucleate at a
faster rate than A even though the change in free energy is greater
for A (GA!Gi) than for B (GB!Gi).
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Figure 1.6: Schematic diagram with the hypothetical transition reactions of two fferent
solid phases I and II; GX i the initial free ene gy, G∗ and G ar the maximal and minimal
energy states of each solid (Rodrı`guez-Sponga et al., 2004).
Transformation and the Underlying Mec anisms
Other than the above mentioned mechanisms of solid-solid (solid-state) and the solid-
liquid (melt) transition, also solution and solution-mediated transition are mechanisms
leading to transformation. In the latter mechanisms the influence of solvents and water
are the critical parameters. The four types of phase transition are discussed below (Zhang
et al., 2004):
• Solid-state transition occurs by (1) molecular loosening, followed by (2) an inter-
mediate solid solution, where (3) the new solid-phase can nucleate and (4) grow
(Vippagunta et al., 2001). The process can be induced by a change in temperature,
pressure, and relative humidity or by crystal defects and impurities.
• Melt transition occurs through the cooling of melted solid, another form can crys-
tallize. The final solid phase is determined by the rates of cooling, nucleation, and
crystal growth. Furthermore, impurities and excipients influence the crystallization
process.
• Transition in solution only occurs in the fraction of the drug that is dissolved. After
removing the solvent the substance may be present in a different solid state often
resulting in polymorphic mixtures.
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Table 1.3: Classification of phase transitions by type of transition and resulting solid phase
(Zhang et al., 2004).
Solid-state Polymorphic transition
Hydration/dehydration
Amorphous crystallization/ vitrification
Melt Polymorphic transition
Vitrification
Solution Polymorphic transition
Hydration/dehydration
Amorphous crystallization/ vitrification
Solution-mediated Polymorphic transition
Hydration/dehydration
Amorphous crystallization
Only from the metastable phases to the stable phases
• Solution-mediated transition occurs in direction of the phase of higher stability. The
mechanism is by (1) dissolution of the metastable phase, (2) nucleation of the sta-
ble phase, and (3) growth of the stable phase. This transformation is usually faster
than the solid-state transformation as the mobility necessary for the rearrangement
is provided by the solution. In general, nucleation or crystal growth are the rate-
controlling steps of the transformation. The kinetics of both are affected by solubil-
ity difference between the phases, contact surface (particle size), as well as tempera-
ture and agitation of the solution, and soluble impurities and excipients. Nucleation
is further influenced by the solubility and crystal growth by the solid/solvent ratio
(Vippagunta et al., 2001; Zhang et al., 2004).
Depending on the resulting solid phase the types of transition can be further classified
into polymorphic transition, hydration/dehydration, and vitrification. Table 1.3 provides
an overview (Zhang et al., 2004).
• Polymorphic transition is explained in the paragraph on polymorphic transformation
above. It is further interesting to note, that polymorphic transformation often occurs
over a sequence of phase transitions. A typical transition sequence in manufacturing
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could start with hydration and be followed by dehydrate or begin with vitrification
an proceed with a crystallization step.
• Hydration and dehydration are the transitions between crystalline anhydrates and
hydrates, and between lower and higher hydrates. The transitions depend on tem-
perature, pressure, and on the water activity. Water activity and transformation is
discussed below.
• Vitrification and amorphous crystallization is the transition between crystalline solid
and amorphous phase. Amorphous phase can convert to crystalline solid over all
types of transition. If temperature is above the glass transition and in presence of
moisture (plasticizer and anti-solvent) kinetics drive the system towards a faster
crystallization as both cases result in increased mobility. The transition of crystal-
line to amorphous phase (vitrification) is most likely to occur by a fast cooling or
solvent evaporation, as the crystal nucleation and growth are the slower processes.
Furthermore, also mechanical stresses on hydrates can easily lead to vitrification.
Water Activity
Water plays an important role in phase transition, especially if they are by solution or
solution-mediated. Khankari and Grant (1995) have described the thermodynamics of
the hydration - dehydration process. The equilibrium of the two phases is given by the
Equations 1.3 and 1.4,
A(S) +mH2O
Kh−−￿￿− A ·mH2O(S) (1.3)
Kh =
a[A ·mH2O(S)]
a[A(S)]a[H2O]m
(1.4)
where m is the number of moles of water taken up by 1 mol of anhydrate, a[A(S)], a[A ·
mH2O(S)], and a[H2O] are the thermodynamic activity of the anhydrate, the hydrate, and
the water, respectively. In which direction the transformation occurs is indicated by the
equilibrium constant Kh (Khankari and Grant, 1995).
Kh = a[H2O]
−m (1.5)
The equilibrium constant can be simplified as to Equation 1.5, if hydrate and anhy-
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drate are pure solids and are considered as one unit expressing thermodynamic activity
(Rodrı`guez-Sponga et al., 2004).
Water activity is a key parameter in the transformation process, the driving force for
the transition increases with the water activity aw (Equation 1.6), where xw is the mole
fraction of water in the system and γw the activity coefficient (Rodrı`guez-Sponga et al.,
2004).
aw = γwxw (1.6)
Water activity can be monitored by measuring the equilibrium relative humidity (ERH)
of a system (Equation 1.7),
ERH =
p
p0
= aw · 100 (1.7)
where p is the partial vapor pressure and p0 the vapor pressure of pure water. All parame-
ters are temperature dependent (Wrolstad et al., 2005).
Stability Issues in Pharmaceutical Solids
The stability of a system correlates well with the water activity, whereas the amount of
water may not always relate to the stability (Rockland and Beuchat, 1986). The molecu-
lar bases of moisture effects on drug stability is discussed in a review article by Ahlneck
and Zografi (1990). In case of excipient-drug interactions there are two mechanisms de-
scribing how water can be involved. The first mechanism is a redistribution of water by a
vapor phase from the excipients to the drug and the second mechanism is by direct phys-
ical contact of sorbed water located between the drug and the excipients. The amount of
freely available water in a system depends on temperature and pressure and is expressed
by the water activity. If water adsorbs to the drug its viscosity can change, molecular
mobility increases, and as a consequence leads to higher reactivity and instability. An
important study on stability issues related to moisture has been published by Du¨rig and
Fassihi (1993). They studied the destabilizing effects of moisture and elevated temper-
ature on the excipient-drug interaction. Interaction of the moisture-sensitive drug pyri-
doxal hydrochloride was tested with the following excipients: colloidal silicone dioxide,
anhydrous lactose, modified lactose (Ludipress®, BASF), corn starch, microcrystalline
cellulose (Avicel® PH101), methylcellulose, ethylcellulose, polymethacrylate derivates
(Eudragit® RSPM), stearic acid, and magnesium stearate. They suggested that hygro-
scopic excipients such as microcrystalline cellulose (MCC) can function as ”moisture
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scavengers”. Although MCC adsorbs a high amount of water, it appears to bind strongly
to the hydroxy groups in the cellulose, water was not freely available for the interaction,
thus the system presented a low water activity. Colloidal silicone dioxide and the various
cellulose derivates showed strong destabilizing effect.
A critical point are crystal defects in form of local disorder; they present an activated
state. These regions are able to take up more water compared to the intact crystal sur-
face and can thus show higher molecular mobility and less stability. Therefore, special
care has to be taken in many pharmaceutical processes causing crystal defects (Ahlneck
and Zografi, 1990). The following pharmaceutical processes have been associated with
possible phase transitions (Zhang et al., 2004):
• Size reduction by milling
• Size enlargement by granulation, i.e., wet granulation followed by drying, dry gran-
ulation, melt granulation, spray-dry and freeze-dry methods
• Granulation milling/sizing and blending; minimal risk
• Compaction and encapsulation; solid-solid transitions with minimal risk
• Coating by coating pans or fluid bed
1.2.4 Polymorphism and Physical Properties
The various solid phases exhibit different physical properties (Aaltonen et al., 2009), an
overview is given in Table 1.4. The question arrises, what is the impact of polymorphism
on the physical properties of the drug and can they be predicted?
Summers et al. (1977) proposed a semi-empirical rule to predict the effect of solid-
state on its compressibility and bonding strength by the crystal packing of the polymorphic
form. The more stable form is expected to have higher packing density and stronger inter-
particle bonds but with less ability to deform. Thus the weaker tablets are obtained. The
density rule by Burger and Ramberger (1979) also states that the polymorphic form with
the less densely packed molecules is the less stable form. However, the density rule
only applies for polymorphs where the molecular packing is dominated by van der Waals
interaction (Rodrı`guez-Sponga et al., 2004). Moreover, mechanical properties may only
be predicted taking also the crystal morphology into account (Roberts et al., 2000).
The effect of polymorphism on the final dosage form depends on the absolute differ-
ence among the physical properties of a polymorphic drug, the drug load, and the influence
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Table 1.4: Physical properties that vary among the different solid phases of a drug, table
taken from Aaltonen et al. (2009).
Packing properties Unit cell volume (crystalline forms only),
Density,
Hygroscopicity,
Refractive index
Thermodynamic properties Enthalpy, Entropy, Free energy,
Melting point,
Solubility
Spectroscopic properties Electronic transitions (UV-Vis spectra),
Vibrational transitions (IR and Raman spectra),
Rotational transitions (far-Infrared spectra),
Nuclear spin transitions (NMR spectra)
Kinetic properties Dissolution rate,
Rates of solid-state reactions,
Stability
Surface properties Surface free energy,
Interfacial tensions,
Crystal habit
Mechanical properties Hardness, Tensile strength,
Compactibility, Tableting,
Flowability
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of the manufacturing on polymorphic stability. To ensure a reproducible bioavailability of
the dosage form, the thermodynamically most stable polymorph should be selected. The
most stable polymorph shows the lowest risk of transformation during manufacturing and
storage under real-world conditions. Only if a drug cannot be crystallized or if tremen-
dous advantages in dissolution are observed also the amorphous or the metastable state
may be selected. However, metastable and amorphous solids need to be kinetically stabi-
lized by excipients or special processing (Singhal and Curatolo, 2004). Also the hydrate
may be selected for the dosage formulation, however also here mechanical, thermal, and
chemical stresses can induce phase transition and thereby threaten the stability of the final
drug formulation (Rodrı`guez-Sponga et al., 2004).
1.2.5 Analytical Techniques
Several analytical techniques are available to study the solid-state properties of polymor-
phic drugs. They can be grouped according to the aspect of solid-state properties they
characterize (Tables 1.5–1.8). Table 1.5 gives an overview on crystallographic analyses
by X-ray diffraction and Table 1.6 shows the thermal methods that allow analyzing phase
transitions. The spectroscopical methods analyzing molecular motion, chemical environ-
ment of the molecules, and intramolecular and lattice vibrations are presented in Table 1.7,
and the microscopical methods to study morphology are shown in Table 1.8 together with
other methods such as the density measurement. In general, a combination of techniques
is selected, as there is no superior method for all solid-state properties (Chieng et al.,
2011). Although the tools available for solid form screening have evolved drastically over
the past decade, they do not replace basic thermodynamic understanding in successful
data analysis (Aaltonen et al., 2009). The major challenges remain the differentiation be-
tween two structurally similar polymorphs, the quantitative analysis of a single-solid state
in mixtures of polymorphs, and the quantitative determination of amorphous or crystalline
state in a system (Vippagunta et al., 2001).
X-ray Powder Diffraction (Suryanarayanan and Rastogi, 2007)
X-ray powder diffraction (XRPD) is the ”gold” standard for qualitative and quantitative
solid-phase identification. The specific diffraction pattern of a pharmaceutical solid is
generated by directing X-rays at a single crystal or at a flattened surface of a tightly packed
powder sample, the rays are then diffracted from the crystal lattice and scattered in all
directions. At some directions the scattered beams become in phase and are reinforced.
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Table 1.5: Analytical methods to study the crystalline structure; (+) advantages and (–)
disadvantages (Chieng et al., 2011; Zhang et al., 2004).
Crystallography – X-ray Diffraction
X-ray powder diffraction (XRPD) (+) ”gold” standard for phase identification
(+) qualitative and quantitative
(+) non-destructive
(–) preferred orientation
Single crystal X-ray diffraction (+) ultimate phase identification
(+) solves the crystal structure
(+) non-destructive
(–) a single crystal of > 0.1 mm necessary
Small angle X-ray scattering (+) probes structures in nm–µm range
(+) non-destructive
(–) relatively long data acquisition time
(–) needs advanced interpretation of the data
This phenomenon is described by the Bragg law (Equation 1.8),
nλ = 2d sin θ (1.8)
where λ is the angle of incident on the sample, n the order of reflection as integer number,
and d the distance between the successive planes in the crystal lattice [A˚]. Each crystalline
compound shows a distinct peak pattern and also solvates can be identified, as long as their
crystal lattices differ. Disordered lattices (amorphous powder) are represented in the form
of a characteristic broad halo in the XRPD pattern.
A powder sample often exists as an intermediate state of ordered (crystalline) and
disordered lattice. By Equation 1.9 the proportion of crystalline state can be determined
as the degree of crystallinity (xcr) in [%],
xcr =
Ic100
Ic +
qIa
p
(1.9)
where Ic and Ia are the intensities measured for the crystalline and amorphous state, and
p and q are proportionality constants. The intensities are best measured as integrated line
intensity (area under the curve) and not as peak intensity (peak height).
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Table 1.6: Analytical methods to study phase transitions; (+) advantages and (–) disad-
vantages (Chieng et al., 2011; Zhang et al., 2004).
Thermal Methods
Differential scanning calorimetry (+) information on phase transition
(DSC) (+) information on interaction with excipients
(+) qualitative and quantitative
(+) small sample size
(–) no information on the nature of
the transformation
(–) no separation of thermal events at
the same temperature
Modulated temperature DSC (+) improve clarity of small (i.e., Tg) and
overlapping thermal events
(–) more experimental variables (i.e.,
amplitude and period settings)
(–) relative long data acquisition time
Thermogravimetric analysis, (+) quantitative information on stoichiometry
Dynamic vapor sorption of solvates/hydrates
(+) small samples size
(–) interference of water-containing excipients
(–) samples is destroyed during analysis
Isothermal microcalorimetry (+) high sensitivity
(+) qualitative and quantitative
(+) non destructive
(+) stability studies directly under the
storage conditions
(–) low specificity
(–) large amount of samples necessary
Solution calorimetry (+) qualitative and quantitative
(–) low specificity
(–) large amount of samples necessary
(–) sample not recovered
(–) long measurement time
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Table 1.7: Analytical methods to study solid phase at particulate level; (+) advantages and
(–) disadvantages (Chieng et al., 2011; Zhang et al., 2004).
Molecular Motion - Vibrational Spectroscopy
Mid-IR: (+) small sample size,
FT-IR (Fourier transformed infrared), (+) relatively fast methods,
DRIFTS (diffused reflectance infrared (+) spectral libraries available
transmission spectroscopy), (–) possible solid-state transformation
ATR (attenuated total reflectance) in sample preparation
(–) environmental humidity interference
(+) no sample preparation (ATR)
Raman (+) small sample size, no preparation,
(+) non-destructive
(–) local heating of sample
(–) photodegradation
Near infrared (NIR) (+) non-invasive and fast
(+) no sample preparation
(–) low sensitivity, chemometrics
Chemical Environment at Molecular Level
Solid-state nuclear magnetic resonance (+) non-destructive phase identification
(+) qualitative and quantitative,
(+) no calibration
(–) relative long data acquisition time
(–) relatively expensive
Intramolecular and Lattice Vibrations
Far-infrared: (+) small samples (5–40 mg)
terahertz pulsed spectroscopy (+) fast data acquisition (milliseconds)
(–) spectrum affected by water
(–) relatively expensive
(–) pellet compression needed
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Table 1.8: Analytical techniques to study morphology, water content, surface area, and
true density; (+) advantages and (–) disadvantages (Chieng et al., 2011; Zhang et al.,
2004).
Morphology
Polarized light microscopy (PSM) (+) small sample size
(+) easy to use
(+) very little sample preparation
(–) no quantitative information
PSM with hot/cryo/freeze drying stage (+) temperature variability
(–) careful sample preparation needed
Scanning electron microscopy (SEM) (+) high resolution, small sample size
(–) sample preparation, vacuum setting
Bulk level/Other
Karl Fischer titration (+) water content (adsorbed or hydrate)
with high sensitivity
(+) rapid analysis
(–) sample must dissolve in the medium
(–) sample size > 50 mg is preferred
Brunauer, Emmett and Teller method (+) non-destructive
(+) simple and straightforward method
(–) degassing step required
(–) sample size 50–100 mg
Density (gas pycnometer) (+) simple and straightforward method
(+) non-destructive
(–) degassing step
(–) sample size > 50 mg is preferred
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Drug – excipient interactions are easily detected by XRPD if all components are crys-
talline. The diffraction pattern of a powder mixture is the summation of diffraction pattern
of each individual component. Interaction is visible as extra peaks or amorphous product
is detected by the broad halo (Suryanarayanan and Rastogi, 2007). XRPD can also give
the percentages of each component although the limit of detection varies strongly and can
be as high as 15% (Vippagunta et al., 2001).
Most pharmaceutical compounds are organic molecules and they can be a challenge to
the XRPDmeasurement because organic compounds tend to crystallize with crystal lattice
of large d-spacings (accuracy in XRPD ↓), with unit cells of lower symmetry (complex
patterns), and with low mass attenuation coefficients (beam transparency errors ↑).
A further challenge is the sample preparation. Non-random distribution, referred to as
preferred orientation, leads to inaccurate peak pattern because the system sees a secondary
cell structure. Preferred orientation can be reduced by particle size reduction. However,
grinding may result in reduced crystallinity and in small particles, both leading to a peak
broadening in the XRPD pattern.
Differential Scanning Calorimetry (Clas et al., 2007).
Differential Scanning Calorimetry (DSC) is the analytical technique of choice to de-
termine melting points, purity, and glass transition temperature (Tg) of pharmaceutical
compounds. Qualitative and quantitative information can be gained on the physical and
chemical changes of a sample. These changes are measured as a function of time and
temperature.
DSC instruments present a closed system where the internal energy dU can not be
created or destroyed. The system is governed by the First Law of Thermodynamics,
dU = dq + dw (1.10)
where dq and dw are the heat transferred and the work done to the system. At constant
pressure ( )p, the system experiences energy exchange with the environment in form of a
change in enthalpy dH ,
(dH)p = (dU)p + (PdV )p (1.11)
where PdV is the change in amount of work. As a approximation for solids and liquids,
the change in volume can be neglected. If the system is also at zero net work, Equa-
1.2. POLYMORPHISM 23
tion 1.11 reduces to
(dH)p = (dU)p = (dq)p (1.12)
In this case, the heat flow (dq) in the DSC heating a sample is equal a change in enthalpy.
A change in enthalpy is further related to the heat capacity Cp,
dq = dH =
T1￿
T2
CpdT (1.13)
where the increase in temperature (T1 to T2) is a function of the heat capacity of the
system.
There are two types of instrumentation for DSC, a heat-flux and a power-compensated
DSC (Figure 1.7). The samples S is heated in an aluminum pan together with an empty
pan as the reference R. In case of heat-flux DSC, sample and reference are heated in a
single furnace and the temperature difference between sample and reference is measured
by heat-flux. In case of power-compensated DSC, sample and reference are heated by
dual heaters and the difference in power consumption to keep sample and reference at the
same temperature is measured. The power-compensated DSC has a higher sensitivity and
allows analysis at higher temperatures.
function of sample temperature [Fig. 1(b)]. Heat flux DSCs uti-
lize a single furnace. Heat flows into both the sample and the
reference material via an electrically heated constantan thermo-
electric disk5 and is proportional to the difference in output of
the two thermocouple junctions [Fig. 1(c)]2,5–8.
Modulated differential scanning calorimetry (MDSC) is a
similar technique to conventional DSC because it also measures
the difference in heat flow from a sample and a reference ma-
terial as a function of time and temperature6,9–11. Modulated
differential scanning calorimetry is based on the conventional
heat flux DSC furnace design. In modulated DSC, a controlled
temperature modulation is overlaid on the conventional linear
heating or cooling rate to produce a continuously changing
non-linear sample temperature.This can be viewed as running
two experiments at once.The first experiment consists of heat-
ing the sample at a constant linear rate to obtain the total heat
flow, much like conventional DSC. During the second experi-
ment, the heat capacity component of the heat flow is obtained
by applying a controlled oscillating temperature modulation
with a zero net temperature-change during the course of the
modulation. Selection of the average heating rate, the period of
modulation and the temperature amplitude of modulation are
three important variables that are modified to optimize the ex-
perimental parameters.
The total heat flow is comprised of a heat capacity compo-
nent and a kinetic component. Unlike conventional DSC, MDSC
determines the total heat flow and the heat capacity component
of heat flow. As the heating rate continuously changes during
the modulation cycle, the heat capacity of the sample is deter-
mined by dividing the modulated heat flow amplitude by the
modulated heating rate amplitude.The measured amplitudes of
the sample temperature and heat flow modulation are com-
pared with a reference wave of the same frequency.The kinetic
component of heat flow is obtained from the difference of the
total heat flow and the heat capacity component of the heat
flow.
Dynamic differential scanning calorimetry (DDSC) provides
heat capacity and kinetic component information in a manner
different from MDSC.The temperature program consists of an
‘Iso-Scan’, in which the traditional heating rate program 
is combined with several isothermal holds or a ‘Heat-Cool’
program, which consists of combined heating and cooling
temperature programs.The user selects the appropriate method
depending on the type of experiment being performed12.
The complex heat capacity may be calculated from the dy-
namic component of the sample response. The complex heat
capacity, Cp*, is the vector sum of the storage, Cp!, and loss
heat capacity, Cp!!. It is generally the same as the storage heat
capacity, except in the melting region where heat losses domi-
nate.The storage heat capacity is associated with molecular mo-
tions within the sample in a manner similar to the storage
modulus in dynamic mechanical measurements. The out-of-
phase component, the loss heat capacity, Cp!!, is associated
with the dissipative properties of the material.The loss heat ca-
pacity is out-of-phase with the temperature change because
heat flow has resulted in a structural change in the material.The
loss tangent is the ratio of the loss heat capacity to the storage
capacity and is a measure of the relative importance of each
component12.
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Figure 1. Schematic diagrams of (a) differential thermal analysis (DTA),
(b) power-compensated differential scanning calorimetry (adapted
from Wendlandt63), and (c) heat-flux differential scanning calorimetry
cells (DSC). (Adapted from a brochure from TA Instruments Systems,
New Castle, DE, USA.)
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Figure 1.7: Schematic diagram of heat-flux (a) and power-compensated (b) DSC adapted
from Clas et al. (1999).
The physical and chemical changes occurring in DSC measurements give thermal
events in form of enthalpies. They may stem from diverse thermal reactions and they can
be grouped into exothermic or endothermic transitions; an overview is given in Table 1.9.
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Table 1.9: Enthalpic transitions observed by DSC (Clas et al., 1999).
Endothermic Exothermic
Fusion Crystallization
Vaporization Condensation
Sublimation Solidification
Desorbtion Adsorption
— Chemisorption
Desolvation Solvation
Decomposition Decomposition
Reduction Oxidation
Degradation Degradation
— Curing of resins
Glass transition —
(baseline shift)
Relaxation of glass —
1.3 Morphology
A crystalline solid may exhibit different crystal or particle shape although same polymor-
phic form is specified. The external shape of a crystalline compound is referred to as the
crystal morphology. There are numerous crystal morphologies such as acicular, dendritic,
cubic, fiber-like, plate-like, prismatic, rod-shaped, needle-like, as aggregates, or with crys-
tal defects, to name a few (Rodrı`guez-Hornedo et al., 2007). In a review on the solid-state
properties of powders York (1983) showed that variations in crystal morphology influence
the processing and product development. Morphological changes can effect particle size
distribution, powder flow, mixing and agglomeration, dissolution, compression, and tablet
hardness.
The crystal habit may also be engineered to improve the solubility and the dissolution
rate of a drug. The bigger the surface area and the smaller the particle size, the better the
wettability and the dissolution rate of the drug (Blagden et al., 2007).
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1.3.1 Crystal Habit
The final crystal shape is given by several parameters. The polymorphic form is deter-
mined by the geometric arrangement of the molecules to a specific crystal lattice, the unit
cell. Further, the unit cell can be described by crystal planes, the faces of a crystal. When
a crystal grows, not all crystal faces grow the same and a distinct crystal habit is obtained.
Crystal faces can be described by the Miller indices h, k, and l. They are the intercept
of the planes with the unit cell axes and they are given as reciprocals and even numbers. If
a plane is parallel to a crystal axis the Miller index is zero. Describing a single plane the
Miller indices are written in parenthesis (hkl), while describing a whole family of faces
they are written in braces {hkl}. An example on how the faces can grow into different
crystal habit is shown in Figure 1.8 (Rodrı`guez-Hornedo et al., 2007).
morphology of paracetamol (70). Recently, there has been
much work exploiting the selective interaction of additives
with crystal faces in order to “tailor” the crystal
morphology to a more favorable habit (122).
Monitoring the changes in morphology by visual
examination can be a powerful tool when troubleshooting
formulation problems. The appearance of crystals with
different morphology is indicative of changes in the
processing conditions, such as in the degree of super-
saturation, rate of heating or cooling, or the presence (or
absence) of impurities. Changes in morphology could also
be the first suggestion of the appearance of a new crystal
form (polymorph or solvate). Characterization techniques,
such as x-ray powder diffraction, thermal analysis, or
spectroscopy, can be used to identify the appearance of new
forms first identified by observing changes in morphology.
Morphology Prediction
and Other Computational Strategies
With the objective of predicting the morphology of
crystals, several models have been developed. One of the
first models for predicting crystal morphology is based on
the general Law of Bravais (123), which states that crystal
faces with the most morphological importance have the
greatest interplanar distance, dhkl. The Bravais–Friedel
Donnay–Harker (BFDH) model predicts that the morpho-
logical importance of a face is proportional to the
interplanar spacing corrected for extinction conditions and
translational repetitions of the crystal space group
(123–125). Consequently, the growth rate of any given
face is inversely proportional to its interplanar spacing:
Ghkl / 1
dhkl
ð16Þ
where Ghkl is the growth rate of a face and dhkl is the
interplanar spacing. This model has been used to predict
the morphology for many small molecules including
compounds of pharmaceutical interest. (3, 73, 120,
126, 127). The observed (Fig. 13a) and predicted mor-
phology (Fig. 13b) of carbamazepine dihydrate shows that
the BFDH model correctly predicts the axis of elongation
as well as the appearance of the {002}, {200}, and {111}
faces. This model, however, did not correctly predict the
aspect ratio of the crystal because it is based on geometric
parameters solely. It considers neither molecular inter-
actions nor the effect of anisotropic forces, such as
intermolecular hydrogen bonding or p–p interactions.
Early work by Hartman and Perdok (128) described
crystal growth in terms of the formation of strong bonds
between neighboring crystallizing units. Uninterrupted
straight chains of these bonds were classified as periodic
bond chains (PBC). This theory led to the classification of
three types of crystal faces: F-faces (flat), S-faces (stepped),
and K-faces (kinked), based on the number of PBCs in a
slice thickness, dhkl. K-faces, which had no PBCs present in
a slice were shown to be the fastest growing, whereas the F-
faces, which had two or more PBCs, grew the slowest.
Consequently, the F-faces were the most morphologically
important faces. The PBC theory ultimately led to the
development of the attachment energy (AE) model
(122, 129) which states that the growth rate of a face,
Ghkl, is proportional to its attachment energy, Eatt:
Ghkl / Eatt ð17Þ
where the attachment energy can be defined as the energy
released when one growth layer (dhkl) crystallizes on the
surface of a crystal. The attachment energy can be calcu-
lated as the difference between the energy of crystallization
(or lattice energy) and the energy of a growth slice:
Eatt ¼ Ecrystal $ Eslice ð18Þ
The values for the energy of crystallization can be
calculated by summation of the intermolecular interactions
Fig. 11 Two-dimensional representation of the effect of sodium
taurocholate (STC) on the crystal morphology of dihydrate
carbamazepine (CBZ(D)). STC interacts specifically with the
{111} faces of CBZ(D), resulting in inhibition of the growth of
those faces and changing the morphology from needles to prisms.
STC interaction with
CBZ(D) {111} faces
STC interaction with
CBZ(D) {111} faces
b
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Figure 1.8: Crystal growth in favor of one crystal face leads to a distinct crystal habit: CBZ
dihydrate shows much stronger growth from the {002} face than fro the {111} faces if
crystallized in presence of sodium taurocholate (STC); figure a cording to R drı`guez-
Hornedo et al. (2007).
1.3.2 Crystallization
When studying the crystal morphol gy of drug it is further important to understand the
process of crystallization. Crystallization starts with aggregation of mole ules to prenu-
cleation clusters. A nucleus of certain size existing during sufficient time may grow into
a macroscopic crystal. Accor ing to Rodrı`guez-Hornedo et al. (2007) the rate and mech-
anism of crystallization from liquid s lution is influenc d by a wide range of facto ,
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namely:
• Solubility of the crystallizing compound
• Solvent
• Supersaturation of components participating the crystallization process
• Rate at which a supersaturation is created, e.g., cooling or pH-change
• Temperature
• pH
• Soluble additives and impurities
• Reactivity of surfaces toward nucleation
• Diffusivity or viscosity
• Volume of solutions
Supersaturated states of drug or excipients may easily occur during pharmaceutical
processing and drug delivery and thus facilitate crystallization. Furthermore, excipients
can function as impurity and influence the habit of the crystal formed. A change in mor-
phology could have a negative effect on processing and delivery (Rodrı`guez-Hornedo
et al., 2007).
Nucleation. The step of nucleation can occur over a homogeneous or over a surface-
catalyzed mechanism. Homogeneous nucleation is the usual mechanism in small scales
of less than 100 ml. The surface-catalyzed nucleation can occur either catalyzed by the
surfaces of the crystallizing solutes (secondary nucleation) or as a so-called heterogeneous
nucleation catalyzed by interfaces or surfaces other than the crystallizing solutes. Hetero-
geneous nucleation is of practical importance in drug formulations, as excipients may
provide the surfaces or interfaces necessary to promote nucleation. Furthermore, hetero-
geneous nucleation occurs at low driving forces and the favorable dissolution properties
of a metastable drug may be lost because of fast nucleation of the stable form (Rodrı`guez-
Hornedo et al., 2007; Blagden et al., 2007).
Crystal Growth. If a nucleus overcomes a certain critical cluster size it is stable enough
and can grow into macroscopic crystals. The process of crystal growth can be described
by four stages: (1) the growth unit is transported to the impingement site, (2) it adsorbs,
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(3) the growth unit diffuses from the impingement site to the growth site, and (4) is in-
corporated into the space lattice to form the crystal structure. The mechanism of crystal
growth can be volume-diffusion controlled or surface-integration controlled. Further, the
surface-integration can occur as continuous crystal growth or by layers. The process of
crystal growth in influenced by the general factors mentioned above. However, also the
three dimensional structure and crystal defects can influence the growth rates and thus
determine the interaction between surface and solution at a molecular level (Rodrı`guez-
Hornedo et al., 2007).
1.3.3 Analytical Techniques
Crystal morphology is best assessed by microscopical methods like scanning electron
microscopy.
Scanning Electron Microscopy (SEM)
Electron microscopy uses electrons instead of light for the imaging, however, the same
principles as for any light microscopy apply.
The Abbe’s equation determines the resolving power as the minimum resolvable sep-
aration distance d0 in [nm],
d0 =
0.61 · λ
n sinα
(1.14)
where λ is the wavelength of the light, n the refractive index of the medium between sam-
ple and objective, and α the half-angle subtended by the objective at the sample (Schmidt,
2007).
The dual character of an electron to move as a particle or to radiate with a distinct
wavelength was shown by Louis de Broglie (Equation 1.15),
λ =
h
mυ
(1.15)
where λ is the wavelength [nm], h the Planck’s constant, m the mass of the electron, and
υ the velocity of the electron. This phenomenon is the basis for the electron microscopy,
where on incidence of a primary electron beam a current of secondary electrons is re-
flected that can be collected for the imaging (Schmidt, 2007).
The visualization of a sample at high resolution is of great interest to study crystal
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morphology. In pharmaceutical technology also the visualization of powder mixtures,
granules, or tablet surfaces are essential to a deeper understanding of the sample behavior
in drug development and drug delivery (Schmidt, 2007).
Powder Flow
Highly dependent on the particle morphology is the powder flow, an important parameter
in pharmaceutical solids. Only powder with good flowability reaches uniform dosing in
tablet press, by a good material flow from tablet hopper to the die. Flowability can be
evaluated by the Hausner Ratio HR (Equation 1.16) and the Compressibility Index CI [%]
also named Carr Index (Equation 1.17),
HR =
ρt
ρb
(1.16)
CI =
ρt − ρb
ρt
· 100 (1.17)
where ρb is the bulk density and ρt is the tapped density in [g/cm3]. The Hausner ratio
shows a cut-off value of 1.25. Powder with a Hausner ratio below 1.25 indicates good
flow, while poor flow is indicated by a Hausner ratios above 1.25. The compressibility
index can classify powder flow according to Table 1.3.3 (USP 31, 2008).
Table 1.10: The classification of powder flow by the Compressibility Index (USP 31,
2008).
Compressibility Index [%] Flow Character
≤ 10 excellent
11 – 15 good
16 – 20 fair
21 – 25 passable
26 – 31 poor
32 – 37 very poor
> 38 extremely poor
1.4. SOLUBILITY AND DISSOLUTION RATE 29
1.4 Solubility and Dissolution Rate
Solubility is defined as the concentration of drug dissolved per amount of solvent medium
at the equilibrium. It is temperature and pressure dependent. In case of poorly soluble
drugs a dissolution rate can assess the relative solubility of polymorphs much faster than
over the time consuming equilibration process for the solubility assessment and with less
medium. The dissolution rate is defined as the amount of solid drug dissolving per time
unit under controlled liquid-solid interface, media condition, and temperature (Brittain
and Grant, 1999). The Noyes-Whitney Equation (1.18) describes the process as a disso-
lution of a planar surface,
dC
dt
=
DS
V h
(Cs − C) (1.18)
where, C is the concentration of the solute in time t [mg/ml/min], D the diffusion coeffi-
cient, S the surface area [cm2], V the volume of dissolution media [ml], h the thickness of
the diffusion layer [mm], and Cs is the saturated concentration [mg/ml]. The dissolution
is described as mass transfer through a stagnant film by diffusion, where the gradient is
the most important driving force (Wesselingh and Frijlink, 2008). A schematic view of
the diffusional dissolution process is shown in Figure 1.9.
!"
#$
%&
&
&
&
&
&
&
&
%$''(!$")&
#*+,-&
.&
/012&
/&
&
&
%$!!"#(3$")&
4,%$*!
!
Figure 1.9: Dissolution principles of a solid drug by diffusion through a stagnant film
(diffusion layer); schematic figure adapted from Wang and Flanagan (2008).
In perfect sink, the concentration in the dissolution media is much less than in sat-
urated state (Csat ￿ Csol). In experimental conditions, the volume of the dissolution
media should be at least tree times as large as for the saturated state of the solid analyzed
(Hanson and Gray, 2004a).
A common method to characterize pharmaceutical solids is by intrinsic dissolution
rate (IDR). The mathematical expression describing IDR can be deducted from Equa-
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tion (1.18). If Cs ￿ C, and D/h is expressed as intrinsic dissolution constant k, Equa-
tion (1.18) can be written as,
dC
dt
=
S
V
· k · Cs (1.19)
and rearranged to Equation (1.20), the general expression for IDR (Kobayashi et al., 2000;
Sethia and Squillante, 2004),
IDR =
dC
dt
· V
S
= k · Cs (1.20)
where (dCdt ) is the amount of drug dissolving over time, (S) the surface area of the compact,
V the volume of the dissolution media, (k) the intrinsic dissolution constant, and (Cs) the
solubility of the drug. Intrinsic dissolution curves are linear and the slope is the amount
of drug dissolved per cm2.
The IDR depends on the solid state properties of the drug, e.g., crystalline state, mor-
phology, particle size, and particle surface area. Furthermore, experimental conditions
such as disk rotation (hydrodynamics), fluid viscosity, dissolved gasses, temperature, and
pH may influence the dissolution rate (Hanson and Gray, 2004b).
Under fixed experimental conditions IDR value is characteristic for a given substance.
Compared to the equilibrium solubility IDR is a rate phenomenon and may therefore
correlate better with the in vivo dissolution dynamics. IDR also presents an alternative
measure to the equilibrium solubility to classify drugs, where an IDR < 0.1 mg/min/cm2
classifies for low solubility (Yu et al., 2004; Zakeri-Milani et al., 2009). Lately, Tsinman
et al. (2009) were able to determine IDR with sample quantities of 10’000-fold smaller
than by the traditional rotating disk method using powder-based IDR measurement and
bioexponential equations. Their findings promote IDR measurements as the method of
choice to assess drug solubility in early drug development.
1.4.1 Disk Intrinsic Dissolution Rate (DIDR)
Intrinsic dissolution rate is measured from a constant surface area. The powder sample
is compressed into a pellet and presented to the dissolution media in a disk allowing
contact to one surface only. The settings for DIDR measurements can be in two modes,
by a static disk and a paddle to stir the dissolution medium or by a rotating disk. In this
PhD study a commercially available dissolution machine (SotaxAT7smart) was modified
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at its rotating basket unit to a rotating disk unit. Powder samples were compacted with
controlled compaction parameters externally and placed into the sample holder (disk)
after elastic recovery. The compacts were embedded with melted paraffin wax so only
one surface was available to the dissolution medium (Figure 1.10).
Sample holder !
Paraffin layer !
Compact !
Figure 1.10: Schematic picture of a rotating disk apparatus to measure IDR. Modified
rotating basket mode as developed within the PhD studies.
DIDR was reported to increase directly proportional to the square root of the rota-
tional speed, whereas the distance between disk and paddle has no effect (Yu et al., 2004).
Further, the robustness of the values measured decreases with the rotation speed and with
time (Mauger et al., 2003).
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1.5 Carbamazepine (CBZ)
Carbamazepine, 5H-dibenz[b,f]azepine-5-carboxamide (Figure 1.11), and its antiepileptic
activity was discovered by Schindler and Ha¨fliger (1954). By now Carbamazepine (CBZ)
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perpendicular to the molecular axis. Estimates for 
libration corrections to be added to the apparent 
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Abstract. C15H~2N20, M r = 236.27, monoclinic, 
P21/n, a = 7 .537( I ) ,  b = 11.156(2),  c = 
13.912 (3)/k, fl = 92-86 (2) °, Z = 4, O m = 1.34 (2) 
(flotation), D x = 1.343 Mg m -3, g(Mo K~t) = 0.080 
mm-~; R = 0.040 for 1751 observed reflections. In the 
tricyclic framework of carbamazepine, the central 
azepine ring has a boat conformation and the dihedral 
angle between the planar benzene moieties is 126.6 ° . 
Intermolecular hydrogen bonding between carboxa- 
mide groups forms centrosymmetric dimers. (CAS 
Reg. No. 298-46-4.) 
Introduction. Carbamazepine (1) has clinical use 
because of its analgesic and anticonvulsant properties 
and is prescribed in the treatment of epilepsy and 
trigeminal neuralgia. X-ray structure determinations 
are used in pharmacological studies aimed at relating 
the molecular conformation of a given tricyclic drug to 
* From a dissertation to be submitted to the Graduate School, 
The Catholic University of America, Washington, DC 20064, in 
partial fulfillment of the requirements for the PhD degree in 
chemistry. 
its physiological activity at the receptor site. In 
addition, accurate cell dimensions and molecular 
parameters are needed for (1) as it has been reported to 
exist in polymorphic forms (De Camp, Brannon & 
Maienthal, 1981). Here we report the results of a 
single-crystal X-ray analysis on carbam zepi  ob- 
tained by recrystallization from absolute eth nol. 
H H 
I 
o~CxNI.12 
(1) 
At the proof stage, it was discovered that this 
paper was being processed simultaneously with an 
independent structure determination of carbamazepine 
(Reboul, Cristau, Soyfer & Astier, 1981). As the co- 
ordinates of the latter structure can be transformed to 
ours (x' = x -  z , y '  = -! + y, z' = ! -  z), the com- 
pounds are the same and not polymorphic substances. 
A short comparison is given at the end of this paper. 
Figure 1.11: Carbamazepine (Himes et al., 1981).
is a well established drug on the international market and several generics are available.
CBZ is poorly soluble and with a dissolution controlled bioavailability, it is a class II
according the Biopharmaceutics Classification System (BCS) and shows a narrow ther-
apeutic index (Lindenberg et al., 2004). Furthermore, CBZ is a polymorphic drug and
it exhibits at least four polymorphic forms, referring to p-monoclinic (form III), triclinic
(form I), c-monoclinic (form IV), and trigonal (form II) crystal lattice. In literature CBZ
polymorphs show dissimilar naming. In this study CBZ polymorphs are named according
to Grzesiak et al. (2003) to avoid confusion. The different packing of the four polymor-
phic forms is shown in Figure 1.12. The CBZ molecules arrange to an anti-carboxamide
dimer motif and the four polymorphic forms are then formed by a distinct packing of these
dimers (Rodrı`guez-Sponga et al., 2004).
The thermal transitions between the CBZ polymorphs is shown in Figure 1.13. CBZ
form II, III, and IV can all transform to form I (Grzesiak et al., 2003). Form III and I
show an enantiotropic relation with a transition temperature (Tt) of 71°C, above this tem-
perature form I is the stable form (Behme and Brooke, 1991). At room temperature CBZ
form III is the thermodynamically most stable form and it is also the form commercially
available. The order of thermal stability is reported as form III > form I > form IV >
form II. The order complies with the rule of density, with 1.34, 1.31, 1.27, and 1.24 g/cm3
for form III, I, IV, and II, respectively (Grzesiak et al., 2003). Interestingly, form IV it is
not the thermodynamically least stable form, although it was the last CBZ polymorph dis-
covered (Lang et al., 2002). An explanation may be the crystallization procedure, form IV
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characterized [101–103] in the 1980s and the struc-
ture of the third form was recently solved by single
crystal X-ray diffraction [44]. Remarkably, after 30
years of study a fourth polymorph [104] was discov-
ered by the technique of polymer heteronucleation
(Section 7.2.5) [68]. All four polymorphs adopt an
essentially identical anti-carboxamide dimer motif.
This is in contrast to many other highly polymorphic
systems, which display differences in either confor-
mation or strong hydrogen bonding pattern (see sul-
fapyridine). The distinction among crystal forms lies
in the packing of the dimer units. This is illustrated in
the diagrams presented in Fig. 10. The triclinic (form
I) and trigonal (form II) polymorphs pack in a similar
manner. Both modifications form two CUH: : : O
intermolecular interactions between an oxygen and
two different hydrogen donors. These contacts take
place between a benzenic hydrogen and the oxygen
of the urea. Forms III and IV also feature important
CUH: : : O close contacts. However, these involve a
hydrogen on the double bond of the azepine ring to
the oxygen of the urea, which link adjacent dimers
into infinite chains. The densities of the carbamaze-
pine polymorphs cover a large range of values with
form II possessing the lowest density of 1.24 g/cm3
and form III having the highest density of 1.34 g/
cm3. The relative stabilities of the four polymorphs
are in accordance with the density rule with the
densest structure, form III, being the most stable
(Section 2.2.3).
5.2.3. Sulfapyridine
Sulfapyridine is an anti-bacterial sulfonamide drug
used to treat pneumonia and is known to crystallize
Fig. 10. Packing diagrams of carbamazepine polymorphs. From top left clockwise: form I, II, III, and IV.
B. Rodrı´guez-Spong et al. / Advanced Drug Delivery Reviews 56 (2004) 241–274 255
Form I Form II 
Form III 
Form IV 
Figure 1.12: Packing diagrams of carbamazepine polymorphs form I, II, III, and IV
(Rodrı`guez-Sponga et al., 2004).
Form III 
p- monoclinic 
Form II 
trigonal 
Form IV 
c- monoclinic 
Form I 
triclinic 
!188°C3  !130°C 
monotropic2 
 !176°C 
enantiotropic - Tt 71°C1 
Supersaturated  
ethanol solution 
5°C  
25°C  
Evaporation of methanol 
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Figure 1.13: Schematic overview of thermal transition between CBZ polymorphs, adapted
from Grzesiak et al. (2003); 1Behme and Brooke (1991), 2Edwards et al. (2001), and
3Grzesiak et al. (2003).
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has only been reported to crystallize in presence of the polymer hydroxypropyl cellulose
(Florence et al., 2006).
CBZ can further exist as solvate with acetone or as cocrystal with saccharin, nicoti-
namide, acetic acid, or with 5-nitroisophthalic acid (Fleischman et al., 2003; Rodrı`guez-
Sponga et al., 2004). The most common solvate is with two molecules of water, the CBZ
dihydrate and it is the thermodynamically most stable form in aqueous solutions and at
high relative humidity (Figure 1.14).
molecular assemblies with fine-tunable pharmacolog-
ic activity [10,138].
A supramolecular design strategy was recently
used to prepare 13 new cocrystals of carbamazepine
[13]. The crystal packing of carbamazepine in poly-
morphs and solvates shows the formation of dimers,
with the carboxamide unit acting as both a hydrogen
bond donor and acceptor (Fig. 14). Two design
strategies were utilized using this moiety as the
primary supramolecular synthon where interactions
either retain or disrupt the carbamazepine dimer
formation. Fig. 14a–d shows how carbamazepine
can form cocrystals with water, acetone, saccharin,
or nicotinamide that retain the carboxamide dimer and
hydrogen bond instead with available donor/acceptor
groups. In contrast, formic acid and trimesic acid
cocrystals of carbamazepine disrupt dimer formation
(Fig. 14e–f). Given that these cocrystals significantly
alter intermolecular associations and modify crystal
packing, physical and pharmaceutical properties may
Fig. 14. Molecular assemblies in multiple-component crystals of carbamazepine: (a) hydrate, (b) acetone, (c) saccharin, (d) nicotinamide,
(e) acetic acid, and (f) 5-nitroisophthalic acid. Adapted from reference [130].
B. Rodrı´guez-Spong et al. / Advanced Drug Delivery Reviews 56 (2004) 241–274 261
Figure 1.14: The geometrical arrangement of carbamazepine dihydrate (Rodrı`guez-
Sponga et al., 2004).
CBZ is a prominent model drug to study polymorphism and phase transitions. CBZ is
also selected because of its low solubility to investigate process methods as to their ability
to enhance solubility.
1.5.1 Transformation of Anhydrous CBZ to its Dihydrate Form
The transformation process best studied is the one from anhydrous CBZ to the dihydrate
form. Laine et al. (1984) described the transformation as solution-mediated process and
the formation of dihydrate crystals by whisker growth. The dehydration mechanism of
CBZ was described by Han and Suryanarayanan (1998), they reported the transformation
to occur phase boundary or nucleation controlled. Anhydrous CBZ (form III) and CBZ
dihydrate were reported to coexist in the water activity range of 0.601–0.641 at 20 °C (Qu
et al., 2006; Li et al., 2008).
Several attempts have been made to control the transformation of CBZ anhydrous to
dihydrate, mostly by inhibiting the nucleation and the formation of CBZ diyhdrate crys-
tals. Dihydrate formation is strongly inhibite in solutions (1–4% w/v) of hydroxypropyl
methylcellulose (HPMC), hydroxypropyl cellulose (HPC), methyl cellulose (MC), or poly-
vinyl pyrrolidone (PVP), whereas solutions of polyvinyl alcohol (PVA), polyethylene gly-
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col (PEG), sodium carboxymethyl cellulose (CMC), and polysorbate 80 (Tween® 80)
have only weak inhibitory activity (Gift et al., 2008; Tian et al., 2006; EL-Massik et al.,
2006; Otsuka et al., 2000; Luhtala, 1992). In contrast, surfactants, such as sodium lauryl-
sulphate (SLS) and sodium taurocholate (STC) promote the dihydrate formation during
the dissolution test (Rodrı`guez-Hornedo and Murphy, 2004).
Few authors studied the effect on transformation by including the excipient directly
into the tablet formulation. Katzhendler et al. (1998, 2000) analyzed the gel layer of
matrix tablets containing HPMC and later also egg albumin during the dissolution pro-
cess. HPMC inhibits the transformation to the CBZ dihydrate form, however, HPMC
also participates in its crystallization process and induces amorphous CBZ. Egg albumin
also inhibits the transformation, though with a dose dependence. Salameh and Taylor
(2006) studied the transformation exposing physical mixtures of anhydrous CBZ or theo-
phylline with mannitol, microcrystalline cellulose (MCC), PVP K12, or PVP K90 to var-
ious relative humidity. MCC has only minimal effect on both drugs, mannitol enhances
dehydration, whereas PVP K12 and PVP K90 showed contradictory results. The authors
concluded, that the effect of excipients on hydrate forming drugs depends on a multi-
tude of factors and knowledge is still limited. Recently, Schulz et al. (2010) successfully
adsorbed CBZ to crospovidone (CrosPVP) to prevent recrystallization to CBZ dihydrate
during the solvent disposition. However, transformation is prevented only in small drug
loads (≤ 9.1%). Also a surface modification of the CBZ crystals seems to inhibit dihy-
drate formation. Otsuka et al. (2003) adsorbed n-butanol on CBZ crystals of triclinic form
(form I). Compared to the untreated crystals, surface-modified crystals were more stable
towards the influence of moisture and showed a faster dissolution rate.
Transformation of anhydrous CBZ (form III) to its dihydrate has also been studied at
the level of a single crystal (Tian et al., 2006). Carbamazepine crystals transform first at
the sites of defect and the crystal faces transform with different speed. The smaller faces
of the CBZ crystal (010 and 001) grow the most dihydrate crystals, whereas the largest
face (100) grows much less. Larger crystal faces interact less with polar solvents such
as water and by dissolving at a slower rate, less dihydrate crystals can be formed. CBZ
dihydrate crystallized from water are of characteristic needle shape, the crystal grows
fastest along the direction of (010), the crystal face {111}. Also in presence of SLS the
needle-shaped habit is grown. In contrast, presence of STC inhibits the growth along
the {111} direction and the CBZ dihydrate crystal grows more along the direction of the
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{200} and {002} faces (see also Figure 1.8 in Section 1.3.1). (Rodrı`guez-Hornedo and
Murphy, 2004)
1.5.2 Mechanical Properties of CBZ
CBZ is poorly compressible, and its compactibility depends on the polymorphic form.
Roberts and Rowe (1996) compared CBZ form III and I in Young’s modulus and yield
stress. The thermodynamically more stable form has a higher true density, higher yield
stress, higher Young’s modulus, it is less compressible and it is therefore more difficult
to form compacts. In a later study they were able to predict the mechanical properties
of CBZ by an atom-atom potential model applied to lattice dynamics. However, this was
only possible if the crystal morphology was also considered (Roberts et al., 2000). The
compaction of CBZ shows high amount of elastic behavior and also compaction-induced
disorders and polymorphic transition can occur (Koivisto et al., 2006). CBZ dihydrate
shows the best compactibility, however, it is not stable under compression (Lefebvre et al.,
1986).
1.5.3 CBZ and Analytical Methods
Analysis methods to study CBZ polymorphs and their transformations have evolved fast
over the last decades. To verify polymorphic form, X-ray powder diffraction (XRPD) is
the method of choice. Figure 1.15 shows the typical patterns for the CBZ polymorphs.
Also the thermal analysis by differential scanning calorimetry (DSC) is a prominent anal-
ysis tool to study polymorphic transition. Figure 1.16 shows the typical thermograms of
CBZ polymorphs and of amorphous CBZ. Upon heating CBZ form II, III, IV, and amor-
phous all transform to form I.
Edwards et al. (2001) proposed the use of time and temperature resolved X-ray diffrac-
tion techniques to analyze polymorphic transition of CBZ. However, to reduce the ef-
fect of particle size, morphology, and preferred orientation limiting the analysis by X-ray
diffraction Tian et al. (2007) suggested the use of Raman spectroscopy. They successfully
applied in situ Raman spectroscopy to follow CBZ anhydrous to dihydrate transformation
quantitatively. Raman spectroscopy also seems more discriminative towards CBZ poly-
morphs and dihydrate than the analysis by near infrared spectroscopy (NIR) (Kogermann
et al., 2008). Earlier, O’Brien et al. (2004) successfully applied in situ FT-Raman spec-
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Figure 1.15: Diffractograms of CBZ polymorphic forms I–IV (Rodrı`guez-Sponga et al.,
2004).
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Figure 1.16: DSC of CBZ polymorphic forms I–IV (a) and amorphous CBZ (b) upon
heating (Rodrı`guez-Sponga et al., 2004; Li et al., 2008).
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troscopy to study the kinetics of thermal transitions in CBZ. Another in-situ technique
to analyze CBZ transformation was reported by Brittain (2004), they were able to follow
the solution-mediated transformation of CBZ anhydrous (form III) to its dihydrate using
fluorescence studies and they reported first-order reaction kinetics for the transformation
process. Following the thermal transformation of CBZ form III to I by time-resolved
terahertz spectroscopy Zeitler et al. (2007) could quantitatively follow its solid-gas-solid
transitions.
CBZ polymorphs can also be distinguished by their intrinsic dissolution rate (IDR).
However, IDR values strongly depend on the measurement parameters. For CBZ IDR
values are reported in the range of 0.024–0.077 mg/min/cm2 (Kobayashi et al., 2000; Yu
et al., 2004; Zakeri-Milani et al., 2009; Sˇehic´ et al., 2010). CBZ dihydrate shows IDR
values of up to 2.5 times lower than for anhydrous CBZ (Ono et al., 2002). The IDR
analysis is in water or in aqueous solutions, therefore CBZ anhydrous transforms to the
slower dissolving dihydrate form. This transformation is visible in IDR profiles as a
change in slope, also named transformation point (Kobayashi et al., 2000; Sˇehic´ et al.,
2010). Kobayashi et al. (2000) found that the transformation depends on the polymorphic
form. Sˇehic´ et al. (2010) reported different transformation points within CBZ samples
of same polymorphic form but of different commercial suppliers. The difference also
continued to exist in tablet formulations using Ludipress® as tablet filler.
The dissolution test described in the USP monograph for CBZ immediate release
tablets requires a dissolution medium of 1% SLS in water. This can lead to inhomo-
geneous dissolution behavior of CBZ tablets because SLS enhances transformation of
CBZ to its dihydrate. EL-Massik et al. (2006) proposed an alternative composition of
the dissolution medium containing 0.5% SLS and 0.01% MC. This composition removes
induction of transformation without compromising the solubility enhancement by SLS, it
provides suitable sink for up to 400 mg CBZ, and it is robust to various dosing strength of
same CBZ formulation.
1.5.4 Techniques to Enhance CBZ Dissolution Rate
Several techniques are reported to enhance the dissolution rate of CBZ, e.g., crystal en-
gineering, formation of water-soluble complexes, solid dispersion with surfactants, for-
mulation of a metastable or amorphous state, or reducing particle size by micronization
(Javadzadeh et al., 2007). A process method may include more than one aspect enhancing
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the dissolution rate, a solid dispersion with surfactants may enhance dissolution also by
the process-induced particle size reduction and by a changed solid state.
Crystal Engineering. The dissolution rate of CBZ can be enhanced by a different crys-
tal habit and smaller crystals. Bolourtchian et al. (2001) reported an improved dissolution
rate and compactibility of CBZ crystals prepared by different solvent techniques. Crystal-
lization from ethanol or acetone resulted in polyhedral and thin plate-like crystals, respec-
tively. Using a watering-out method needle-shaped crystals were obtained. Nokhodchi
et al. (2005) studied recrystallization of CBZ from alcohol solutions in presence of the
additives PEG 4000, PVP K30, and Tween 80. The obtained crystals were of different
crystal habit but of same polymorphic form (CBZ form III). However, only the recrystal-
lization in presence of 1% PVP K30 resulted in more block-shaped crystals with improved
dissolution rate and tensile strength.
Also the formation of cocrystals can provide a possibility to enhance the dissolution
rate of CBZ (Rodrı`guez-Sponga et al., 2004). Hickey et al. (2007) reported favorable
dissolution properties of the CBZ:saccharin cocrystals in table formulation.
Solid Dispersions. Attia and Habib (1985) studied the effect of sugars (i.e., mannitol,
lactose, and galactose), PEG 6000, and PVP on the dissolution rate of CBZ using solid
dispersions. Highest dissolution rates were obtained from the CBZ–PVP coprecipitate.
Zerrouk et al. (2001) included PEG 6000 in CBZ solid dispersions by a melt technique,
however, CBZ transformed to its form II during the processing. The solid dispersion by
coprecipitates or melts allow particle size reduction to a molecular level. Nonetheless, the
solid dispersion method has to be selected and controlled carefully because of possible
phase transitions induced by the process. El-Zein et al. (1998) studied different carriers
to improve dissolution of CBZ. Solid dispersion with the hydroxypropyl-β-cyclodextrin
showed the best dissolution rate and in-vivo absorption, the absorption was also higher
than from the original product, the Tegretol suspension. Nair et al. (2002) prepared solid
dispersions from methanol solutions. They reported amorphous CBZ in solid dispersion
prepared in presence of PVP K30, whereas solid dispersions prepared in presence of high
amounts of PEG 4000 (PEG:CBZ, 6:4) resulted in CBZ form I. Both solid dispersions
showed an enhanced dissolution rate. Compared to untreated CBZ, the formation of di-
hydrate was much higher because of the change to a less stable solid state. A solvent free
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method was applied by Moneghini et al. (2001) using supercritical carbon dioxide to ob-
tain CBZ solid dispersions. The processed CBZ did not change polymorphic form (form
III), but dissolution rate was enhanced due to a smaller particle size. Also Gosselin et al.
(2003) successfully micronized CBZ without changing the polymorphic form. They ap-
plied a method using rapid expansion of supercritical carbon dioxide solutions (RESS) for
the micronization. CBZ form III was obtained keeping the process below 40°C and below
240 bar. Ugaonkar et al. (2007) prepared amorphous CBZ by a solid dispersion method
using near-supercritical carbon dioxide (n-scCO2) and the polymer PVP. A metastable
or amorphous solid has the advantage of a higher solubility and dissolution rate. The
disadvantage is that a pure phase should be obtained and kinetically stabilized.
Liquisolid Technique. Javadzadeh et al. (2007) successfully applied the liquisolid tech-
nique to improve dissolution properties of CBZ. MCC was used as carrier and aerosil as
coating material, the liquid load was up to 0.6 and the excipient ratio was 15 or 20. Pres-
ence of PVP could increase the dissolution rate and by including PEG 35000 an increased
liquid load was achieved without decreasing powder flowability. No polymorphic changes
were detected by XRPD or DSC measurements after the liquisolid processing.
Adsorption on Nanopores. Ambrogi et al. (2008) reported increased drug release of
CBZ adsorbed to mesoporous silicate MCM-41. CBZ loading was 14% and in noncrys-
talline state. Moreover, the system was not sensitive to moisture and elevated temperature.
1.5.5 Irregular Dissolution, Bioinequivalence, and Clinical Failures
in CBZ Tablets
CBZ tablet formulations show a history of irregular dissolution behavior, bioinequiva-
lence, and clinical failures. A large difference in bioavailability and in vitro dissolution
rate among CBZ tablets was reported by Meyer et al. (1992). The analyzed CBZ tablets
were of different lots withdrawn from the market due to several reports of clinical failures.
In a later study, Meyer et al. (1998) simulated steady-states of the various CBZ tablets.
However, they could not show clinical relevance by these simulations, despite an observed
bioinequivalence of single doses. Bioinequivalence of various marketed CBZ tablets are
also shown by Jung et al. (1997) and Lake et al. (1999), where the area under the plasma
level curve (AUC) and maximum plasma level (Cmax) clearly differ. Wang et al. (1993)
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provided a possible reason for the clinical failures of CBZ tablets. They reported an exten-
sive effect of high humidity and temperature on disintegration and on drug release of CBZ
tablets. In a multinational survey on in vitro dissolution, Davidson (1995) showed high
variability in commercial CBZ tablets even among the same brand. The variability was
highest after 15 min dissolution testing, where 45–75% drug must be released according
to the USP monograph for CBZ tablets. Almost ten years later, marketed CBZ tablets still
vary widely in their dissolution behavior Mittapalli et al. (2008).
1.5.6 CBZ Tablets Registered in Switzerland
By the beginning of 2011 the following CBZ tablet formulations are registered on the
Swiss market (Kompendium, 2011):
• Tegretol® by Novartis Pharma (original); tablets and CR divitabs of 200 mg and
400 mg.
• Carsol® by Sandoz; CR tablets of 200 mg and 400 mg.
• Timonil® /-retard by Desitin; tablets of 200 mg, 300 mg, 400 mg, and 600 mg.
• Neurotop® retard by Orion Pharma; Tablets of 300 mg and 600 mg. Excipients
known to the public: Eudragit RS PO and L 30 D, highly disperse silicium dioxide,
magnesium stearate, talcum, sodium carboxymethylstarch, and MCC.
1.6 Formulation Studies
”....it is a medicine, not a molecule, that we are giving to the patient.” (Brown, 2005).
After careful preformulation studies an active pharmaceutical ingredient (API) is for-
mulated into an appropriate dosage form – the medicine. The most popular dosage form
is the oral tablet formulation. To formulate an API into a tablet of satisfactory quality
the solid state of the API must have the following three essential attributes by itself or in
a formulation with selected excipients. (1) a rapid and reproducible flow into the die of
the tablet press to ensure uniformity in tablet weight and content, (2) the particles must
cohere under compression and that coherence should remain after the compression force
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is removed, and (3) the formed compact should be removed from the tablet press without
damage of the compact or the tablet press. APIs rarely possess all three attributes, thus
preliminary treatment are paramount. The most important methods to incorporate these
attributes to a tablet formulation are the wet granulation, dry granulation, and the direct
compaction methods (Armstrong, 2007a).
1.7 Direct Compaction
To manufacture tablets of thermolabile and moisture-sensitive drugs such as CBZ direct
compaction is the technique of choice. Direct compaction is sometimes also referred to
as direct compression. However, compressibility is defined as the ability of a powder
to densify under pressure, whereas compactibility is the ability to form a tablet of spe-
cific hardness (Alderborn and Nystro¨m, 1996). Therefore, direct compaction is the term
selected referring to the process method within this work.
Direct compaction provides the following advantages over wet or dry granulation
(Jivraj et al., 2000):
• Requires fewer operation steps, resulting in shorter processing time and lower en-
ergy consumption.
• Fewer stability issues for actives that are sensitive to heat or moisture.
• Fewer excipients may be needed in a direct compaction formula, see Table 1.11.
Also the following disadvantages should be considered (Jivraj et al., 2000):
• Segregation issues – however, reduced by matching the particle size and density of
the API with the excipients.
• Low bulk density, poor flowability and compactibility of the drug can jeopardize
direct compaction, especially in low potency drugs (Carlin, 2008).
• Static charges may develop on the drug particles or excipients during mixing and
thereby lead to agglomeration of particles resulting in poor mixing.
• For high potency drugs with a dosing of less than 1% content uniformity direct
compaction is a challenge and with a dosing of less than 0.1% other processes such
as the adsorption of the drug on carriers cannot be avoided (Carlin, 2008).
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In direct compacted tablets the physicochemical properties of the drug dominates the
final tablet properties. At low drug loads, however, the effect of the excipients dominate
and variations in their physicochemical properties could critically influence the tablet per-
formance. The excipients for direct compaction have to be selected with care. There are
many specialities available for direct compaction and in most cases, these are common
materials that are physically modified to provide better flow and compactibility character-
istics (Carlin, 2008).
1.8 Choice of Excipients for Direct Compaction
The choice of excipients is critical for a successful tablet production by direct compaction.
They should be specified for particle size, bulk density, flow, and compactibility. Most ex-
cipients for direct compaction are preprocessed. A tablet formula for direct compaction
usually consists of the API and excipients functioning as filler-binder, disintegrant, and
lubricant (Carlin, 2008). Table 1.11 gives an overview of the excipients and their concen-
trations in a tablet formula for direct compaction.
Table 1.11: General tablet formula for direct compaction (Carlin, 2008).
Active pharmaceutical ingredient (API) 0.1–99%
Filler-binder (dependent on API loading and compactibility) 1.0–99%
Disintegrant 0.5–2%
Lubricant 0.5–2%
1.8.1 Filler-binder
The filler-binder is the most important excipient in direct compacted tablets, it often serves
as the tablet matrix or vehicle. Filler-binder include a range of excipients from high
compactibility and dilution capacity (e.g., MCC) to tablet fillers of low dilution capacity
(e.g., spray-dried lactose). The dilution capacity of an excipient is its ability to carry poor
compactible drug.
There are several factors to consider when selecting the appropriate filler-binder (Car-
lin, 2008):
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• good compactibility
• good flowability
• bulk density
• particle size and distribution
• dilution capacity
• moisture content, water activity (free or bound water), hygroscopicity, effect of
moisture on compactibility
• compatibility with API and stability in the final product
• solubility (influence on dissolution)
• physiological acceptability such as toxicity, osmotic effect, and taste
• cost and availability, security of supply
• regulatory acceptability (pharmacopoeial status, FDA’s GRAS list of excipients;
GRAS = generally recognized as safe)
Filler-binders can be classified according to their chemical similarity, Figure 1.12
gives an overview.
Table 1.12: Filler-binders suitable for direct compaction listed according to their chemical
constitution (Bolhuis and Armstrong, 2006).
Cellulose Microcrystalline Cellulose (MCC),
Powdered Cellulose
Starch/Starch derivatives Native Starches, Compressible Starch,
Modified Starches
Inorganic salts Dicalcium Phosphates, Tricalcium Phosphate,
Calcium Sulfate Dihydrate
Polyols Sorbitol, Mannitol
Lactose α–Lactose Monohydrate,
Anhydrous α–Lactose , Anhydrous β–Lactose
Spray-Dried Lactose, Agglomerated Lactose
Other Sugars Compressible Sugar, Dextrose, Dextrate
Co-processed Products Ludipress®, Cellactose®, Pharmatose® DCL 40
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Microcrystalline Cellulose (MCC)
MCC is the most prominent filler-binder, it is highly compactible and can therefore dilute
a poorly compactible drug. MCC is the only true binder, compact hardness can increase
significantly by adding only small amounts (3–5% MCC). MCC is hygroscopic and prac-
tically insoluble in water. There are a number of grades available that are suitable for
direct compaction, they differ in compactibility, particle size, and moisture content. The
grades PH 102 and PH 101 are most common, they are of partially spray-dried MCC and
particle size is around 100 µm and 50 µm, respectively (Rowe et al., 2006).
Figure 1.17: Repeat dimer unit of cellulose, linear chains of β(1–4)-linked-D-
glucopyranosyl units (Carlin, 2008).
MCC is gained from natural α-wood cellulose by acid hydrolysis (Rowe et al., 2006).
The smallest unit of cellulose is shown in Figure 1.17. Cellulose is a β(1–4)-linked poly-
mer of glucose, two D-glucopyranosyl molecules build the repeat dimer of a linear chain
(Carlin, 2008).
Mannitol
Mannitol belongs to the polyols and is an isomer of sorbitol (Figure 1.18). Direct com-
pressible forms of several particle sizes are available (Armstrong, 2007a). Mannitol is non
hygroscopic, water soluble, and exhibits three polymorphic forms (Rowe et al., 2006).
Figure 1.18: Structural formula of D-Mannitol (Rowe et al., 2006).
Form III shows the best compactibility and it is of high kinetic stability, however, form I is
the thermodynamically most stable form at room temperature (Burger et al., 2000). Man-
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nitol is a favored excipient in chewable tablets and lozenges because it shows a negative
heat of solution and provides a cooling effect (Armstrong, 2007a).
Hydroxypropyl Cellulose (HPC)
HPC can express different functions depending on the degree of substitution and on the
particle size. Alvarez-Lorenzo et al. (2000) evaluated low-substituted HPC (L-HPC) as
filler-binders for direct compaction. Whereas HPC with a medium or high degree of
substitution are suitable for matrix tablets, low-substituted HPC can be proposed as ex-
cipients for conventional tablets. Depending on the particle size L-HPC is effective as
tablet binder or as tablet disintegrant. As fine powders, L-HPC shows low viscosity and
sustained release. Drug release can also be regulated by the amount of L-HPC in the for-
mulation (Kawashima et al., 1993). The compaction behavior of HPC has been studied by
Picker-Freyer and Du¨rig (2007). They reported viscoelastic compaction behavior of HPC
with increased compactibility and plasticity for lower degree of substitution and smaller
particle size. These grades are therefore suitable for the use in direct compaction.
1.8.2 Disintegrant
A physically strong tablet can slow down the dissolution of the API, therefore tablet for-
mulations often include a disintegrant. An excipient acting as a disintegrant disrupts the
tablet structure and leads to fragmentation when it comes into contact with water; it fa-
cilitates the dissolution by exposing a larger surface area to the dissolution media (Arm-
strong, 2007b). Traditional disintegrants are the native and modified starches. They are
poorly compactible and of low efficiency. Partially pregelatinized starches can be used as
a disintegrant in formulations for direct compaction at 10–15% w/w (Moreton, 2008).
Superdisintegrants are much more effective and can be used at lower concentrations
and they are thus better suited for tablets prepared by direct compaction. The most
prominent superdisintegrants are croscarmellose (AcDiSol®), sodium starch glycolate
(Eplotab®, Primogel®), and crospovidone (Polyplastone® XL). They are effective at
levels of 0.5–4% (Carlin, 2008). Tablet disintegration occurs through different mecha-
nisms. Sodium starch glycolate mainly acts as disintegrant through swelling, whereas
the fiber-structured croscarmellose sodium further acts through energy recovering of elas-
tic deformation and wicking (Moreton, 2008). The disintegrant activity of crospovidone
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is believed to occur mainly through the water wicking, the ability to draw water into
the porous network of the tablet. The disintegration activity is not fully understood and
several mechanisms may be needed to explain the complex behavior (Augsburger et al.,
2002). Crospovidone is cross-linked polyvinylpyrrolidone (Figure 1.19), it is hygroscopic
Figure 1.19: Molecular unit of polyvinylpyrrolidone (PVP) and its cross-linked form
Crospovidone (Rowe et al., 2006).
and practically insoluble in water. The particles are of porous morphology and irregu-
lar shape, and the use of bigger particle size results in faster disintegrating tablets. For
immediate release tablets the recommended level of incorporation is 2–5% (Rowe et al.,
2006).
MCC. Tablets of pure MCC self-disintegrate in aqueous media when prepared by direct
compaction. For an adequate disintegration, MCC levels of at least 20% are required and
in case of hydrophobic API no sufficient disintegration may be obtained. The disintegra-
tion activity of MCC is believed to occur mainly through a combination of wicking and
disruption of particle-particle bonds by the presence of water (Moreton, 2008).
L-HPC can provide another option of disintegrant in formulations for direct compac-
tion. The fibrous and coarse grades are the ones used as disintegrant at levels of 2–10%
(Moreton, 2008; Kawashima et al., 1993).
1.8.3 Lubricant
The main role of lubricants is to decrease the friction in tableting at the interface between
tablet surface and die wall during ejection and to reduce the wear on punches and dies.
Hydrophobic lubricants also decrease the interparticulate friction and thus enhance the
powder flow. Furthermore, they are anti-adherent and can thereby prevent sticking to
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punch faces (Armstrong, 2008). Magnesium stearate is the most widely used lubricant
and concentrations of 0.25–5% are used (Rowe et al., 2006). As a hydrophobic lubricant
magnesium stearate can cause problems. In direct compaction with plastically deform-
ing materials a thin film of magnesium stearate can cover the surface and interfere with
the bonding. The result are weaker tablets with higher friability and because of the hy-
drophobic film with slower dissolution. The softening and hydrophobic effects can be
minimized by adding magnesium stearate as the last step to the blend and by a very short
mixing time of 2–5 min. Other lubricants may be required in some tablet formulation for
direct compaction. Alternative lubricants are stearic acid, hydrogenated vegetable oil, or
sodium stearyl fumarate (Carlin, 2008).
1.9 Analysis of Tablet Properties
A tablet formulation should deliver the active ingredient in an accurate and reproducible
manner. Three general test categories ascertain the product quality. The first category
includes tests on the nature of the API such as identity, quantity, and impurity and on the
product properties such as tablet hardness and friability. In the second category bioavail-
ability is established by in vitro and in vivo tests. The third category include tests on the
product stability (Qureshi, 2007).
1.9.1 Tablet Hardness
Tablets experience a series of stresses during manufacturing, packing, shipping, and dis-
pensing and the tablets should exhibit sufficient mechanical strength (Qureshi, 2007).
Tablet strength can be assessed by the force required to fracture a tablet in a defined
direction, the crushing strength. The physical strength of a tablet also depends on its di-
mensions and tensile strength provides a measure that includes tablet dimension. Tensile
strength σ [MPa] of a tablet is given by the Equation (1.21),
σ =
2F
πdt
(1.21)
where F is the force [N] needed to fracture the tablet by a hardness tester, d the diameter
[mm], and t the thickness [mm] of the cylindrical tablet (Armstrong, 2007b).
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1.9.2 Tablet Friability
Tablet friability provides another measure to estimate the mechanical strength of the
tablet. The abrasion of uncoated tablets is measured by subjecting them to controlled
mechanical shock and attrition. The apparatuses to test friability are drums of specific
diameter, width, and with a curved ramp over which the tablets role, slide, and fall at each
turn. The standard method is performed with tablet of a total weight around 6.5 g, the
drum is rotated at 25 rpm and with a total of 100 turns. The abrasion is measured as the
loss in weight and should be less than 1% to pass the friability test (Qureshi, 2007).
1.9.3 Tablet Porosity
Tablet porosity is an important parameter in formulation studies. Although robust tablets
of strongly coherent particles are essential, their low porosity can be an impediment to dis-
solution. The surface area exposed to the dissolution media increases with tablet porosity.
Porosity (￿) can be calculated by the Equation (3.3) based on tablet volume,
￿ = (1− m
Vtρt
)100 (1.22)
where m is the tablet mass, Vt the tablet volume, and ρt the true density of the powder
blends (Armstrong, 2007b). Mercury intrusion porosimetry provides a further option to
assess tablet porosity (Augsburger and Zellhofer, 2007).
1.9.4 Disintegration Testing
The disintegration test is a method of quality-assurance for conventional tablets. There
are pharmacopoeial standards on test conditions, settings and outcome. The apparatus for
the disintegration measurement consists of a basket rack with six tubes open at the top and
confined by a 10-mesh screen at the bottom. One tablet is placed per tube and the basket
rack is moved vertically at specific rate in aqueous media at 37 ± 2 °C. The test measures
the time all six tablet need to disintegrate into aggregates and/or fine particles. Disinte-
gration test does not necessarily correlate with the dissolution rate, therefore dissolution
testing is often favored over disintegration (Qureshi, 2007; USP 31, 2008).
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1.9.5 In Vitro Dissolution Testing
The dissolution can be measured by four general methods described by USP 31 (2008).
The most prominent dissolution methods are the basket and the paddle method, the USP
Apparatuses 1 and 2 (Figure 1.20). Dissolution can also be tested by the reciprocating
cylinder method or in flow-through cell (Figure 1.21), the USP Apparatuses 3 and 4.
In basket, paddle, and reciprocating cylinder method the dissolution media is of limited
volume, while the flow-through cells allow measuring in an open system, the drug release
is studied under continuous flow of fresh dissolution medium. This method is especially
useful for analysis including pH changes and for analysis of poorly soluble drugs, the open
system provides infinite sink. The flow rate is the critical parameter for the dissolution
rate, typically a flow rate of 16 mL/min is applied (Hanson and Gray, 2004b). Also the
size of the dosage form, its orientation within the dissolution cell, the cell size, and the
gases dissolved in the media effect the flow of the media and thereby the dissolution rate.
In contrast, deviations in temperature and conductivity of the medium have less impact
on the dissolution (Cammarn and Sakr, 2000; Jørgensen and Jacobsen, 1992). The flow-
through method can further be used to study intrinsic dissolution, Peltonena et al. (2003)
reported a good correlation between the dissolution profiles obtained by channel-flow and
intrinsic dissolution method.
Generally, the dosage form has to be placed with absolute care in dissolution mea-
surements. Depending on the physical location, the dosage form experiences different
shear strain environment, which is directly linked to different dissolution rate (Hanson
and Gray, 2004b). Kukura et al. (2004) studied the paddle method using computational
fluid dynamics. The dissolution vessel shows a heterogeneous shear strain distribution
that cannot be improved by increasing the rotation speed. The fluid mechanics in the
flow-through cells are discussed extensively by Kakhi (2009a) and the fluid dynamics
were successfully predicted by computational fluid dynamics (Kakhi, 2009b).
Dissolution Media
The dissolution measurements should be performed in dissolution media which can best
predict the dissolution in vivo. Most common, buffer solutions are used to mimic gas-
tric or intestinal pH. More sophisticated media include further ingredients like pepsin,
lecithin, bile salts, or lipids. An update on the various dissolution media simulating prox-
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Figure 1.20: The schematic figure of the basket and paddle methods for dissolution testing
(Hanson and Gray, 2004b).
Figure 1.21: The schematic figure of the flow-through method, the flow-through cells in
the open and packed mode, figure taken from Kakhi (2009a).
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imal human gastrointestinal tract has been published by Jantratid et al. (2008). In case of
poorly soluble drugs, sink condition can be obtained adding surfactants such as sodium
dodecylsulfate (SDS) or sodium laurylsulfate (SLS) at concentrations above their critical
micelle concentration. However, the opinions about the use of surfactants are divided.
Tang et al. (2001) analyzed the bio-relevance of dissolution media containing SLS. Al-
though a concentration of 1% resulted in sink conditions, the dissolution data obtained
in vitro did not correlate with the in vivo data. Only lower concentrations of 0.25% SLS
showed bio-relevant dissolution data, despite the over-saturated condition in the dissolu-
tion medium.
Evaluation of Dissolution Profiles (Costa and Sousa Lobo, 2001)
There are several mathematical models available to describe drug dissolution profiles.
Depending on the focus, drug release can be analyzed as a function of the dosage form
characteristics using mathematical models or by quantitative and statistical measures, the
non-model dependent parameters. The mathematical models describing dissolution kinet-
ics are often empirical equations. The common models are zero order, first order, Hixson-
Crowell, Weibull, Higuchi, and Korsmeyer-Peppas. The common non-model dependent
release parameters are dissolution time, assay time, dissolution efficiency, difference fac-
tor and similarity factor. These release parameters provide very limited information about
the release mechanism and are suitable to compare dissolution profiles of same dosage
form or to a reference.
The dissolution time tx% presents the time necessary to release a determined percent-
age of drug, e.g., t15 or t60. The assay time tx min presents the amount of drug dissolved
at a specific time. Both parameters are very common in pharmacopoial monographs to
determined the test limits, e.g., t15 ≥ 75%. Mean dissolution time and dissolution effi-
ciency present further parameters to compare dissolution profiles. The mean dissolution
timeMDT is given by Equation (1.23),
MDT =
￿n
i=1 tˆi ·∆Mi
∆Mi
(1.23)
where i is the sample number, n the number of dissolution sample times, tˆi the time at
midpoint between t1 and ti−1, and ∆Mi the additional amount of drug dissolved between
ti and ti−1. The dissolution efficiency (DE) is described by the area under the dissolu-
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tion curve AUCti up to a certain time ti expressed as a percentage of the area under the
rectangle described by 100% dissolution in the same time ctot.
DE =
AUCti
ctotti
· 100 (1.24)
When comparing full dissolution profiles the multivariate analysis of variance (MAN-
OVA) or the difference factor (f1) and similarity factor (f2) can be applied. f1 and f2 are
calculated as of Equations (1.25) and (1.26),
f1 =
￿￿n
t=1 |Rt − Tt|￿n
t=1Rt
￿
· 100 (1.25)
f2 = 50 · log
￿
(1 +
1
n
n￿
t=1
(Rt − Tt)2
￿−0.5
· 100) (1.26)
where n is the number of dissolution samplings, and Rt, Tt are the percent dissolved of the
reference and test dissolution profile at each time point (Yuksel et al., 2000; FDA, 1997).
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Chapter 2
Objectives
Physicochemical properties of raw materials can vary among drug suppliers with con-
sequence on the drug performance in the final dosage form. Depending on the way of
production, the raw materials show impurities in form of solvent inclusions or polymor-
phic mixtures, and particle morphology can be remarkably different among the various
raw materials.
Carbamazepine (CBZ) is one example where variability in raw materials has been
linked to irregular dissolution behavior, bioinequivalence, and clinical failures of the final
dosage form. The purpose of this study was to investigate the impact of variability in CBZ
raw materials on the drug release. Hence, the aims of the study include the following
issues:
• Polymorphic and morphological characterization of CBZ raw materials of four dif-
ferent suppliers and investigation on intrinsic dissolution behavior of the samples.
• Evaluation of the effect of two commonly used tablet fillers on the variability of
CBZ raw materials.
• Investigation on the recrystallization of CBZ samples to reduce variability.
• Development of a tablet formulation that is robust towards the variability in CBZ
samples and that conforms to the USP requirements of CBZ tablets for immediate
release.
• Proposition of a strategy to control the variability in CBZ raw materials.
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Chapter 3
Original Publications
3.1 Variability in Commercial Carbamazepine Samples
– Impact on Drug Release
Abstract
The aim of this study was to characterize the variability of commercial carbamazepine
(CBZ) samples and to investigate the influence of two commonly used tablet fillers,
i.e., mannitol and microcrystalline cellulose (MCC) on the CBZ sample variability. Poly-
morphism and morphology of CBZ samples were analyzed by differential scanning calo-
rimetry, X-ray powder diffraction, sieve analysis, and scanning electron microscopy. Drug
release from CBZ samples and binary mixtures (30–90% drug load) was characterized by
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a unidirectional dissolution method measuring disk intrinsic dissolution rate (DIDR) and
drug release, respectively. All CBZ samples were of p-monoclinic form but differed in
their polymorphic purity, particle size, morphology, and intrinsic dissolution rate. Two
characteristic inflection points, determined in the DIDR profiles, characterized the spe-
cific transformation behavior of each CBZ sample. The variability in CBZ samples was
also exhibited in the drug release profiles from their binary mixtures. Mannitol increased
initial drug release of CBZ samples up to 10-fold in mixtures of 30% drug load. The
presence of MCC resulted in reduced variability in drug release. The unidirectional disso-
lution method is presented as a straightforward monitoring tool to characterize variability
of CBZ raw materials and effect of tablet fillers.
Keywords: Carbamazepine, Dihydrate, Preformulation, Morphology, Polymorphism,
Tablet filler.
Introduction
Carbamazepine (CBZ) is a well-established drug to treat epilepsy and trigeminal neuralgia
and there are already several generics on the market. Nevertheless, CBZ products present
a history of irregular drug performance and clinical failures. Several reports show high
dissolution variability in CBZ tablets on the market world-wide and even among CBZ
tablets of the same brand (Meyer et al., 1992, 1998; Davidson, 1995; Al-Zein et al., 1999;
Lake et al., 1999; Mittapalli et al., 2008).
CBZ is poorly soluble in water with a narrow therapeutic index, classified as class II
drug according to the Biopharmaceutics Classification System (Lindenberg et al., 2004).
Furthermore, CBZ exhibits at least four polymorphic forms referring to p-monoclinic
(form III), triclinic (form I), c-monoclinic (form IV), and trigonal (form II) crystal lattice.
At room temperature CBZ form III is the thermodynamically most stable form and also the
form commercially available. CBZ further exists as several solvates, e.g., CBZ monoace-
tonate (Fleischman et al., 2003). Both, CBZ polymorphs and solvates show differences in
crystal form and consequently also difference in melting point, solubility, compactability,
and chemical reactivity.
Information about the processes used in raw drug production is generally limited.
Polymorphic form may be the same among various commercial sources, however, differ-
ent solvents and additives can be used for the crystallization of drug raw materials. These
dissimilar processes lead to different crystal habits and possible solvent inclusions, which
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result in changed solubility and dissolution behavior of CBZ crystals (Mahalaxmi et al.,
2009; Blagden et al., 2007; Bolourtchian et al., 2001). Furthermore, physical processes,
such as milling or grinding, can cause crystal defects, mechanical activation, and small
amount of amorphous, which then also lead to faster and inhomogeneous dissolution be-
havior of CBZ samples (Tian et al., 2006b; Murphy et al., 2002; Mosharraf et al., 1999;
Lefebvre et al., 1986).
In aqueous media, anhydrous CBZ transforms into its dihydrate. This transformation
critically influences dissolution and bioavailability of CBZ formulations and it has been
in the focus of many investigations over the last 20 years. The mechanism of transforma-
tion is a solution-mediated process where dihydrate is formed by whisker growth, clearly
visible by optical microscopy (Laine et al., 1984). Raman spectroscopy and fluorescence
studies are presented as non-invasive methods to study the transformation behavior of
CBZ (Tian et al., 2006a,b; Brittain, 2004). Furthermore, the influence of transformation
on the dissolution rate has been investigated. A decrease in dissolution rate is expected
as soon as the less soluble CBZ dihydrate is formed. This phenomenon is detected as
an inflection point in the disk intrinsic dissolution rate (DIDR) profile of CBZ samples
(Kobayashi et al., 2000; Sˇehic´ et al., 2010). Kobayashi et al. (2000) reported that the
transformation depends on the polymorphic form. CBZ form I transforms faster to di-
hydrate than form III in vitro and results in lower bioavailability in vivo. Sˇehic´ et al.
(2010), however, reported different transformation points within commercial CBZ sam-
ples, though same polymorphic form was specified. This difference also shows in tablet
formulation using Ludipress® as tablet filler. To date, DIDR profiles focused on the onset
of transformation only.
Composition of the dissolution media also influences the transformation of CBZ.
Dihydrate formation is strongly inhibited in solutions (1–4%, w/v) of hydroxypropyl
methylcellulose (HPMC), hydroxypropylcellulose (HPC), or polyvinylpyrrolidone (PVP)
whereas solutions of polyvinyl alcohol (PVA), polyethylene glycol (PEG), and sodium
carboxymethylcellulose (CMC) have only weak inhibitory activity (Gift et al., 2008; Tian
et al., 2006a; Otsuka et al., 2000). In contrast, surfactants, such as sodium lauryl sul-
phate and sodium taurocholate promote the dihydrate formation during the dissolution
test (Rodrı`guez-Hornedo and Murphy, 2004). Nevertheless, the knowledge about the ef-
fect of commonly used tablet fillers is still limited (Salameh and Taylor, 2006).
In this study, a unidirectional dissolution method was developed building on the DIDR
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method of Sˇehic´ et al. (2010) to characterize CBZ samples by DIDR profiles of the trans-
formation range and to investigate their initial drug release of binary mixtures with com-
monly used tablet fillers. For this purpose, two different types of direct compacted filler
were selected, mannitol as water soluble and microcrystalline cellulose (MCC) as water
insoluble tablet filler.
Materials and Methods
CBZ samples were obtained from four different suppliers; for confidential reasons they
were designated as CBZ A, B, C, and D. All samples were of commercial grade, no further
specification for the drug substance was made from our side. Samples were stored at room
temperature (20-25 °C) and controlled relative humidity (43% RH). CBZ dihydrate was
prepared according to McMahon et al. (1996). Anhydrous CBZ was stirred in water for
24 h. Crystals were filtered under suction and dried at ambient conditions over night. The
obtained CBZ dihydrate was kept at room temperature and 80% RH.
Excipients for the binary mixtures: Mannitol (Parteck® M300, MERCK KGaA, Ger-
many) and microcrystalline cellulose (MCC SANAQ® 102L, Pharmatrans
SANAQAG, Switzerland) were used as the tablet fillers. All other chemicals and reagents
purchased from commercial sources were of analytical grade.
Morphological Characterization
For morphological characterization scanning electron microscopy (SEM) (ESEM XL 30
FEG, Philips, The Netherlands) was applied at a voltage of 10 kV and magnifications of
100–2000 times. Before analysis, powder was sprinkled on carbon adhesive, and com-
pacts were fixed to the sample holder by conductive silver. The samples were then sput-
tered with gold.
Sieve analysis was performed with 100 g samples on standard sieving tower (Retsch
Type Vibro, Schieritz & Hauenstein AG, Switzerland) and 10 min shaking time at 40 Hz.
Polymorphic Characterization
Polymorphic form of CBZ samples was characterized by X-ray powder diffractometry
(XRPD) using a diffractometer (D5000, Siemens, Germany). The powder was filled into
special holders and the surface was pressed flat. Operating conditions were Ni filtered
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Cu Kα radiation (λ =1.5406 A˚), 40 kV, and 30 mA. Step was 0.02° 2θ, step time 1.0 s,
angular scanning speed 1° 2θ/min, and angular range between 5° and 40° 2θ scale.
Thermal behavior of all samples was analyzed by differential scanning calorimetry
(DSC), using heat flux DSC (4000, PerkinElmer, USA). DSC was calibrated with indium
prior to the measurement. A sample of 3–6 mg was accurately weighted into an aluminum
pan with holes and scanned between 40 °C and 220 °C at 10 °C/min under dry nitrogen
gas purge (20 ml/min).
True density of all samples was assessed by a gas displacement pycnometer (AccuPyc
1330, Micromeritics, USA). Powder was purged with helium by five repetitive purging
cycles and the density was reported as average value. The test was performed in triplicate.
Water Activity Measurement
Water activity (aW ) is the partial vapor pressure (p) of a sample relative to the vapor
pressure of pure water (p0). It is equal to the equilibrium relative humidity (ERH) of air
over the sample, e.g., powder or tablets (Wrolstad et al., 2005); see Equation (3.1). All
parameters are temperature dependent.
aW =
p
p0
= ERH (3.1)
Water activity of all samples was monitored with the digital water activity analyzer (Hy-
gropalm, Rotronic AG, Switzerland) at 23.5 ± 1.5 °C.
Intrinsic Dissolution of CBZ Samples
CBZ samples were analyzed by disk intrinsic dissolution. Intrinsic dissolution rate (IDR)
is the specific dissolution rate of a pure drug from one surface only. IDR is described by
Equation (3.2),
IDR =
dC
dt
× V
S
= k × CS (3.2)
where dCdt is the amount of drug dissolving over time, S the surface area of the compact,
k the intrinsic dissolution constant, and CS the solubility of the drug. Disk intrinsic dis-
solution curves are linear and the slope is the amount of drug dissolved per cm2. Under
fixed experimental conditions IDR value is characteristic for a given substance. It is used
in preformulation studies to classify and predict possible problems in bioavailability of a
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drug (Zakeri-Milani et al., 2009; Hanson and Gray, 2004).
Sample Preparation. Flat-faced compacts of 400 mg and 0.95 cm2 surface area were
produced from CBZ samples and CBZ dihydrate using a material tester (Zwick 1478,
Germany). Compact porosity was controlled to 11.3 ± 0.7% and hardness was 20–41 N.
For compacts of CBZ A, porosity was 16%, as higher compaction forces resulted in lami-
nation. Compaction force was set between 6 and10 kN, while compaction, decompaction,
and ejection speed were set at 10 mm/min, 50 mm/min, and 10 mm/min, respectively.
Porosity of CBZ compacts was measured by a mercury porosimeter (AutoPore IV
9500, Micrometrics, USA). Pressure in the range of 0.014–0.227 MPa corresponding to
the mean pore diameter of 6 nm to 400 µm, was applied. Surface tension (γ) of mercury
was 485 dynes/cm and contact angle (θ) was 130°.
Unidirectional Dissolution Method. To obtain disk intrinsic dissolution rate (DIDR)
profiles of the CBZ samples unidirectional dissolution was performed by a modified USP
Apparatus I. The compact was placed in a sample holder fitting to the rotating unit of
the dissolution apparatus (SotaxAT7smart, SOTAX AG, Switzerland) and the compact
was embedded in melted paraffin that only one surface was available to the dissolution
media. Unidirectional dissolution method was performed at two conditions: one for the
analysis of first inflection point referring to the start of transformation, and another for the
second inflection point referring to the stabilized transformation rate. Release media was
500 ml and 1000 ml water, and run time was 2 h and 10–11 h for these two conditions,
respectively. Dissolution media was at 37 ± 0.5 °C and a rotation speed of 100 rpm
was selected as it showed the lowest standard deviation for drug release of each sample.
Drug content of the media was measured at predetermined time intervals by UV-VIS
spectrophotometer (Lambda 25, PerkinElmer, USA) at 285 nm.
Evaluation of DIDR Profiles. IDR was determined by the slope in the DIDR profile
prior to the first inflection point, the slope referring to the release of anhydrous CBZ
before transforming to the dihydrate.
The inflection point was determined by the intercept of two linear regressions with
the best fit (R2 ≥ 0.999). The linear regressions a and b in the DIDR profiles of 2-h run
and c and d in the profiles of 10-11-h run were used to determine the first and second
inflection point, respectively (Figure 3.1). For the first inflection point, approximation
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Figure 3.1: Inflection point in DIDR profiles of 2-h run (left) and 10–11-h run (right)
determined by the intercept of slope a and b, and slope c and d, respectively. In the
10–11-h run only every second data point is shown.
of the best linear regression (a) included the initial DIDR profile starting from 2.6 min
DIDR measurement. The linear regression b was set through all data points of the later
stage in the DIDR profile that were not included in the regression line a. For the second
inflection point, approximation of the best linear regression (d) included the late stage in
DIDR profile, where release rate stabilized. The linear regression c was set through the
ten preceding release values not included in regression d.
Binary Mixtures
CBZ samples were mixed with mannitol or MCC for 10 min in a mixer (Turbula® type
T2C, W. Bachofen, Switzerland) and for a further 2 min after adding 1% magnesium
stearate (Sandoz, Switzerland) to the mixture. Drug loads were set at 90%, 70%, 50%,
and 30% and mixtures of 20 g were prepared. Binary mixtures were compacted by
the same procedure as the compaction of CBZ samples at the condition of 50 mm/min,
100 mm/min, and 50 mm/min for compaction, decompaction, and ejection speed, respec-
tively. Porosity was kept at approximately 12% based on tablet volume. To compare drug
release of the binary mixtures and CBZ samples, initial drug release of binary mixtures
was tested by the dissolution method of 2 h (Section Unidirectional Dissolution Method).
Drug release profiles of binary mixtures were compared by the amount of drug dissolved
after 120 min dissolution test. For all statistical comparison, one-way ANOVA followed
by Student’s t-test was applied.
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Results and Discussion
Morphological Characterization
With SEM a difference in morphology and surface texture was clearly visible among the
CBZ samples (Figure 3.2). CBZ A showed very crystalline particles of prismatic shape,
whereas CBZ B and D showed particles with rough and uneven edges and a lot of fine
particles. Samples of CBZ Cwere more round and with smoother surface. Prismatic shape
was reported characteristic for CBZ form III (Krahn and Mielck, 1987). CBZ dihydrate
powders were of fine needle-like structure in loose aggregates as expected (Sˇehic´ et al.,
2010).
(a) CBZ A (b) CBZ B (c) CBZ C
(d) CBZ D (e) CBZ dihydrate
Figure 3.2: SEM pictures of CBZ samples and CBZ dihydrate.
CBZ samples also differed in particle size distribution, in average and in median par-
ticle size (Table 3.1). CBZ A and D showed mono-modal particle size distribution with
a very broad peak found in CBZ D. For CBZ B and C, particle size distribution was
bi-modal showing two maxima at 0–90 µm and 125–180 µm, and at 125-180 µm and
250–355 µm, respectively. All CBZ samples except for CBZ A contained fines (particle
size ≤ 90 µm) of at least 11% with the ranking of CBZ B > C > D> A.
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Table 3.1: Sieve fractions of CBZ in [%] total sample weight (n = 3).
[µm] CBZ A CBZ B CBZ C CBZ D
≥710 0.5 0.1 3.1 2.8
500–710 3.5 0.1 11.8 26.5
355–500 10.7 1.2 11.3 17.2
250–355 23.8 16.2 15.4 17.5
180–250 20.9 23.0 10.4 10.3
125–180 21.3 24.9 20.0 7.9
90–125 12.1 13.2 15.3 6.9
≤90 7.3 21.4 12.8 11.0
Average 233± 5 166± 4 241± 21 333± 32
Median 209± 9 155± 4 192± 8 331± 20
Polymorphic Characterization
XRPD results are shown in Figure 3.3. The diffractograms of all CBZ samples showed
the characteristic peaks reported for CBZ p-monoclinic (Getsoian et al., 2008; Grzesiak
et al., 2003). Peaks at angles smaller than 10°, indicating presence of CBZ trinclinic or
the trigonal form, were not detected. However, there were some indications as to the
presence of form IV. There are peaks at 12.68° and 29.91° 2θ with increasing intensity
for CBZ B, C, and D. Diffractograms of CBZ D further showed an extra peak at 19.15°,
and at 22.91° 2θ (see arrows). The presence of CBZ form IV in commercial CBZ samples
was suspected previously (Kipouros et al., 2005). At lower angles of 5–20° 2θ, XRPD
results showed difference in peak intensities, which could be due to different degree in
crystallinity, smaller particle size, or due to preferred orientation of the particles in the
sample holder. XRPD data did not show any change in the diffraction pattern in CBZ
samples after compaction (data not shown). CBZ dihydrate was also confirmed by XRPD.
Characteristic peaks for CBZ dihydrate were at 2θ = 8.9°, 18.9°, and 19.4°, and they are
in agreement with the literature (Kobayashi et al., 2000).
DSC results are presented in Figure 3.4. Most CBZ samples showed the character-
istic thermal events of CBZ form III as reported previously (Grzesiak et al., 2003). The
onset of each thermal event (Tonset) and the enthalpy (∆H) were used to compare the
endothermic and exothermic peaks among the CBZ samples. Melting of form III was
visible around 176 °C, followed by crystallization to form I around 182 °C and melting
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Figure 3.3: X-ray powder diffraction of CBZ samples; 5–40° 2θ at 1° 2θ/min.
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Figure 3.4: DSC profiles of CBZ samples and CBZ dihydrate; 40–220 °C at 10 °C/min
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of form I around 191 °C. However, DSC profiles of CBZ samples differed visibly. Ther-
mograms of CBZ A and B showed the characteristic peaks for form III clearly. However,
there was a difference in melting enthalpy around 176 °C (form III), whereas melting en-
thalpy around 191 °C (form I) was the same. This indicates presence of form I in CBZ B.
Nonetheless, only small amounts can be assumed, as no specific peaks for form I were
detected by XRPD. Further difference among CBZ samples was seen for CBZ D, where
the endothermic peak around 176 °C was missing and an endotherm showed at lower tem-
perature of around 164 °C instead. For both, CBZ C and D samples a further endothermic
peak was visible at 185 °C (arrows) indicating presence of CBZ form IV (Grzesiak et al.,
2003). This finding is consistent with the XRPD results, where small amounts of form IV
were suspected in both CBZ C and D. However, for CBZ B, no indications of form IV
were detected by DSC. It has to be noted here, that the detection limit for CBZ poly-
morphic form is reported to be the best with 1% and 5–10% for Hyper-DSC and XRPD,
respectively (McGregor et al., 2004; Lefebvre et al., 1986). Furthermore, thermograms for
CBZ B and C showed a shoulder to the endothermic peak around 176 °C starting around
164 °C. This shoulder has been identified to be due to a direct solid–solid conversion of
Form III to form I (Zeitler et al., 2007). Deviations in thermal behavior can further be
due to solvent inclusion in crystal pores, contamination by other polymorphic form, and
amorphous traces. CBZ dihydrate had two endothermic events in DSC measurements.
Dehydration was visible as a wide endothermic peak in temperature range of 50–85 °C.
Second endothermic peak was at 192 °C showing melting of CBZ from I.
True density of all CBZ samples was 1.338 ± 0.001 g/cm3 indicating CBZ polymor-
phic form III (Krahn and Mielck, 1989; Grzesiak et al., 2003).
Water Activity
For all CBZ anhydrous samples water activity was between 0.241 and 0.423. At a specific
water activity hydration of drug can occur (Qiu et al., 2009). Also the phase conversion
of anhydrous CBZ to CBZ dihydrate depends on the water activity of the system. In
the water activity range of 0.601–0.641 at 20 °C, CBZ form III and CBZ dihydrate are
reported to coexist in equilibrium (Qu et al., 2006; Li et al., 2008). Our samples were
therefore below the critical range for transformation.
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DIDR Profiles of CBZ Samples
DIDR profiles of the four CBZ samples and the CBZ dihydrate are shown in Figure 3.5
and Table 3.2 presents the IDR values. Initial phase in DIDR profiles showed a sig-
nificant difference in IDR for each CBZ samples (p < 0.05). IDR was in the rank
of CBZ A>D>B>C and the IDR values were in the same range (29, 35.5, and 37.6
µg/cm2/min) as reported previously (Yu et al., 2004; Zakeri-Milani et al., 2009; Murphy
et al., 2002). IDR value of CBZ dihydrate was 1.2–2.2 times lower than for anhydrous
CBZ samples. The comparatively low dissolution rate of CBZ C might be explained by
presence of small amounts of the less soluble CBZ form IV and compact hardness. CBZ C
compacts showed breaking strength about 2 times higher than of the other compacts.
It is interesting to note, that the amount of drug dissolved after 120 min inversely
correlated with the amount of fines in the CBZ samples. Generally, samples with higher
amount of fines show faster dissolution rate, in case of CBZ, however, the opposite was
the case. This leads to the conclusion, that CBZ fines transformed faster to the slower
dissolving CBZ dihydrate and therefore decreased the actual amount of drug dissolved
after 120 min.
Table 3.2: Intrinsic dissolution rate of CBZ samples and CBZ dihydrate (CBZ dihyr) in
the initial DIDR values prior to the first inflection point.
Sample n ≥ 3 IDR [µg/cm2/min]
CBZ A 43.9± 3.1
CBZ B 38.6± 0.8
CBZ C 24.0± 0.4
CBZ D 39.9± 0.7
CBZ dihyr 19.5± 0.7
Inflection Point. DIDR profiles showed not only one point of transformation at the early
stage of dissolution, but transformation continued over a time range stabilizing at a later
stage within 10 h. The results for the first and second inflection points are shown in Ta-
ble 6.5. First inflection points were in the same range as reported previously (Sˇehic´ et al.,
2010; Kobayashi et al., 2000). CBZ samples differed significantly in their first and second
inflection point (p < 0.05). Both inflection points could be ranked as C≤B<A<D. The
ranking was significant only for the second inflection point (p < 0.05), except for CBZ B
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Figure 3.5: DIDR profiles of pure carbamazepine from suppliers A, B, C, and D; 2 h (top)
and 10–11 h (bottom) dissolution time. Average values (n≥3) are presented.
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Table 3.3: First and second inflection point in DIDR profiles of CBZ samples.
Sample n ≥ 3 First inflection point [min] Second inflection point [min]
CBZ A 33± 6 570± 25
CBZ B 28± 10 443± 93
CBZ C 16± 3 350± 11
CBZ D 41± 7 635± 19
over C (p = 0.059). CBZ B showed the highest standard deviation for both inflection
points, which might be due to the high amount of fines.
The two inflection points could describe the transformation process from CBZ an-
hydrous to dihydrate in dissolution. The first inflection point reflected the onset of the
gradual change in dissolution rate induced by the forming and dissolution of CBZ dihy-
drate. The second inflection point reflected onset of the constant dissolution rate, where
the transformation process and dissolution were in equilibrium. Transformation as a pro-
cess over time has been studied on CBZ compact surface during intrinsic dissolution by in
situ Raman spectroscopy (Lehto et al., 2008). Based on the knowledge of previous studies
gained by Raman spectroscopy, fluorescence studies, or XRPD (Tian et al., 2006a; Brit-
tain, 2004; Suryanarayanan, 1989), the transformation range could be derived from the
DIDR profiles and thereby characterize the CBZ samples. To confirm the formation of
CBZ dihydrate compact surfaces were analyzed by SEM at several time points in DIDR
test as described in the following section.
Surface Change of CBZ Compacts During DIDR Test. To avoid recrystallization due
to sample preparation, the CBZ compacts were removed from the samples holder inclusive
the paraffin layer and gently placed upside down on a kitchen paper for a few seconds.
Samples were then kept under controlled RH of 43% for a maximum of 24 h hours prior
the the analysis. SEM pictures of the compact surfaces after 30, 60, 120, and 480 min
DIDR test confirmed CBZ dihydrate formation (Figure 3.6). The needle-shaped dihydrate
crystals on compact surface were visible at a later stage in DIDR test than their onset
of dissolution in the DIDR profiles. Dihydrate was first visible on the CBZ B and D
compacts after 60 min and on CBZ A and C compacts after 120 min. CBZ dihydrate
crystals grow at disrupted crystal structure of CBZ anhydrate induced, e.g., by grinding
(Murphy et al., 2002). CBZ B and D showed the most irregular particle shapes in SEM,
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(a) 30 min (b) 60 min (c) 120 min
(d) 480 min
Figure 3.6: SEM pictures of compact surface from CBZ B during DIDR test.
they were therefore expected to have the most crystal defects and transform the fastest. For
CBZ D, however, the first inflection point showed later compared to the other samples. A
reason could be that CBZ D showed less fines compared to CBZ B. The amount of fines
may be indicative for crystal defects in a sample, as fines can be caused by milling or
grinding.
Binary Mixtures
DSC results for binary mixtures are shown in Figure 3.7. An effect of tablet filler on
the thermal behavior of CBZ was observed. In presence of MCC, the intensity of the
thermal events was reduced and broken peaks were visible around 190 °C. In presence
of mannitol, a change in the thermal behavior of CBZ was observed. Mannitol melted
around 164 °C and CBZ seemed to dissolve fully in melted mannitol of 30% drug load
and partially at the higher drug loads resulting in a broadening of melting point for CBZ
form III and a shift towards lower temperature around 172 °C compared to melting of pure
form III at 176 °C. The same mixtures did not show any change in crystallinity in XRPD
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Figure 3.7: DSC profiles of binary mixtures of CBZ B in MCC and mannitol; 40 °C–
220 °C at 10 °C/min
results (data shown in Appendix 6.1.8). Therefore, the interaction with mannitol is limited
to temperatures of 164 °C and above. Also Joshi et al. (2002) reported the interaction of
CBZ with mannitol as a temperature related phenomenon detected in DSC.
Drug Release of Binary Mixtures. Drug release profiles of the binary mixtures com-
paring CBZ samples at same drug load are presented in Figure 3.8 and 3.9 shows the com-
parison of drug release of different drug loads with CBZ B as an example. An overview of
amount of CBZ released from the binary mixtures after 120 min dissolution test is shown
in Table 3.4.
It is interesting to note that the variability in DIDR profiles found in the CBZ samples
was present also in the drug release profiles of the binary mixtures. Amount of CBZ
released after 120 min differed significantly among CBZ samples of the same drug load
(ANOVA; p < 0.001, except for the 50% CBZ–MCC mixture). Difference in amount of
drug dissolved among the various CBZ samples was much less with the presence of MCC
than of mannitol. Methods for the analysis of dissolution curves were found to be either
over discriminative, i.e., analysis by one-way repeated measures ANOVA (MANOVA), or
not discriminative enough, i.e., difference factor (f1) and similarity factor (f2) proposed
by FDA (1997).
Drug release profiles of binary mixtures showed dependence on drug load. Dissolution
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Figure 3.8: Initial drug release profiles of binary mixtures at 70% drug load with mannitol
(top) and with MCC (bottom).
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Table 3.4: Amount of CBZ dissolved [%] from binary mixtures with mannitol and MCC
at different drug loads after 120 min.
Mannitol MCC
30% CBZ
A 16.06 ± 2.95 4.39 ± 0.22
B 10.73 ± 0.73 3.67 ± 0.27
C 13.39 ± 1.71 4.98 ± 0.08
D 10.61 ± 1.51 4.41± 0.28
50% CBZ
A 3.70 ± 0.18 2.49 ± 0.56
B 3.28 ± 0.24 3.30 ± 0.37
C 2.58 ± 0.18 2.92 ± 0.59
D 3.33 ± 0.10 3.31± 0.39
70% CBZ
A 1.85 ± 0.09 2.19 ± 0.09
B 2.05 ± 0.07 1.99 ± 0.04
C 2.43 ± 0.02 2.08 ± 0.12
D 1.52 ± 0.01 1.96 ± 0.07
90% CBZ
A 2.00 ± 0.09 3.23± 0.26
B 1.70 ± 0.05 1.47± 0.09
C 1.47 ± 0.03 1.22± 0.01
D 1.63 ± 0.06 1.58± 0.10
100% CBZ
A 2.33 ± 0.03
B 2.18 ± 0.02
C 1.39 ± 0.02
D 2.17 ± 0.03
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Figure 3.9: Initial drug release profiles of binary mixture with mannitol (top) and with
MCC (bottom).
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rate was increased at the lower drug loads of 50% and 30%, especially in binary mixtures
with mannitol. Amount of drug dissolved was 2 times higher for compacts of 50% and
7–10 times higher for compacts of 30% drug load with mannitol. For all binary mixtures
with 90% drug load, drug release was slower than for pure CBZ compacts.
A possible reason for the different effects of mannitol and MCC on drug release could
be their solubility difference. Mannitol dissolved very fast compared to the drug. CBZ
samples could express their dissolution variability, even at the lower drug loads, where
mannitol enhanced the solubility of CBZ. In contrast, compacts with the insoluble MCC
showed swollen surfaces with wide cracks after the drug release measurements. The fiber-
like structure of MCC could form a matrix that was able to control the amount of CBZ
released.
Conclusions
The unidirectional dissolution method proved to be a straightforward monitoring tool for
preformulation studies. Commercial CBZ samples could be specified by two inflection
points in the DIDR profiles reflecting the individual transformation to CBZ dihydrate. In
presence of the excipient mannitol or MCC, variability among CBZ samples regarding
drug release persisted. However, high amount of mannitol strongly increased release rate
of CBZ, and MCC was able to reduce the variability of CBZ samples. To control drug
release and bioavailability of CBZ in tablet formulation, MCC is suggested as a suitable
tablet filler.
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3.2 Effect of Crospovidone and Hydroxypropyl Cellulose
on Carbamazepine in High-Dose Tablet Formulation
Abstract
The aim of this study was to develop a high-dose tablet formulation of the poorly soluble
carbamazepine (CBZ) with sufficient tablet hardness and immediate drug release. A fur-
ther aim was to investigate the influence of various commercial CBZ raw materials on the
optimized tablet formulation. Materials and Methods: Hydroxypropyl cellulose (HPC-
SL) was selected as a dry binder and crospovidone (CrosPVP) as a superdisintegrant. A
direct compacted tablet formulation of 70% CBZ was optimized by a 32 full factorial de-
sign with two input variables, HPC (0–10%) and CrosPVP (0–5%). Response variables
included disintegration time, amount of drug released at 15 and 60 min, and tablet hard-
ness, all analyzed according to USP 31. Results and Discussion: Increasing HPC-SL
together with CrosPVP not only increased tablet hardness but also reduced disintegration
time. Optimal condition was achieved in the range of 5–9% HPC and 3–5% CrosPVP,
where tablet properties were at least 70 N tablet hardness, less than 1 min disintegration,
and within the USP requirements for drug release. Testing the optimized formulation with
four different commercial CBZ samples, its variability was still observed. Nonetheless,
all formulations conformed to the USP specifications. Conclusion: With the excipients
CrosPVP and HPC-SL an immediate release tablet formulation was successfully formu-
lated for high-dose CBZ of various commercial sources.
Keywords: Immediate Release, Direct Compaction, Superdisintegrant, CrosPVP, Dry
Binder, HPC-SL, Experimental Design.
Introduction
Carbamazepine (CBZ) is a well established drug against epilepsy and trigeminal neural-
gia. It is poorly soluble with dissolution controlled absorption, and hence a class II drug
according to the Biopharmaceutical Classification System (Lindenberg et al., 2004). CBZ
shows a history of erratic dissolution behavior with high variability between and within
different marketed CBZ tablets world-wide and clinical failures are a longstanding prob-
lem (Wang et al., 1993; Meyer et al., 1992, 1998; Davidson, 1995; Jung et al., 1997; Lake
et al., 1999; Mittapalli et al., 2008).
CBZ is a polymorphic drug with at least four polymorphic forms. Form III is the
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thermodynamically most stable form at ambient condition and it is also the commercially
available form. There are several CBZ solvates and cocrystals, e.g., CBZ monoacetonate
and CBZ:saccharin cocrystal (Fleischman et al., 2003; Hickey et al., 2007). At high rela-
tive humidity and in water CBZ transforms to its slower dissolving CBZ dihydrate form.
This transformation critically influences dissolution and bioavailability of CBZ formula-
tions and it has been in the focus of many investigations over the last 20 years. Laine
et al. (1984) described the transformation as solution-mediated process and the forma-
tion of dihydrate crystals by whisker growth. A decrease in dissolution rate is expected
as soon as the less soluble CBZ dihydrate is formed. This phenomenon is detected as
an inflection point in the disc intrinsic dissolution rate (DIDR) profile of CBZ samples.
Kobayashi et al. (2000) found that the transformation depends on the polymorphic form.
Sˇehic´ et al. (2010), however, reported different transformation points within commercial
CBZ samples, though same polymorphic form was specified. This difference also shows
in tablet formulation using Ludipress® as tablet filler. Building on the method of Sˇehic´
et al. (2010) a unidirectional dissolution method was developed to characterize DIDR of
CBZ samples over a longer time range describing the transformation as a process with
onset (first inflection point) and equilibrium stage of transformation (Flicker et al., 2011).
The unidirectional dissolution method was further applied to study the initial drug release
of CBZ of binary mixtures with commonly used tablet fillers. The water-soluble mannitol
increases initial drug release of CBZ samples up to 10-fold in mixtures of 30% drug load
and the presence of MCC results in reduced variability in drug release. DIDR method
is presented as a straightforward monitoring tool to characterize variability of CBZ raw
materials and effect of tablet fillers.
There have been several attempts to control transformation of CBZ anhydrous to di-
hydrate. Dihydrate formation is strongly inhibited in solutions (1–4% w/v) of hydrox-
ypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), or polyvinyl pyrroli-
done (PVP), whereas solutions of polyvinyl alcohol (PVA), polyethylene glycol (PEG),
and sodium carboxymethyl cellulose (CMC) have only weak inhibitory activity (Gift
et al., 2008; Tian et al., 2006; Otsuka et al., 2000). In contrast, surfactants, such as
sodium laurylsulphate and sodium taurocholate promote the dihydrate formation during
the dissolution test (Rodrı`guez-Hornedo and Murphy, 2004). Few authors studied the
effect on transformation by including the excipient directly into the tablet formulation.
Katzhendler et al. (1998, 2000) analyzed the gel layer of matrix tablets containing HPMC
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and later also egg albumin during the dissolution process. HPMC was found to inhibit the
transformation to the CBZ dihydrate form, however, HPMC also participates in its crys-
tallization process and induces amorphous CBZ. Egg albumin was also found to inhibit
the transformation, though with a dose dependence. Salameh and Taylor (2006) studied
the transformation exposing physical mixtures of anhydrous CBZ or theophylline with
mannitol, microcrystalline cellulose (MCC), PVP K12, or PVP K90 to various relative
humidity. MCC has only minimal effect on both drugs, mannitol enhances dehydration,
whereas PVP K12 and PVP K90 show contradictory results for CBZ and theophylline.
The authors concluded, that the effect of excipients on hydrate forming drugs depends
on a multitude of factors and knowledge is still limited. Recently, Schulz et al. (2010)
successfully adsorbed CBZ to crospovidone to prevent recrystallization to CBZ dihydrate
during the solvent disposition. However, transformation is prevented only in small drug
loads (≤ 9.1%).
Information about excipients used in marketed CBZ tablet formulations is sparse.
Lake et al. (1999) published in their studies the excipients of four marketed tablet for-
mulations. Not surprisingly, all formulations contained excipients (starch or cellulose
derivates) enhancing the disintegration properties.
The excipients crospovidone (CrosPVP) and HPC are both promising to control the
dissolution behavior to be more homogeneous as they are both reported to inhibit nucle-
ation of the CBZ dihydrate (Otsuka et al., 2000; Tian et al., 2006; Schulz et al., 2010).
CrosPVP is a water-insoluble and non-gelling polymer used as tablet disintegrant and sol-
ubility enhancer (2–5%). It is free-flowing and suitable for direct compaction (Rowe et al.,
2006). Mixing CBZ with CrosPVP in a drug:polymer weight ratio of 1:2 results in drasti-
cally increased dissolution rate of the drug (Machiste et al., 1995). The excipient HPC is
a water-soluble polymer widely used in tablet formulation. Depending on the substitution
level and on the particle size, HPC is effective as tablet binder or as tablet disintegrant. At
low substitution and as fine powders, HPC shows low viscosity and sustained release and
is suitable for direct compression (Rowe et al., 2006; Kawashima et al., 1993). So far, the
combination of the excipients CrosPVP and HPC has not been studied.
In this study the effect of the two excipients CrosPVP and HPC on CBZ high-dose
tablet formulation were investigated by experimental design. In a second step, CBZ raw
materials of different commercial sources were tested with the optimized tablet formula-
tion for immediate release.
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Materials and Methods
Materials
Carbamazepine (CBZ) was obtained from four different commercial suppliers; in this
study they were designated as CBZ A, B, C, and D. Crospovidone (CrosPVP) a cross-
linked polyvinylpyrrolidone (Polyplastone® XL-10, ISP Corp., USA) was used as the su-
perdisintegrant. Hydroxypropylcellulose (HPC) of special low viscosity and fine powder
type (HPC-SL, Nisso, Japan) was used as the dry binder. Microcrystalline celluloseMCC
SANAQ® 102L was donated by Pharmatrans SANAQ AG, Switzerland. All samples
were stored at room temperature (20–25°C) and controlled relative humidity (43% RH).
All other chemicals and reagents were of analytical grade.
Experimental Design
The effect of CrosPVP and HPC on CBZ tablet formulation was studied by a 32 full
factorial design. Input variables were HPC (0–10%) and CrosPVP (0–5%) at the levels
minimal (–), mid-point (0), and maximal (+) concentration according to the design. Re-
sponse variables included disintegration time, amount of drug released at 15 and 60 min,
and tablet hardness. The software STAVEX® 5.0 (Aicos, Switzerland) was used for gen-
erating the experimental design, modeling the response surface plots, and calculating the
statistical evaluation.
Preparation of Carbamazepine Tablet Formulation
Powder Blends
All powder blends were of 70% CBZ and MCC was selected as the tablet filler, as sug-
gested in previous studies (Flicker et al., 2011). CrosPVP and HPC were added accord-
ing to the experimental design. Powder blends were mixed for 10 minutes with a Tur-
bula® type T2A mixer (Willy A. Bachofen, Switzerland) and for further 2 minutes after
adding 1% magnesium stearate (Sandoz, Switzerland). For the design of experiments and
the validation of the experimental design, only CBZ of supplier C was used.
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Tablet Formulation
A direct compaction method was selected to prepare tablet formulations. Tablets of
400 mg were prepared by a compaction simulator (Presster®, Metropolitan Computing
Co., USA) using a 10-mm flat-faced punch. The rotary press Korsch 336 with 36 stations
was simulated at a speed of 0.5 m/s. Compaction force was between 6–10 kN for all
tablets, with the exception of tablets containing CBZ A (14–17 kN).
Porosity was kept at 11.9 ± 0.3%. Porosity (￿) was calculated by the Equation (3.3)
based on tablet volume,
￿ = (1− m
Vtρt
)100 (3.3)
where m is the tablet mass and Vt the tablet volume, and ρt the true density of the powder
blends. Density of the powder blends was calculated as weighted mean from the true
density of each component. True density was assessed by a gas displacement pycnometer
(AccuPyc 1330, Micromeritics, USA).
Disintegration Test
Disintegration time was measured with a disintegration apparatus, without disk, (So-
taxDT2, SOTAX AG, Switzerland). Disintegration medium was distilled water at 37°C
± 2°C.
Dissolution Test
Dissolution test was performed by a USP Apparatus II (SotaxAT7smart, SOTAX AG,
Switzerland). The conditions were according to the USP monograph for CBZ immedi-
ate release tablets. Paddle speed was 75 rpm and media was 900 ml water containing
1% sodium laurylsulfate (w/V) at 37°C. Samples were analyzed by UV-VIS Spectropho-
tometer (Lambda 25, PerkinElmer) at 287 nm. Dissolution curves of CBZ tablets were
evaluated according to the criteria for immediate release CBZ tablets described in the USP
monograph. CBZ tablets are within specification, if 45–75% CBZ is released after 15 min
(t15) and not less than 75% after 60 min dissolution (t60).
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Tablet Hardness
Breaking strength was measured by a tablet hardness tester (Dr. Schleuniger® model 8M,
Pharmatron, USA). Tensile strength (σ) was calculated by the Equation (4.1),
σ =
2F
πDt
(3.4)
where F is the force needed to fracture the tablet by the hardness tester, D the diameter,
and t the thickness of the cylindrical tablet.
Interaction Studies of CBZ Samples in Powder Blends
All powder blends and excipients were analyzed by X-ray powder diffractometry (XRPD)
using a diffractometer (D5000, Siemens, Germany). The powder was filled into special
holders and the surface was pressed flat. Operating conditions were Ni filtered Cu-Kα
radiation (λ =1.5406 A˚), 40 kV, 30 mA, 0.02° 2θ, 1.0 s,1° 2θ/min, and angular range was
5°–40° 2θ.
Thermal behavior of all powder blends and excipients were analyzed by differen-
tial scanning calorimetry (DSC), using heat flux DSC (4000, PerkinElmer, USA). DSC
was calibrated with indium prior to the measurement. A sample of 4–6 mg was accu-
rately weighed into an aluminum pan with holes and scanned between 40°C and 220°C at
10°C/min under dry nitrogen gas purge (20 ml/min).
To ensure a stable condition for the anhydrous CBZ, not to transform to its dihydrate
form, water activity of all powder blends was monitored with the digital water activity
analyzer (Hygropalm, Rotronic AG, Switzerland) at 23.5 ± 1.5°C.
Friability Test
Friability of CBZ tablets with different CBZ raw material was measured by a USP con-
form friability tester (Erweka® type TAD-UZ, Apparatebau GmbH, Germany). Each 17
tablets, weighing close to 6.5 g were tested. The drum was rotated 100 times at 25 rpm
and the weight loss (%) was recorded.
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Statistical Analysis
Mean dissolution curves of the tablets with different CBZ raw materials were compared
by difference factor (f1) and similarity factor (f2), as of Equations (3.5) and (3.6),
f1 =
￿￿n
t=1 |Rt − Tt|￿n
t=1Rt
￿
× 100 (3.5)
f2 = 50× log
￿
(1 +
1
n
n￿
t=1
(Rt − Tt)2
￿−0.5
× 100) (3.6)
where n is the number of dissolution samplings, and Rt, Tt are the percent dissolved of
the reference and test dissolution profile at each time point t.
Mean dissolution curves were further compared by Turkey test. At time points t15 and
t60 individual amount of drug released was compared using one-way ANOVA.
Results and Discussion
Experimental Design
The results of response variable to the 32 full factorial design are displayed in Table 3.5.
The responses disintegration time and amount of drug dissolved varied strongly. Disin-
tegration time varied from 0.18 min (11 sec) to 240 min. The amount of drug dissolved
was 2-75% and 7-92% after 15 and 60 min, respectively (Figure 3.10). This is expected
as the factors covered a wide concentration range. The amount of drug dissolved was
2–75% and 7–92% after 15 and 60 min, respectively (). The tablet hardness was 63–80 N
in breaking strength corresponding to 0.970–1.193 tensile strength.
The response variables could be described by the following equations, where D and
B are the factors disintegrant CrosPVP and binder HPC. Equation (3.7) describes the
disintegration time by a logarithmic function [log(DT)], Equations (3.8) and (3.9) describe
the amount of drug dissolved at 15 and 60 min dissolution time (dd15, dd60), and Equation
(3.10) the breaking strength (BS). Table 3.6 shows the goodness of fit (R2) and adjusted
goodness of fit (Rc2) for the equations. All equations showed good correlation for the
experimental data (Rc2 > 0.840).
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Table 3.5: The 32 full factorial design for the factors CrosPVP and HPC at low (–), mid-
point (0), and high (+) level concentration and its responses disintegration time (DT), drug
dissolved after 15 and 60 min (dd15, dd60), and breaking strength (BS).
levels % (w/w) response variables
Nr. CrosPVP HPC CrosPVP HPC DT [min] dd15[%] dd60[%] BS [N]
1 – – 0 0 35.00 12.4 ± 1.4 25.7 ± 1.6 69 ± 1
2 0 – 2.5 0 0.83 71.0 ± 3.5 87.8 ± 4.8 74 ± 2
3 + – 5 0 0.18 73.9 ± 1.3 90.3 ± 1.9 76 ± 3
4 – 0 0 5 105.00 4.6 ± 0.2 14.5 ± 0.6 65 ± 2
5 0 0 2.5 5 0.43 66.1 ± 7.6 88.1 ± 5.6 68 ± 1
6 + 0 5 5 0.33 63.4 ± 4.0 88.1 ± 2.3 73 ± 1
7 – + 0 10 240.00 2.5 ± 0.3 8.1 ± 0.8 75 ± 2
8 0 + 2.5 10 1.40 25.5 ± 6.6 64.1 ± 5.1 77 ± 2
9 + + 5 10 0.82 49.1 ± 7.7 77.3 ± 5.5 78 ± 2
Figure 3.10: Dissolution curves of CBZ formulations Stavex Nr. 1–9
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log(DT ) = 3.90− 2.78 ∗D+ 0.028 ∗B + 0.32 ∗D2 + 0.01 ∗B2 − 0.01 ∗D ∗B (3.7)
dd15 = 14.24 + 28.52 ∗D + 0.35 ∗B − 3.18 ∗D2 − 0.23 ∗B2 − 0.30 ∗D ∗B (3.8)
dd60 = 24.74 + 36.83 ∗D − 0.17 ∗B − 4.69 ∗D2 − 0.19 ∗B2 + 0.09 ∗D ∗B (3.9)
BS = 68.89 + 1.87 ∗D − 1.90 ∗B − 0.05 ∗D2 + 0.25 ∗B2 − 0.08 ∗D ∗B (3.10)
Table 3.6: Goodness of fit for the response equations of disintegration time (DT), drug
dissolved after 15 and 60 min (dd15, dd60), and breaking strength (BS).
responses Equation Goodness of fit Adj. goodness of fit
R2 Rc2
log(DT) (3.7) 0.9845 0.9595
dd15 (3.8) 0.9401 0.8403
dd60 (3.9) 0.9901 0.9736
BS (3.10) 0.9680 0.9146
-35.0 -17.5 0.0 17.5 35.0 
D  
B 
D^2 
B^2 
D*B 
%dd 60' %dd 15' log(DT)*10 BS 
** 
** 
** 
* 
* ** 
* 
* 
* 
Figure 3.11: Coefficient values (coded parameters) to each factor showing the positive
and negative impact on the response variables: (*) p < 0.05, (**) p < 0.01.
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The impact of each factor on the response variables is shown in the pareto chart in
Figure 3.11. The coefficient values for each factor by itself (D, B), concentration depen-
dent (D2, B2), and in interaction (D∗B) are displayed as coded units and labeled with the
significance of the factor.
Effect of CrosPVP and HPC
The effect of each factor on the tablet formulation was studied. Effect of increasing
amount of CrosPVP was a shorter disintegration and faster drug release. From the model
of experimental design, the minimal disintegration time was for tablet formulation of 3.8%
CrosPVP, the maximal drug release at 15 and 60 minutes were found for tablets with 4.6%
and 3.9% CrosPVP, and maximal tablet hardness was achieved with 5% CrosPVP.
Presence of HPC resulted in increased disintegration time and slower dissolution, and
mostly in stronger tablets. Adding HPC alone improved compactability, however, drug
release was prolonged. Tablet hardness is critical in CBZ formulation of high drug load.
CBZ is poorly compactable and is prone to capping and lamination (Lefebvre et al., 1986;
Nokhodchi et al., 2007).
Combined Effect of CrosPVP and HPC
The combined effect of CrosPVP and HPC is shown in Figure 3.12. The shortest disinte-
gration time was achieved with medium to high amount of CrosPVP combined with same
or up to the double amount of HPC. However, with this optimal amount of CrosPVP, the
dissolution was faster with low to medium amounts of HPC and tablet hardness was best
with either low or high amount of HPC.
Design Space for Optimal Formulation
Figure 3.13 shows the contour plots of all responses overlapped to one figure. It presents
a rough visualization of the design space. The light grey window depicts the region of
the optimal formulation with disintegration time of less than 1 min, drug dissolved of 45–
75% at 15 min and more than 75% at 60 min dissolution time, and of sufficient breaking
strength (more than 70 N). The window is confined by insufficient breaking strength and
prolongued disintegration time from the left, excess in drug released after 15 min from
the bottom-right, and by insufficient drug released after 60 min from bottom-left and top-
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Figure 3.12: Effect of interaction in the responses disintegration time (DT), drug dissolved
after 15 and 60 min (dd15, dd60), and breaking strength (BS)
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Figure 3.13: Contour plots of response variables log(DT), dd15, dd60, and BS, overlapped
to one figure, roughly visualizing the region for the design space for the optimal formula-
tion (light grey window).
right. The optimal conditions were achieved with approximately 3–5% CrosPVP and 5–
9%HPC. The amount of CrosPVP is within the concentration range suggested in literature
(2–5%). However, higher amount of HPC was necessary to achieve optimal formulation
than the suggested 2–6% HPC as a dry binder. Nonetheless, the optimal amount of HPC is
still lower than the suggested amount of 15–35% HPC for extended release formulations
(Rowe et al., 2006).
Model Validation
The result of the validation is displayed in Table 3.7. The responses of three additional
formulations within the design space for optimal formulation were tested and the devi-
ation from the predicted responses was calculated. Formulation x (4.5% CrosPVP and
7.0% HPC) and z (5% CrosPVP and 6% HPC) were selected to test the upper region of
the optimal window and formulation y (3% CrosPVP and 1% HPC) to test the lower re-
gion. The response variables were predicted with deviations of 14% and less. Only the
disintegration time could not be predicted for the short disintegrations of less than 1 min
(deviation > 65%).
The dissolution curves of test formulations x, y, and z are shown in Figure 3.14. All
test formulations were within the USP specifications for CBZ immediate release tablets.
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Table 3.7: Model validation for the response variables disintegration time (DT), drug
dissolved after 15 and 60 min (dd15 and dd60), and breaking strengthe (BS), for the test
formulations x, y, and z.
response predicted observed % deviation
formulation x: 4.5% CrosPVP, 7% HPC
log(DT) [min] 0.71 0.5 65.4
dd15[%] 60.1 58.4 2.9
dd60[%] 88.0 87.0 1.2
BS [N] 76.11 84.6 11.2
formulation y: 3% CrosPVP, 1% HPC
log(DT) [min] -0.61 0.32 68.1
dd15[%] 71.5 73.0 2.1
dd60[%] 92.9 88.1 -5.2
BS [N] 72.81 76.0 4.4
formulation z: 5% CrosPVP, 6% HPC
log(DT) [min] 0.71 0.4 66.1
dd15[%] 62.3 53.6 14.0
dd60[%] 86.6 84.0 3.0
BS [N] 75.71 79.7 5.4
1predicted by partial equation, p < 0.1
Formulation z was selected as the optimal formulation because its dissolution curve was
with 53.6% drug dissolved at t15 in the middle between the range required by USP (dd15
45–75%) and it showed the smallest relative standard deviation within the first 60 min of
dissolution (RSD60 3.8%). Furthermore, tablets were with 79.9 N of sufficient hardness.
Observations on Disintegration Behavior and Dissolution Variability
Tablet formulations showed a remarkable wide range in RSD60 that could be attributed to
the effect of CrosPVP and HPC-SL. Dissolution curves of tablets from experiment num-
ber 3 showed a RSD60 of less than 2%, dissolution curves of tablets from experiment
numbers 7–9 showed a RSD60 of more than 12%. Analyzing RSD60 as an additional re-
sponse variable to the experimental design, a good correlation with the input variables
was found (Rc2 0.9087). CrosPVP showed a positive effect on the RSD60, where increas-
ing amount of CrosPVP reduced the RSD60 (p < 0.05). HPC-SL had a negative effect on
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Figure 3.14: Dissolution curves of test formulations x, y, and z.
RSD60 with a maximal RSD60 at the highest amount. The reason for the negative effect
of HPC-SL may be due to its function as binder and its morphological structure. Tablet
formulations containing high amounts of HPC-SL formed sticky, irregular, and flake-like
agglomerates, whereas tablets containing high amounts of CrosPVP presented fine par-
ticles. These effects were best visible during the disintegration and dissolution testing.
The compact presenting the irregular and flake-like agglomerates also showed the highest
RSD60.
Optimized Tablet Formulation of CBZ of Different Suppliers
CBZ samples of four different suppliers were tested with the formulation z. As the effect
of CrosPVP and HPC-SL on drug release variability was observed in the dissolution test,
the influence of total amount of these excipients was tested for its ability to reduce the
variability found for the different CBZ samples. A formulation of high level CrosPVP
and HPC-SL was selected (formulations CBZ h: 7.5% CrosPVP and 9% HPC-SL). The
ratio of CrosPVP to HPC-SL was the same as in the optimal formulation z, but out of the
design space. As a counter point a formulation of low level CrosPVP and HPC-SL was
selected within the design space (formulations CBZ l: 2% CrosPVP and 1% HPC-SL).
The dissolution curves of the formulations CBZ l and CBZ h are shown in Figure 3.15
together with formulation z, each with CBZ A, B, C, or D.
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(a) low amount of CrosPVP and HPC (b) intermediate amount of CrosPVP and HPC: for-
mulation z
(c) high amount of CrosPVP and HPC
Figure 3.15: Dissolution curves with CBZ A, B, C, and D of low (l), intermediate (z), and
high (h) concentration of CrosPVP and HPC.
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Table 3.8: Similarity and difference factor (f1, f2) for dissolution curves of tablets with
CBZ A, B, C, and D at low (CBZ l), intermediate (CBZ z), and high (CBZ h) total con-
centration of CrosPVP and HPC.
f1; f2 f1; f2 f1; f2
A B D
CBZ l C 11 ; 52 12 ; 50 1 ; 94
CBZ z C 11 ; 52 9 ; 58 8 ; 61
CBZ h C 15 ; 50 20 ; 43 1 ; 91
The dissolution curves were compared by the similarity and difference factor (f1, f2).
The results are shown in Table 3.8. Dissolution curves of tablets with CBZ C were used
as the reference. According to the FDA guidance for industry (FDA, 1997) sameness or
equivalence of two curves is assumed if f1 values are 0–15 and f2 values 50–100. Applying
this rule to the results, dissolution curves were the same among tablets of CBZ A, B, C,
and D at all three concentration levels, with the exception of the dissimilar dissolution
curves of tablets containing CBZ B and C at high total amount of excipients. Dissolution
curves of tablets containing CBZ A and C were with f1 of 15 and f2 of 50 at the upper
limit to still conclude sameness.
In contrast, pairwise comparison by Turkey Test (95% CI) showed significant differ-
ence among each sample at all concentration levels (p < 0.01), except between low level
tablets of CBZ A and B, and between low and high level tablets of CBZ C and D. Com-
paring amount of drug dissolved at one time point (15 and 60 min), the difference among
tablets with CBZ A, B, C, and D was even more pronounced (ANOVA p < 0.005). Also
Yuksel et al. (2000) observed the ANOVA-based methods to be more discriminative and
more informative on differences in dissolution curves than the f-factors.
It has to be noted, that the dissolution curves of the formulations with high excipient
levels showed a RSD60 of more than 10%. At low excipient level dissolution curves
showed also elevated RSD60, but less than 8%. The high RSD60 obscured the different
dissolution behavior of each CBZ raw material. Increasing or decreasing the total amount
of CrosPVP and HPC-SL could not reduce the influence of raw drug variability on the
dissolution behavior, proving the optimal concentration of 5% CrosPVP and 6% HPC-SL
in formulation z.
As to the fast disintegration of less than 1 min, the inhibitory effect of HPC and
CrosPVP on the CBZ transformation could not be detected during the dissolution. The
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CBZ samples used in this study were reported to show individual transformation behavior
in previous work and MCC is suggested as a tablet filler to reduce variability in drug re-
lease (Flicker et al., 2011). Furthermore, CrosPVP and HPC were also reported to reduce
variability in drug release, because of their ability to inhibit transformation. However, the
results of the current study still show variability in CBZ tablet formulation according to
the CBZ source used.
To verify the reason for this variability, the samples could be analyzed by in-situ Ra-
man spectroscopy during the dissolution process (Tian et al., 2007; Savolainen et al.,
2009). Besides an individual transformation behavior, morphological differences can not
be excluded as a reason to the differences among tablets of different CBZ source.
Tablet Hardness and Friability
Tablets of the optimized formulation z showed different hardness depending on the CBZ
sample. Breaking strength was 150 ± 1 N, 79 ± 2 N, 80 ± 2 N, and 81 ±2 N for tablets
with CBZ A, B, C, and D, respectively.
Friability was 0.5%, 1.2%, 1.3%, and 0.9% for the optimized formulation z with CBZ
A, B, C, and D, respectively. Only the formulation with CBZ A and D showed enough
robustness for possible film coating. The variability of tablet hardness and friability re-
garding CBZ raw materials emphasizes a concern of appropriate selection of raw material
supply.
Interaction Studies in Powder Blends
The results for XRPD and DSC analysis of the powder blends are shown in Figure 3.16.
No interaction or change in polymorphic form was detected.
For all powder blends water activity was between 0.435 and 0.528. Phase conversion
of CBZ p-monoclinic form to CBZ dihydrate depends on the water activity of the system
(Qu et al., 2006) as both forms were found to coexist in equilibrium at the water activity
range 0.601 to 0.641 and 20°C (Li et al., 2008). Our samples were therefore not in the
critical range.
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(a) XRPD: 5°–40° 2θ at 0.02° 2θ and 1° 2θ/min.
(b) DSC: 40–220°C at 10°C/min
Figure 3.16: X-ray powder diffraction (top) and DSC (bottom) of CBZ N, powder blend
of formulation z, and components HPC-SL, CrosPVP, and MCC.
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Conclusions
High-dose CBZ tablets were successfully prepared with the aid of CrosPVP and HPC-
SL. Effect of CrosPVP and HPC on a high-dose CBZ tablet formulation were clearly
visible. An optimal formulation was found containing 5% CrosPVP and 6% HPC, where
tablet formulation of different CBZ raw materials conformed to the USP requirements
for CBZ immediate release tablets. Nonetheless, variability in commercial CBZ samples
effected the tablet properties including the dissolution behavior and its influence could
not be reduced. We therefore suggest selecting the CBZ raw material carefully to obtain
a robust high-dose formulation.
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Chapter 4
Recrystallization Project
Abstract
Physical properties of commercial CBZ samples can significantly influence drug release
and thereby jeopardized bioequivalence of the final dosage form. The aim of this project
was to reduce variability in commercial CBZ samples by recrystallization. CBZ sam-
ples of four different suppliers were recrystallized in ethanol solution containing 1% PVP.
The obtained crystals were analyzed by disk intrinsic dissolution rate (DIDR), differen-
tial scanning calorimetry (DSC), and X-ray powder diffraction (XRPD). Recrystallized
CBZ samples showed strongly reduced variability in intrinsic dissolution rate (IDR) and
first inflection point in the DIDR profiles compared to the untreated CBZ samples. Fur-
thermore, transformation process to CBZ dihydrate was inhibited; no dihydrate crystals
were visible on compact surfaces after 8 h intrinsic dissolution measurement. DSC and
XRPD showed no change in polymorphic form. Analyzing recrystallized CBZ in binary
mixtures with MCC drug release showed again significant variability. The low yield of
the recrystallized CBZ samples (53–70%) and the necessary but critical step of grinding
need further improvement. Therefore, the careful selection of the CBZ raw material is
suggested at the actual stage of knowledge.
Introduction
Pharmaceutical companies are facing a fast growing market of drug suppliers, raw mate-
rials can be obtained from suppliers in India and China at lower price. Physicochemical
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properties of raw materials can vary among drug suppliers with consequence on the drug
performance in the final drug formulation.
CBZ is one example where sample variability among different suppliers effects the
dissolution behavior of the tablet formulation. Sˇehic´ et al. (2010) reported different trans-
formation to dihydrate within commercial CBZ samples, though same polymorphic form
was specified. This difference also shows in tablet formulation using Ludipress® as tablet
filler. Developing a CBZ tablet formulation for immediate release, Flicker and Betz (2011)
selected the two excipients crospovidone and hydroxypopyl cellulose, both reported to in-
hibit transformation. However, tablet hardness, friability, and drug release varied with the
CBZ sample. For CBZ the variability in drug release is closely linked to clinical failures
as the bioavailability of CBZ is dissolution controlled and the pharmacological action is
within a narrow therapeutic range (Lindenberg et al., 2004).
Physicochemical properties of raw materials depend on the method of production. The
crystallization step of a drug can be performed with different solvents and additives. They
result in different crystal habits and possible solvent inclusion, both leading to different
solubility and dissolution behavior (Rodrı`guez-Sponga et al., 2004). This phenomenon
has also been studied on CBZ. Bolourtchian et al. (2001) compared CBZ samples recrys-
tallized in ethanol and acetone under different conditions. Crystallization from ethanol or
acetone results in polyhedral and thin plate-like crystals, respectively. Using a watering-
out method needle-shaped crystals are obtained. The recrystallized CBZ samples show
improved dissolution rate and compactibility compared to the untreated samples. How-
ever, interpreting the XRPD results of the CBZ crystals obtained by the watering-out
method, the crystals are most likely of CBZ dihydrate form. The peaks around 5, 9,
12° 2θ conform with the XRPD data reported for CBZ dihydrate (McMahon et al., 1996;
Li et al., 2000). Very similar studies were performed by Mahalaxmi et al. (2009), they
recrystallized CBZ samples in ethanol and acetone at different cooling conditions. The
solvents also lead to different crystal habit and different polymorphic form. Fast cooling
results in smaller crystals with faster dissolution. Nokhodchi et al. (2005) studied the ef-
fect of the additives PEG 4000, PVP K30, and Tween 80 (1% w/v) on the recrystallization
of CBZ in ethanol solutions. Thus obtained crystals are of different crystal habit but of
same polymorphic form (CBZ form III). Recrystallization in presence of PVP K30 re-
sults in more block-shaped crystals showing higher dissolution rate and improved tensile
strength.
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Crystallization is mostly followed by a milling or grinding step. However, these phys-
ical processes cause crystal defects, mechanical activation, and small amounts of amor-
phous that can further lead to faster and inhomogeneous dissolution behavior of CBZ
(Tian et al., 2006b; Murphy et al., 2002; Mosharraf et al., 1999; Lefebvre et al., 1986).
In this study, CBZ samples of four different suppliers were recrystallized in ethanol
containing 1% PVP. The effect of recrystallization on sample variability was investigated
by DSC, XRPD, and intrinsic dissolution profiles using the unidirectional dissolution
method developed earlier (Flicker et al., 2011). Recrystallized samples were also tested
in binary mixtures with MCC at 70% drug load.
Materials and Methods
Carbamazepine of four different suppliers (A, B, C, and D) was recrystallized according to
Nokhodchi et al. (2005). Each sample (42 g) was dissolved in 910ml 1% polyvinylpyrroli-
done (PVP K30, Kollidon®K30 BASF) ethanol solution at 65 °C. After cooling to room
temperature the solutions were placed in the refrigerator (4–8 °C) for 24 h. The crys-
tals were filtered under suction, dried at ambient condition over night, and for 72 h over
pentoxide (0% RH). The crystals were slightly ground with mortar and pistil and kept at
room temperature and 43% RH. Recrystallized CBZ samples were obtained at a yield of
53–70%.
Microcrystalline cellulose (MCC SANAQ®102L; Pharmatrans SANAQ AG, Switzer-
land) was used as a water-insoluble tablet-filler for the binary mixtures. All other chemi-
cals and reagents purchased from commercial sources were of analytical grade.
Polymorphic Characterization
Polymorphic form of CBZ samples was characterized by X-ray powder diffractometry
(XRPD) using a diffractometer (D5000, Siemens, Germany). The powder was filled into
special holders and the surface was pressed flat. Operating conditions were Ni filtered
Cu-Kα radiation (λ =1.5406 A˚), 40 kV, and 30 mA. Step was 0.02° 2θ, step time 1.0 s,
angular scanning speed 1° 2θ/min, and angular range between 5° and 40° 2θ scale.
Thermal behavior of all samples was analyzed by differential scanning calorimetry
(DSC), using heat flux DSC (4000, PerkinElmer, USA). DSC was calibrated with indium
prior to the measurement. A sample of 3-6 mg was accurately weighted into an aluminum
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pan with holes and scanned between 40 °C and 220 °C at 10 °C/min under dry nitrogen
gas purge (20 ml/min).
True density of all samples was assessed by a gas displacement pycnometer (AccuPyc
1330, Micromeritics, USA). Powder was purged with helium by five repetitive purging
cycles and the density was reported as average value. The test was performed in triplicate.
Morphologic Characterization
For morphological characterization scanning electron microscopy (SEM) (ESEM XL 30
FEG, Philips, The Netherlands) was applied at a voltage of 10 kV and magnifications
of 100–2000 times. Before analysis, powder was sprinkled on carbon adhesive and then
sputtered with platinum.
Water Activity Measurement
Water activity of all samples was monitored with a digital water activity analyzer (Hy-
gropalm, Rotronic AG, Switzerland) at 23.5 ± 1.5 °C.
Unidirectional Dissolution Method
Sample preparation. Recrystallized CBZ samples were mixed with MCC for 10 min
in a mixer (Turbula® type T2C, W. Bachofen, Switzerland) and for a further 2 min after
adding 1% magnesium stearate (Sandoz, Switzerland) to the mixture. Drug load was 70%
and mixtures of 10 g were prepared.
Flat-faced compacts of 400 mg were produced from recrystallized CBZ and of binary
mixtures using Zwick 1478 material tester (Zwick, Germany). Surface area was 0.95 cm2
and porosity was 7% and 12% for pure drug and binary mixtures, respectively. Compac-
tion speed was at 10 mm/min and 50 mm/min.
Dissolution. To obtain disc intrinsic dissolution rate (DIDR) profiles of the CBZ sam-
ples, unidirectional dissolution was performed by a modified USP Apparatus I. The com-
pact was placed in a sample holder fitting to the rotating unit of the dissolution apparatus
(SotaxAT7smart, SOTAX AG, Switzerland) and the compact was embedded in melted
paraffin wax so only one surface was available to the dissolution media. Unidirectional
dissolution method was performed at two conditions: one for the analysis of first inflection
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point referring to the start of transformation, and another for the second inflection point
referring to the stabilized transformation rate. Release media was 500 ml and 1000 ml
water, and run time was 2 h and 10–11 h for these two conditions, respectively. Disso-
lution media was at 37 ± 0.5 °C and a rotation speed was 100 rpm. Drug content of
the media was measured at predetermined time intervals by UV-VIS spectrophotometer
(Lambda 25, PerkinElmer, USA) at 285 nm.
Evaluation of DIDR Profiles. IDR was determined by the slope in the DIDR profile
prior to the first inflection point, the slope referring to the release of anhydrous CBZ
before transforming to the dihydrate. DIDR profiles were analyzed by inflection points
as described in earlier work (Flicker et al., 2011). For all statistical comparison, one-way
ANOVA followed by Student’s t-test was applied.
Analysis of Compact Surface. Compact surfaces were analyzed by SEM (see Section
on Morphological Characterization). Prior to the analysis the compacts were kept under
controlled RH of 43% for a maximum of 24 h. The compacts were then fixed to the
sample holder by conductive silver and sputtered with gold.
Tensile strength
Tensile strength (σ) was calculated by the Equation (4.1),
σ =
2F
πDt
(4.1)
where F is the force needed to fracture the tablet by the hardness tester, D the diameter,
and t the thickness of the cylindrical tablet. Tablet dimensions were measured by a digital
caliper and crushing strength by a tablet hardness tester (Dr. Schleuniger® model 8M,
Pharmatron, USA).
Results and Discussion
Polymorphic characterization
Diffractograms of recrystallized CBZ samples are shown in Figure 4.1. The diffrac-
tograms were consistent with XRPD data of the untreated CBZ samples and the data
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reported for CBZ p-monoclinic form, where main peaks show at 2θ = 14.9, 15.2, 15.8,
27.2, 27.5, and 32.0° (Rustichelli et al., 2000). Peaks at angles smaller than 10° 2θ in-
dicating presence of CBZ triclinic (form I) or trigonal (form II) were not detected in our
samples. However, at lower angles of ° 2θ diffractograms peak intensities varied indicat-
ing difference in crystallinity, particle size, and preferred orientation.
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Figure 4.1: X-ray powder diffraction of recrystallized CBZ samples.
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Figure 4.2: DSC profiles of recrystallized CBZ samples; 10 °C/min scanning rate.
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DSC measurements of recrystallized CBZ (Figure 4.2) showed the characteristic ther-
mal events for CBZ p-monoclinic form (Grzesiak et al., 2003; Sˇehic´ et al., 2010). Melting
of form III was visible around 176 °C, followed by an exotherm around 182 °C (crystal-
lization of form I). Around 191 °C form I melted. DSC profiles of all recrystallized CBZ
samples were all alike. The deviations found in untreated CBZ samples were removed by
the recrystallization.
True density of all untreated and recrystallized CBZ samples were both 1.340 ±
0.001 g/cm3 indicating CBZ polymorphic form III (p-monoclinic) (Krahn and Mielck,
1989; Grzesiak et al., 2003).
Morphological Characterization
Figure 4.3 shows the SEM images of recrystallized CBZ samples. CBZ crystals obtained
after recrystallization was very big and agglomerated at the bottom of the beaker. Prior
to the analysis they were broken apart and reduced in size by mortar and pistil. The SEM
images illustrate the inhomogeneous particle size and shape in the recrystallized CBZ
samples.
(a) CBZ A re (b) CBZ B re (c) CBZ C re (d) CBZ D re
Figure 4.3: SEM pictures of recrystallized CBZ samples.
Water activity
Water activity of recrystallized CBZ samples was 0.327–0.346 and therefore below the
critical for transformation to CBZ dihydrate.
DIDR profiles of recrystallized CBZ
DIDR profiles of recrystallized CBZ A, B, C, and D are shown in Figure 4.4. Compared
to the DIDR profiles of untreated CBZ samples (Section 3.1) the variability was clearly
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Figure 4.4: DIDR profiles of recrystallized CBZ A, B, C, and D; 2 h (left) and 8 h (right)
DIDR test.
reduced. IDR values of recrystallized CBZ were with 35.3 ± 2.3 µg/cm2/min slightly
lower than the average IDR of untreated CBZ samples and with less variability. The
average IDR values of untreated CBZ was 36.6 ± 8.5 µg/cm2/min.
Inflection points in DIDR profiles of recrystallized CBZ samples are shown in Ta-
ble 4.1. The values were not distinct (one-way ANOVA, p > 0.05). Furthermore, SEM
images did not show any needle-like dihydrate structures on the compact of recrystallized
CBZ, not even after 8 h of DIDR measurement (Figure 4.5). Therefore, the first inflection
point could not be correlated with the transformation of CBZ to its dihydrate. No second
inflection point was determined.
CBZ samples were recrystallized in presence of 1% PVP. Presence of PVP in re-
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Table 4.1: Inflection points in DIDR profiles of recrystallized CBZ samples.
Sample n = 3 First inflection point [min]
CBZ A re 31 ± 10
CBZ B re 28 ± 4
CBZ C re 24 ± 6
CBZ D re 21 ± 3
Figure 4.5: SEM picture of compact surface of recrystallized CBZ after 8 h DIDR test.
crystallization was reported to partially change the dissolution pattern of acetaminophen
crystals (Wen et al., 2005). This change was associated with the adsorption of the poly-
mer PVP on crystal surface by van der Waals interaction. PVP may have absorbed to the
CBZ samples in the same manner. In addition, PVP is reported to inhibit transformation
of CBZ to its dihydrate if present in the dissolution media at 1% (Tian et al., 2006a). Al-
though the amount of PVP absorbed on the recrystallized CBZ is very small (not detected
by DSC or XRPD) it may be enough to explain the inhibited transformation found in the
present results.
Properties of CBZ Compacts
Compacts of pure CBZ samples were difficult to obtain. There was a narrow compac-
tion force range for each CBZ sample. Binding was insufficient below this range and
above lamination and capping occurred. Best results were obtained for compaction forces
6.3–10.5 MPa for untreated and at much higher compaction force of 21.0 MPa for recrys-
tallized CBZ samples. Compacts of recrystallized CBZ samples did not show any im-
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provement in compaction as expected by the results reported by Nokhodchi et al. (2005).
Nonetheless, the variability in tensile strength observed in compacts of recrystallized CBZ
was reduced compared to tensile strength among compacts of untreated CBZ samples.
Detailed results are shown in the Appendix 6.1.7.
Compared to anhydrous CBZ samples the CBZ dihydrate was of much easier to com-
pact. At compaction forces of 6.3 MPa tensile strength was 1.921± 0.125 MPa.
Recrystallized CBZ in Binary Mixtures
Figure 4.6 shows the initial dissolution profiles of recrystallized CBZ in binary mixtures.
The difference among recrystallized CBZ samples war reduced with the exception of
the dissolution profiles of recrystallized CBZ D deviating significantly from the other
dissolution profiles (p < 0.05). After 2 h dissolution, compacts showed swollen surfaces
with wide creeks. This features were the strongest in MCC formulation with recrystallized
CBZ D. It has to be considered that recrystallized CBZ samples were only slightly ground
by mortar and pistil and particle size distribution was very wide. We therefore can not
exclude inhomogeneous mixture in MCC formulations.
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Conclusions
Recrystallized CBZ samples presented a strongly reduced dissolution variability and the
transformation to CBZ dihydrate was inhibited. Compacts of recrystallized CBZ samples
also presented less variability in tensile strength compared to the untreated samples. The
recrystallization did not induce any change in polymorphic form. Particle morphology of
recrystallized CBZ samples was of irregular size and shape and may thus have resulted in
inhomogeneous mixtures with MCC and to the deviation of one sample in the dissolution
test. Therefore, more detailed studies are necessary to control the critical grinding step.
The recrystallization in presence of 1% PVP can be suggested as a valid approach to
control the dissolution variability in commercial CBZ samples. Although the results are
promising, the careful selection of the CBZ raw material is suggested at the actual stage
of knowledge.
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Chapter 5
Dissolution Project with the Optimized
CBZ Tablet Formulation
Abstract
Although drug release of the tablet formulation developed earlier was within the USP
specification using various CBZ samples, the dissolution curves differed with the CBZ
sample used. The aim of this project was to study drug release of the tablet formulation
in water without any additives. Drug release of CBZ tablet formulation with CBZ A, B,
C, and D was analyzed by flow-through cells. In water, the tablet formulation showed a
robust drug release regarding the tested CBZ samples. Moreover, flow-through cells in
open dissolution mode can be suggested to study effects of various dissolution media on
poorly soluble drugs like CBZ.
Introduction
CBZ tablets have a history of irregular dissolution behavior and bioinequivalence (Mit-
tapalli et al., 2008; Davidson, 1995; Meyer et al., 1992). In water and at high relative
humidity CBZ transforms to the less soluble CBZ dihydrate (Rodrı`guez-Sponga et al.,
2004). This transformation can be critical to the dissolution behavior of the final tablet
formulation. Sˇehic´ et al. (2010) reported different transformation within commercial CBZ
samples and this difference also shows in tablet formulation using Ludipress® as tablet
filler.
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To remove the effect of individual transformation a CBZ tablet formulation was de-
veloped selecting the two excipients crospovidone (CrosPVP) and hydroxypopyl cellulose
(HPC), both reported to inhibit transformation (Flicker and Betz, 2011). The dissolution
conformed to the requirements of the USP monograph for CBZ tablets of immediate re-
lease. Testing different CBZ raw materials in the tablet formulation the dissolution curves
were still within the USP specifications, yet showing significant difference.
The dissolution medium described in USP monograph of CBZ tablets requires 1%
(w/v) of the surfactant sodium laurylsulfate (SLS) in water. SLS strongly enhances the
solubility of CBZ and sink conditions can be maintained in a closed system with 900 ml
dissolution medium and 280 mg CBZ. However, SLS is reported to enhance also the
transformation to CBZ dihydrate (Rodrı`guez-Hornedo andMurphy, 2004; Luhtala, 1992).
Therefore, analysis of CBZ release in presence of SLS may not show the ability of the
excipients CrosPVP and HPC to reduce the dissolution variability.
In this project, the robustness of CBZ tablet formulation towards various commercial
CBZ samples was tested in water without any further additives. Therefore, flow-through
cells were selected to test the CBZ tablet formulation in open dissolution mode providing
sink conditions. Drug dissolution was compared to the dissolution method described in
the USP monograph for CBZ tablet of immediate release.
Materials and Methods
CBZ Tablet Formulation
The CBZ tablet formulation developed within the PhD studies (Section 3.2) was used.
The tablet composition was 70% CBZ (API), 18% MCC (filler), 6% HPC-SL (binder),
5% CrosPVP (superdisintegrant), and 1% magnesium stearate (lubricant). Tablet formu-
lation was prepared using CBZ raw materials of four different suppliers, namely CBZ
A, B, C, and D. Tablets were of 400 mg, flat-faced, 10-mm in diameter, 12.1 ± 0.2%
in porosity, and prepared by direct compaction using a simulated speed of 0.5 m/s and
6–18 kN compaction force.
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Flow-Through Cells (USP 4)
Dissolution test was performed by flow-through cells, the USP Apparatus 4 (SotaxCE7-
smart, SOTAX AG, Switzerland). The 22.6 mm cells were used in laminar mode (packed
column with 1 mm glass beads) and tablets were placed in a tablet holder. Dissolution
was performed in the open system mode, at 16 ml/min flow rate, 37 ± 0.5 °C, and in
dissolution medium of water and 1% SLS, respectively. Samples were analyzed by UV-
VIS Spectrophotometer (Lambda 25, PerkinElmer) at 285 nm and 287 nm respective to
the wavelength of maximum absorption (λmax) of CBZ in water and 1% SLS.
Results and Discussion
Figures 5.1 and 5.2 show the dissolution curves of the CBZ tablet formulation in water
and in 1% SLS. Flow-through cells in open dissolution mode present a small volume of
fresh dissolution medium to the tablet at continuous flow. With the fast disintegrating
CBZ tablet formulation this small volume dissolved a high amount of CBZ in the initial
dissolution phase. The measured CBZ concentration decreased over the dissolution time
(Subfigures 5.1a and 5.2a).
Mean dissolution curves of CBZ tablets with CBZ A, B, C, and D were compared
by one-way ANOVA. While dissolution curves of CBZ tablets analyzed in 1% SLS were
significantly different (p < 0.001), CBZ tablets revealed no significant difference among
tablets with CBZ A, B, C, and D when analyzed in water (p > 0.1).
Figure 5.3 shows the dissolution curves of CBZ tablets with CBZ A, B, C, and D
obtained by the paddle method using 1% SLS as dissolution medium (same results as
shown in Section 3.2). These dissolution curves were compared to the ones obtained
by the flow through cells using same dissolution medium (Figure 5.2(b)). Both showed
amount of drug released that was within the USP specification, where at 15 min amount
of CBZ released is 45–75% and at 60 min more than 75%. Amount of drug dissolved
at t15 and t60 of the different methods are shown in Table 5.1. Also the analysis by one-
way ANOVA showed comparable results, mean dissolution curves of CBZ tablets with
CBZ A, B, C, and D differed significantly in dissolution data obtained by both dissolution
methods (p < 0.01). However, the precision of dissolution curves obtained by the flow
through cells was lower (RSD ≤ 8.6%) compared to the one obtained by paddle method
(RSD ≤ 2.9%). At CBZ concentrations above 640 mg/L in 1% SLS the correlation with
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Figure 5.1: Dissolution of CBZ tablet formulation with CBZ A, B, C, and D in water;
drug concentration (a) and cumulative amount of drug dissolved [%] (b) over time.
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Figure 5.2: Dissolution of CBZ tablet formulation with CBZ A, B, C, and D in 1% SLS;
drug concentration (a) and cumulative amount of drug dissolved [%] (b) over time.
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Figure 5.3: Dissolution curves of CBZ tablets analyzed by the paddle method in 1% SLS
(results of Section 3.2).
the UV absorption was not linear anymore. This may explain the especially high standard
deviation observed for the tablet formulation of CBZ B (Figure 5.2(b)). Nonetheless, the
dissolution variability was comparable.
Table 5.1: Amount of CBZ dissolved at t15 and at t60; CBZ tablets with CBZ A, B, C, and
D dissolved in water and in 1% SLS using flow-through cells (FTC) and paddle method.
n ≥ 3 H2O (FTC) 1% SLS (FTC) 1% SLS (Paddle)
CBZ dd15 [%]
A 23.3 ± 0.8 47.4 ± 1.6 72.1 ± 1.4
B 26.6 ± 0.5 60.2 ± 4.4 68.8 ± 2.6
C 23.5 ± 0.2 55.0 ± 1.9 60.8 ± 2.0
D 25.0 ± 0.2 59.2 ± 0.7 53.2 ± 2.9
CBZ dd60 [%]
A 58.8 ± 2.5 75.4 ± 2.8 96.1 ± 0.7
B 55.2 ± 2.3 92.6 ± 8.4 95.1 ± 1.1
C 51.5 ± 1.4 85.1 ± 3.3 90.5 ± 0.6
D 57.1 ± 0.8 88.5 ± 0.5 84.8 ± 2.9
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Conclusions
Excluding the effect of SLS on the dissolution, the tablet formulation was robust regarding
CBZ raw material of supplier A, B, C, and D. Flow through cells presented the advantage
of keeping sink condition throughout the full dissolution testing by using the open disso-
lution mode. The flow through cells provide a valuable tool to study the effect of different
dissolution media on poorly soluble drug like CBZ.
138 CHAPTER 5. DISSOLUTION PROJECT
Bibliography
Davidson, A., 1995. A multinational survey of the quatity of carbamazepine tablets. Drug
Dev. Ind. Pharm. 21, 2167–2186.
Flicker, F., Betz, G., 2011/12/04 2011. Effect of crospovidone and hydroxypropyl cellu-
lose on carbamazepine in high-dose tablet formulation. Drug Dev. Ind. Pharm., 1–9.
URL http://dx.doi.org/10.3109/03639045.2011.623166
Luhtala, S., 1992. Effect of sodium lauryl sulphate and polysorbate 80 on crystal growth
and aqueous solubility of carbamazepine. Acta Pharm. Nordica 4, 1100–1801.
Meyer, M. C., Straughn, A. B., Jarvi, E. J., Wood, G. C., Pelsor, F. R., Shah, V. P.,
1992. The bioinequivalence of carbamazepine tablets with a history of clinical failures.
Pharm. Res. 9, 1612–1616.
Mittapalli, P. K., Suresh, B., Hussaini, S. S. Q., Rao, Y. M., Apte, S., 2008. Comparative
in vitro study of six carbamazepine products. AAPS PharmSciTech 9 (2), 357.
Rodrı`guez-Hornedo, N., Murphy, D., 2004. Surfactant-facilitated crystallization of dihy-
drate carbamazepine during dissolution of anhydrous polymorph. J. Pharm. Sci. 93,
449–460.
Rodrı`guez-Sponga, B., Priceb, C. P., Jayasankara, A., Matzger, A. J., Rodrı`guez-Hornedo,
N., 2004. General principles of pharmaceutical solid polymorphism: a supramolecular
perspective. Adv. Drug Deliv. Rev. 56, 241–274.
Sˇehic´, S., Betz, G., Hadzˇidedic´, Sˇ., El-Arini, S. K., Leuenberger, H., 2010. Investigation
of intrinsic dissolution behavior of different carbamazepine samples. Int. J. Pharm. 386,
77–90.
139
140 BIBLIOGRAPHY
Chapter 6
Conclusions
During this study, the variability in CBZ raw materials of four different suppliers was
characterized and its impact on drug release was studied. The CBZ samples showed
differences in polymorphic purity, particle morphology, and intrinsic dissolution behav-
ior. Most interestingly, two inflection points were found in the intrinsic dissolution pro-
files that characterized the transformation behavior of each anhydrous CBZ samples to
the CBZ dihydrate as a time range. Furthermore, the applied unidirectional dissolution
method allowed investigating the influence of commonly used tablet fillers already at pre-
formulation level. Presence of MCC reduced the drug release variability found for the
CBZ samples and can be suggested as a suitable tablet filler for CBZ.
Recrystallizing CBZ samples in presence of 1% PVP resulted in strongly reduced dis-
solution variability and the transformation to CBZ dihydrate was inhibited. Nonetheless,
considering the high amount of solvent, the low yield of 53–70%, and the critical grind-
ing step following the recrystallization, the careful selection of the CBZ raw material is
suggested at the actual stage of knowledge.
At the formulation level, high-dose CBZ tablets of immediate release were success-
fully prepared with the novel combination of crospovidone (CrosPVP) as superdisinte-
grant, hydroxypropyl cellulose (HPC-SL) as dry binder, and MCC as the tablet filler. The
optimal formulation was with 5% CrosPVP and 6% HPC, where tablet formulation of the
four CBZ raw materials conformed to the USP requirements for CBZ immediate release
tablets. Moreover, drug release in water was robust towards the variability in the CBZ
samples showing no significant difference among the dissolution curves.
In conclusion, the strategy suggested to control the variability in CBZ samples in-
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cludes the unidirectional dissolution method as a straightforward monitoring tool in pre-
formulation studies. To allow a certain variability in CBZ raw materials, it is further
suggested to design a robust formulation incorporating the excipients CrosPVP, HPC, and
MCC.
Building on the presented studies, it would be illuminative to investigate the robustness
of the CBZ tablet formulation in in-vivo conditions. Furthermore, it would be of great
interest to validate the unidirectional dissolution method on another hydrate-forming drug
like theophylline.
Appendix
The Appendix provides additional information on the original publications and the re-
crystallization project. Section 6.1 presents additional information on Publication 1 and
on the recrystallization project, whereas Section 6.2 presents further information on Pub-
lication 2 and on the dissolution project.
6.1 Additional Information on Publication 1 and on the
Recrystallization Project
6.1.1 Further Analyses on CBZ Samples
Light Microscopy
Morphology of CBZ samples was analyzed by an inverse light microscope (Hund Wetzlar
Wilovert®, Germany). Images were taken by a camera (Canon Digital IXUS 80 IS, Japan)
and through the SPL Ph 20/0.25 objective (Figure 6.1).
(a) CBZ A (b) CBZ B (c) CBZ C (d) CBZ D
(e) CBZ dihydr
Figure 6.1: Images of CBZ A, B, C, and D and CBZ dihydrate by light microscopy.
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The images reveal different morphology of the CBZ samples with very crystalline
particles of prismatic shape in CBZ A, particles with rough and uneven edges and a lot of
fines in CBZ B and D, and more round particles with smooth surface in CBZ C.
Same morphological structure can be reported using the more sophisticated technique,
the SEM (Section 3.1). Nevertheless, light microscopy presents a fast and easy to use tool
with very little sample preparation.
Thermogravimetry
CBZA, B, and D were analyzed by thermogravimetry (Pyris TGA 6, Perkin Elmer, USA).
Samples of 8–15 mg were scanned from 40–200 °C at 10 °C/min with nitrogen gas purge
of 100 ml/min. Loss of mass was registered on a microbalance. Thermogravimetric
analysis was conducted in triplicate.
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Figure 6.2: Weight loss under heating of CBZ dihydrate.
Mass loss was 0.12 ± 0.08%, 0.09 ± 0.02%, and 0.09 ± 0.01% for CBZ A, B, and D,
respectively. The values present no substantial weight loss and it can be concluded that
the CBZ samples did not contain any solvent. In contrast, CBZ dihydrate showed a mass
loss of 9.87 ± 0.20% (Figure 6.2). The theoretical stoichiometric water content of CBZ
dihydrate is 13.2% w/w. The obtained mass loss was of lower value and indicates that
CBZ dihydrate was not fully hydrated. Hence, the IDR values of fully hydrated CBZ are
expected to present even lower values than detected (Section 3.1).
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Flowability of CBZ
Flowability of CBZ samples was determined according to USP 31 (2008) using a tap
volumeter (type STAV 2003, J. Engelsmann AG, Germany). A powder sample of 100 g
was poured into a graduated cylinder. The initial volume (ml) was recorded for the bulk
density in g/cm3 and the volume after tapping 1250 times was recorded for the tap density.
Flowability test was performed in triplicate.
Table 6.1: Flowability of CBZ samples: bulk and tapped density, Hausner ratio, and
Compressibility Index.
CBZ bulk density tapped density Hausner Compressibility
n = 3 [g/cm3] [g/cm3] ratio Index [%]
A 0.61 ± 0.00 0.68 ± 0.00 1.12 ± 0.01 10.4 ± 1.0
B 0.68 ± 0.00 0.78 ± 0.00 1.16 ± 0.00 13.5 ± 0.0
N 0.76 ± 0.01 0.85 ± 0.00 1.11 ± 0.01 9.7 ± 0.8
D 0.76 ± 0.01 0.84 ± 0.01 1.11 ± 0.00 10.1 ± 0.3
The results indicate good flow for all CBZ samples, Hausner ratio was below 1.25
and Compressibility Index (CI) was below 16%. CBZ N even showed a CI of less than
10% indicating excellent flow properties. Therefore, flowability is not expected to limit
manufacturing of the CBZ samples.
6.1.2 Development of the Unidirectional Dissolution Method
The unidirectional dissolution method was developed based on the manual disk intrinsic
dissolution rate (DIDR) method by Sˇehic´ et al. (2010). The unidirectional dissolution
method allows the drug to dissolve from one compact surface only. If the compact is of
pure drug, the unidirectional dissolution method is equal to an automatic DIDR method.
In the following section the automatic DIDR is compared to the manual DIDR method.
Experimental
Sample Preparation. Flat-faced compacts of 400 mg and 0.95 cm2 surface area were
prepared from CBZ A, B, and D using a material tester (Zwick 1478, Germany). Compact
porosity was controlled to 12% and hardness was 20–41 N. For compacts of CBZ A,
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porosity was 16%, as higher compaction forces resulted in lamination. Compaction force
was set between 6–10 kN, while compaction, decompaction, and ejection speed were
set at 10 mm/min, 50 mm/min, and 10 mm/min, respectively. After elastic recovery the
compacts were placed into the sample holder (disk) and embedded with melted paraffin
wax so only one surface was available to the dissolution media.
Manual DIDR Method. Manual DIDR was carried out in 400 ml water at 37 °C. Disk
rotation was 100 rpm and the dissolution medium was additionally stirred by a magnetic
bar. Aliquots of 5 ml were withdrawn every minute during the first 20 min, every 5 min
up to 40 min, every 10 min up to 60 min, and every 20 min up to a total of 120 min dis-
solution time. Dissolution medium was replaced after every sampling. Six samples were
analyzed simultaneously and the disks were lifted out of the medium during the sampling
and replacement of dissolution medium. Drug content of the samples was analyzed by
UV spectrophotometer (DU 530, Beckman, USA) at 285 nm.
Automatic DIDR Method. Automatic DIDR method was performed at 100 rpm in
500 ml water at 37 °C. A commercially available dissolution machine (SotaxAT7smart)
was modified at its rotating basket unit to a rotating disk. The SotaxAT7smart is a closed
system with automatic drug content measurement at predetermined time intervals. Initial
measurement interval was set at 1.3 min during 39 min, then at 2 min up to 65 min, and
at 5 min up to a total of 120 min dissolution time. The interval of 1.3 min was found to
be the smallest possible measuring interval, where sufficient pumping (1.5 times turnover
of the medium in the sampling loop) and no system conflict occurred. Drug content was
measured by UV-VIS spectrophotometer (Lambda 25, PerkinElmer, USA) at 285 nm.
Results and Discussion
Figure 6.3 shows the DIDR profiles of the manual (a) and the automatic (b) DIDRmethod,
respectively. The DIDR profiles of the manual method show a clear inflection around
20 min, and DIDR profiles of the automatic method show comparatively low standard
deviation.
IDR values were determined by the slope in the DIDR profile prior to the inflection
point, the slope referring to the release of anhydrous CBZ before transforming to the
dihydrate. IDR values and their standard deviation (SD) are shown in Table 6.2. Both,
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Figure 6.3: DIDR profiles of the manual (a) and automatic (b) DIDR method.
Table 6.2: Intrinsic dissolution rate (IDR) values obtained by the manual and the auto-
matic DIDR method.
[µg/cm2/min]
Sample n ≥ 5 IDR manual IDR automatic
CBZ A 53.0 ± 10 43.9± 3.1
CBZ B 49.5 ± 5.3 38.6± 0.8
CBZ D 45.0 ± 2.7 39.9± 0.7
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IDR and SD values were higher in the manual method compared to the automatic one.
Inflection point. The inflection point was determined by the intercept of two linear
regressions. First regression line included the initial DIDR profile approximated to the
best fit and second regression line was set through all data points of the later stage in the
DIDR profile that were not included in first regression line. Best fit in linear regression
was R2 0.9973 ± 0.0026 and R2 0.9997 ± 0.0003 for the initial DIDR profiles of the
manual and automatic DIDR method, respectively.
Table 6.3: Inflection point (IP) by the manual and the automatic DIDR method.
Sample n ≥ 5 IP manual [min] IP automatic [min]
CBZ A 16 ± 6 33± 6
CBZ B 14 ± 5 28± 10
CBZ D 29 ± 4 41± 7
DIDR profiles obtained from the automatic DIDRmethod showed the inflection points
in the same order as of the manual DIDR method: CBZ B > A > D. However, inflection
points in DIDR profiles obtained by the automatic method were at a later time. The
manual DIDR method is disruptive and the DIDR profiles do not present real time contact
with the dissolution media. This can explain the later time of inflection points as well as
the higher IDR values in DIDR profiles obtained by the automatic method.
Compact surfaces during the DIDR measurement. When the disks are lifted out of
the dissolution medium for the sample measurement a stagnant film of water stays on
the disk surface. Over-saturation can occur and thereby enhance the transformation to
CBZ dihydrate and the needles can grow without the convective force in the dissolution
medium. Figure 6.4 shows the compact surfaces during the manual DIDR measurement,
whereas Figures 6.5 are the compact surfaces during the automatic mode. In the automatic
DIDR method the dihydrate crystals show at a later time and as much smaller needles
(note the different sampling times and different resolutions).
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(a) CBZ A; 0 min (b) CBZ A; 15 min (c) CBZ A; 30 min (d) CBZ A; 60 min
(e) CBZ B; 0 min (f) CBZ B; 15 min (g) CBZ B; 30 min (h) CBZ B; 60 min
(i) CBZ D; 0 min (j) CBZ D; 15 min (k) CBZ D; 30 min (l) CBZ D; 60 min
Figure 6.4: SEM pictures of compact surface from CBZ A, B, and D at 0, 15, 30, and
60 min manual DIDR test; magnification of ×100.
Conclusions
The results confirm that the manual DIDR method allows the distinction between CBZ
samples of different supplier by an inflection point in the DIDR profiles reflecting trans-
formation to the CBZ dihydrate. However, transformation was found to be enhanced by
the disruptive test settings, which results in an inflection point visible without further cal-
culations. The drawbacks of the manual methods are the precision, the manual sampling,
and the time limitation thereby. The automatic DIDR method presents a system with con-
tinuous dissolution, higher precision, and the ability to analyze the samples over a longer
time range.
6.1.3 Precision and Effect of Particle Size
The effect of particle size on the precision of DIDR profiles was analyzed in the manual
DIDR method. Sieve fractions (125 – 355 µm) of CBZ A, B, and D were compared with
the non-sieved samples (n = 3). Precision of DIDR profiles is described by the coefficient
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(a) CBZ A; 30 min (b) CBZ A; 60 min (c) CBZ A; 120 min
(d) CBZ B; 30 min (e) CBZ B; 60 min (f) CBZ B; 120 min
(g) CBZ D; 30 min (h) CBZ D; 120 min
Figure 6.5: SEM pictures of compact surface from CBZ A, B, and D at 30, 60, and
120 min automatic DIDR test; magnification of ×2000.
of variation (CV), i.e., the relative standard deviation,
CV [%] =
SD
x
· 100 (6.1)
where SD is the standard deviation and x is the arithmetic mean. The average relative
standard deviation over the full DIDR profile was calculated. Surprisingly DIDR profiles
of sieved fractions showed with 13.4± 2.8% the higher relative standard deviation (RSD)
compared to the non-sieved samples with RSD of 7.2 ± 1.4%. Moreover, IDR values
of sieved CBZ were higher than of non-sieved CBZ samples (73.5 ± 8.1 and 69.2 ±
5.1 mg/cm2/min). The physical strain by the sieving process may have induced some
crystal defects and thereby led to the inhomogeneous and faster dissolution of sieved
CBZ samples. Therefore, non-sieved CBZ samples were used in all further experiments.
DIDR profiles in the unidirectional dissolution method showed an average RSD of
less than 4%, with the exception of CBZ D, where DIDR profiles showed average RSD
values up to 10%. In general, RSD was higher in the initial DIDR profiles (up to around
20 min) and was reduced to RSD values less than 2% after 2 h DIDR test.
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6.1.4 Repeatability
Repeatability of IDR values and inflection points of CBZ samples was tested by a second
data set (n = 5). The unidirectional dissolution method was conducted by a different
person (master student V. A. Eberle). The results are compared to the previous data set
(Section 3.1).
Figure 6.6 shows the DIDR profile of the 2 h and 11 h-run. IDR values of the initial
phase and the two inflection points are shown in Table 6.4 and 6.5, respectively.
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Figure 6.6: DIDR profiles of CBZ A, B, C, and D with the 2 h (top) and 11 h (bottom)
dissolution test. Average values (n = 5) are presented.
Initial phase in DIDR profiles showed a significant difference in IDR for CBZ samples
(ANOVA p < 0.001). The IDR values were in the same range as of the first data set.
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Table 6.4: Intrinsic dissolution rate of CBZ samples in the initial DIDR profiles prior to
the first inflection point.
Sample n ≥ 5 IDR [µg/cm2/min]
CBZ A 37.2± 1.0
CBZ B 33.6± 1.8
CBZ C 36.9± 1.7
CBZ D 32.3± 1.7
Table 6.5: First and second inflection point in DIDR profiles of CBZ samples.
Sample n ≥ 3 First inflection point (min) Second inflection point (min)
CBZ A 35± 6 546 ± 26
CBZ B 23± 6 321 ± 52
CBZ C 19± 2 334 ± 196
CBZ D 26± 6 555 ± 26
However, IDR values were not distinct among each other and could not be ranked in the
same order as reported for the previous data set.
CBZ samples differed significantly in their first and second inflection point (ANOVA
p < 0.005). First inflection points could be ranked as CBZ C≤B<D<A (p < 0.05), and
second inflection points as CBZ C≤B<A≤D (p < 0.0005). The ranking was the same as
for the previous data set. However, the ranking did not show the same siginificance.
Conclusions. IDR and inflection points in DIDR profiles were successfully repeated.
The range of the first and second inflection points, their precision, and their ranking were
confirmed by a different data set measured by a different person. Also the range of IDR
values was confirmed, however, with no significant ranking. These findings lead to the
conclusion, that the inflection points present a adequate parameter to characterize vari-
ability among commercial CBZ sample of different suppliers.
6.1.5 Inflection Point in DIDR Profiles of CBZ Dihydrate?
DIDR profiles also showed an inflection point for CBZ dihydrate (around 35 min). The
reason for this phenomenon is most likely the onset of crystal growth and rearrangement
of the dihydrate crystals to bigger crystals aligned in block-like forms. For visualization,
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(a) 0 h (b) 8 h
Figure 6.7: SEM image of CBZ dihydrate, compact surface before and after 8 h DIDR
test.
see compact surface of CBZ dihydrate after 8 h DIDR test in Figure 6.7.
The inflection point in DIDR profiles of CBZ dihydrate does not represent the trans-
formation process as found for the anhydrous CBZ samples. The inflection point for CBZ
dihydrate is therefore not discussed in Publication 1.
6.1.6 Transformation of CBZ to Dihydrate – Contradictory Results
in Literature
As soon as anhydrous CBZ transforms to its dihydrate, the dissolution rate is expected
to decrease because of the lower solubility of CBZ dihydrate (Kaneniwa et al., 1987;
Kobayashi et al., 2000). Interestingly, Tian et al. (2007) reported contrary results. In
presence of excipients inhibiting the transformation, CBZ samples presented a decreased
dissolution rate compared to the dissolution rate in water. The hypothesis was that the
formed dihydrate crystals presented a bigger surface area and thereby enhanced the drug
dissolution. Within the PhD study, the decrease in dissolution rate correlated with the
appearance of the needle-like dihydrate crystals on the compact surfaces.
Transformation of CBZ anhydrous to dihydrate can be induced by physical processes
like grinding leading to disrupted crystal lattice and finally to a chasnged dissolution be-
havior (Murphy et al., 2002; Lefebvre et al., 1986). However, the significance of the effect
on dissolution is reported confusingly. Tenho et al. (2007) compared IDR values between
ground and unground CBZ and reported no significant difference. The IDR values were
calculated excluding the initial 30 min of dissolution and linear regression was placed
through the following linear phase. Moreover, the considered dissolution range showed
two clearly distinct curves that seem to be parallel to each other and the dissolution profile
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of the ground CBZ samples was at a higher concentration compared to the unground CBZ
samples. Therefore, it has to be concluded, that the ground CBZ samples showed a faster
drug release in the initial phase and thereby clearly showing an effect of grinding on drug
release.
6.1.7 Compact Hardness of Untreated and Recrystallized CBZ
Samples
Table 6.6 shows the compaction force necessary to compact untreated and recrystallized
CBZ samples to a fixed porosity and the tensile strength of the obtained compacts.
Table 6.6: Compaction force (CF) and tensile strength (TS) of untreated and recrystallized
CBZ samples. Compacts were of fixed porosity.
untreated CBZ recrystallized CBZ
n ≥ 5 CF [MPa] TS [MPa] CF [MPa] TS [MPa]
CBZ A 10.5 0.355 ± 0.036 21.0 0.630 ± 0.098
CBZ B 8.4 0.505 ± 0.127 21.0 0.556 ± 0.262
CBZ C 6.3 0.294 ± 0.017 21.0 0.436 ± 0.252
CBZ D 8.4 0.651 ± 0.095 21.0 0.498 ± 0.180
x ± SD 8.4 0.451 ± 0.160 21.0 0.530 ± 0.083
6.1.8 Effects of Mannitol and MCC on CBZ
Effect of Mannitol. Binary mixtures of CBZ with mannitol showed an interesting phe-
nomenon on the compact surface during the DIDR test. A new type of crystal shape was
detected on the surface arranged like the spines of a hedgehog (Figure 6.8).
The question arises of which molecules these crystals are formed. Are they of manni-
tol, CBZ, or of a cocrystal? Mannitol itself exhibits polymorphism and it dissolves much
faster than CBZ. Hence, the crystals could be of another less soluble polymorphic form
of mannitol. A further and more likely possibility is that mannitol acts as impurity in
the solution-mediated transformation of CBZ and thereby influence the crystal habit of
CBZ dihydrate. It would be very interesting to analyze these crystals as to their chemical
composition and polymorphic form.
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Figure 6.8: SEM pictures of compact surface from 70% CBZ B in binary mixtures with
mannitol after 120 min DIDR test.
Binary mixtures of CBZ with high amount of mannitol (30% drug load) showed an
increased initial dissolution; the amount of drug dissolved was of up to 10 times higher
compared to the binary mixtures of higher drug load. The high solubility of mannitol may
provide a reason, it dissolves much faster than CBZ and leaves a porous structure of the
less soluble CBZ with increased surface area. The porous structure could be shown on the
compact surface during the DIDR test by SEM imaging (Figure 6.9).
Figure 6.9: SEM pictures of compact surface from 30% CBZ B in binary mixtures with
mannitol after 120 min DIDR test.
Figures 6.10 and 6.11 show the diffractograms of CBZ samples in binary mixtures
with mannitol. No interaction of mannitol with CBZ could be detected. The diffractogram
of mannitol revealed, that the polymorphic form of the preprocessed Parteck® M300 is
mannitol form I according to Burger et al. (2000).
Effect of MCC. Binary mixtures of CBZ with MCC showed a clear reduction in disso-
lution variability. This is surprising considering the compact surface after 120 min DIDR
test (Figure 6.12), where compact surfaces visibly differ with the CBZ sample. A possi-
ble explanation for the reduced variability could be that the fiber-like structure of MCC
stabilized CBZ release.
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Figure 6.10: XRPD of CBZ A and B in binary mixtures with MCC (0–90% drug load)
and pure mannitol.
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Figure 6.11: XRPD of CBZ C and D in binary mixtures with MCC (0–90% drug load)
and pure mannitol.
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(a) CBZ A - MCC (b) CBZ B - MCC (c) CBZ C - MCC (d) CBZ D - MCC
Figure 6.12: SEM pictures of compact surface from 70% CBZ in binary mixtures with
MCC after 120 min DIDR test.
Diffrctograms of CBZ samples in binary mixtures with MCC are shown in Figures
6.13 and 6.14. No interaction could be detected.
6.1.9 UV Calibration
Various UV calibration curves were necessary to analyze the CBZ concentration depen-
dent on the required sensitivity range and on the system used (Table 6.7).
Table 6.7: Calibration curves of CBZ in different dissolution media of type y = ax + b.
Medium rangea λmaxb cell a b R2
H20 0.1 – 20 285 10 mmc 0.0508 -0.0094 0.99988
H20 1 – 15 285 10 mmd 0.05108 0.00970 0.99986
H20 15 – 150 285 1 mmd 0.00515 -0.00003 0.99917
ain [mg/L]
bin [nm]
cUV-VIS spectrophotometer, Beckman, USA
dUV-VIS spectrophotometer, Lambda 25, PerkinElmer, USA
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Figure 6.13: XRPD of CBZ A and B in binary mixtures with MCC (0–90% drug load)
and pure MCC.
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Figure 6.14: XRPD of CBZ C and D in binary mixtures with MCC (0–90% drug load)
and pure MCC.
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6.2 Additional Information on Publication 2 and on the
Dissolution Project
6.2.1 SEM Images of the Excipients in the Tablet Formulation
SEM images of the excipients used for the high-dose CBZ tablets are shown in Fig-
ure 6.15. The particle morphology differs with the function of the excipient. CrosPVP
presents very porous particles indicating the ability to absorb water fast and act as a su-
perdisintegrant. The filler-binder MCC shows aggregated fibrous structure, same can be
said for the binder HPC-SL, although particle shape is less defined.
(a) MCC (b) CrosPVP (c) HPC-SL
Figure 6.15: SEM images of filler-binder MCC, superdisintegrant CrosPVP, and binder
HPC-SL
6.2.2 UV Calibration
Depending on the dissolution medium and the required sensitivity range different UV cal-
ibration curves were acquired using the UV-VIS spectrophotometer (Lambda 25, Perkin-
Elmer, USA). The parameters of the various calibration curves are shown in Table 6.8.
Table 6.8: Calibration curves of CBZ in different dissolution media of type y = ax + b.
Medium rangea λmaxb cell a b R2
1% SLS 11 – 300 287 1 mm 0.00491 -0.00042 0.99999
1% SLS 10 – 640 287 1 mm 0.00456 0.04420 0.99911
H20 25 – 250 285 1 mm 0.00551 0.00429 0.99996
ain [mg/L]
bin [nm]
The dissolution method by the flow through cells required UV calibration of higher
CBZ concentrations to analyzed the initial dissolution profiles. However, in the dissolu-
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tion medium containing 1% SLS CBZ concentrations of ≥ 640 mg/L did not show linear
correlation with the UV absorption and were therefore not included.
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